FIBROBLAST GROWTH FACTOR BINDING PROTEIN 1 (FGFBP1) CONTRIBUTES IN THE ESTABLISHMENT AND MAINTENANCE OF THE BLOOD BRAIN BARRIER by A. Cottarelli
	  
	  
PhD  degree  in  Molecular  Medicine  (curriculum  in  Molecular  Oncology)  
European  School  of  Molecular  Medicine  (SEMM),    
University  of  Milan  and  University  of  Naples  “Federico  II”  




Fibroblast  growth  factor  binding  protein  1  
(FGFBP1)  contributes  in  the    
establishment  and  maintenance  of  the  







Supervisor:     Prof.ssa  Elisabetta  Dejana  
      IFOM,  Milan  
Cosupervisor:  Dr.ssa  Maria  Grazia  Lampugnani  
      IFOM,  Milan  



















"ʺTwo  roads  diverged  in  a  wood,  and  I—    
I  took  the  one  less  traveled  by,    
And  that  has  made  all  the  difference."ʺ  




     
5	  
	  
TABLE  OF  CONTENTS  
LIST  OF  ABBREVIATIONS  ............................................................................................................  9	  
FIGURE  INDEX  ..............................................................................................................................  13	  
ABSTRACT  .....................................................................................................................................  17	  
1.  INTRODUCTION  ......................................................................................................................  19	  
1.1  The  Blood  Brain  Barrier  (BBB)  ...............................................................................................  19	  
1.1.1  Endothelial  junctions  ....................................................................................................  21	  
1.1.2  Molecular  transport  ......................................................................................................  24	  
1.1.3  Leukocyte  adhesion  ......................................................................................................  25	  
1.2  Cellular  and  extracellular  components  of  the  NeuroVascular  Unit  .......................................  26	  
1.2.1  Pericytes  ..........................................................................................................................  27	  
1.2.2  Astrocytes  .......................................................................................................................  33	  
1.2.3  Perivascular  macrophages  and  microglia  .................................................................  34	  
1.2.4  Basement  membrane  ....................................................................................................  35	  
1.3  BBB  development  and  specialization:  the  role  of  canonical  Wnt/β-­‐‑catenin  pathway  .............  37	  
1.4  Fibroblast  Growth  Factor  Binding  Protein  1  (FGFBP1)  ........................................................  42	  
1.5  Aim  of  the  work  .......................................................................................................................  46	  
2.  MATERIALS  AND  METHODS  ...............................................................................................  49	  
2.1  Sequence  aligments  and  phylogenetic  tree  construction  ........................................................  49	  
2.2  Animals  ...................................................................................................................................  49	  
2.3  Mouse  genotyping  ...................................................................................................................  50	  
2.4  Preparation  and  culture  of  bMECs  .........................................................................................  52	  
2.5  Morpholino  microinjections  ....................................................................................................  52	  
2.6  Cell  dissociation  and  sorting  from  zebrafish  embryos  ............................................................  53	  
2.7  Semiquantitative  RT-­‐‑PCR  ......................................................................................................  54	  
2.8  Whole-­‐‑mount  In  Situ  Hybridization  ......................................................................................  54	  
2.9  O-­‐‑dianisidine  staining  ............................................................................................................  55	  
2.10  In  vivo  permeability  assays  ...................................................................................................  55	  
2.11  Tamoxifen  treatment  .............................................................................................................  56	  
2.12  Immunofluorescence  (IF)  analysis  of  brains  and  retinas  ......................................................  56	  
2.13  Transmission  electron  microscopy  ........................................................................................  57	  
6	  
	  
2.14  RNA  interference  ..................................................................................................................  58	  
2.15  Affymetrix  analysis  ...............................................................................................................  58	  
2.16  Immunofluorescence  (IF)  analysis  of  cells  ............................................................................  59	  
2.17  Quantitative  Real  Time  RT-­‐‑PCR  (qRT-­‐‑PCR)  .....................................................................  59	  
2.18  Western  blot  analysis  ............................................................................................................  60	  
2.19  Antibodies  and  reagents  .......................................................................................................  60	  
2.20  Quantifications  .....................................................................................................................  61	  
2.21  Statistical  analysis  ................................................................................................................  62	  
3.  RESULTS  .....................................................................................................................................  63	  
3.1   Fgfbp1   expression   is   regulated   by   canonical  Wnt/β-­‐‑catenin   pathway   both   in   vitro   and   in  
vivo  ................................................................................................................................................  63	  
3.1.1  Fgfbp1  expression  is  upregulated  by  Wnt3a  treatment  in  primary  brain  ECs  ....  63	  
3.1.2  Fgfbp1  expression  is  upregulated  in  brain,  but  not  lung,  ECs  in  a  murine  model  
of  β-­‐‑catenin  gain-­‐‑of-­‐‑function  ................................................................................................  63	  
3.1.3  Fgfbp1  is  upregulated  by  Wnt  pathway  activation  in  a  zebrafish  model  ............  66	  
3.2  Characterization  of  Fgfbp1  expression  and  function  in  the  zebrafish  model  ..........................  68	  
3.2.1  Fgfbp1a  and  b  are  differentially  expressed  during  zebrafish  development  ........  68	  
3.2.2  Fgfbp1a  and  b  knock  down  in  vivo  causes  brain  hemorrhages  in  zebrafish  .......  70	  
3.2.3   Fgfbp1a   and   b   knock   down   in   vivo   causes   defects   in   zebrafish   vascular  
development  ...........................................................................................................................  73	  
3.2.4  Fgfbp1a  knock  down  in  vivo  causes  increased  vascular  permeability  in  zebrafish  
brains  .......................................................................................................................................  78	  
3.3  Characterization  of  Fgfbp1  expression  and  function  in  the  murine  brain  vasculature  ..........  79	  
3.3.1  FGFBP1  is  expressed  age-­‐‑dependently  and  is  localized  perivascularly  ...............  79	  
3.3.2  Fgfbp1  endothelial-­‐‑specific  knock  out  causes  vascular  abnormalities  in  brain  and  
retinas  ......................................................................................................................................  83	  
3.3.3   Fgfbp1  ECKO  mice   show   alterations   in   the   ultrastructural   organization   of   the  
NVU  .........................................................................................................................................  88	  
3.3.4  Fgfbp1  ECKO  brain  vasculature  displays  defects   in  pericyte   coverage  and  BM  
composition  ............................................................................................................................  89	  
3.3.5  Fgfbp1  ECKO  mice  present  increased  BBB  permeability  .....................................  104	  
7	  
	  
3.3.6  Endothelial  Fgfbp1  knock  out  does  not  alter  BBB  molecular  signature  .............  109	  
3.4   Characterization   of   FGFBP1   expression   and   function   in   murine   primary   brain   ECs  
(bMECs)  ......................................................................................................................................  111	  
3.4.1  FGFBP1  is  effectively  downregulated  in  vitro  by  siRNA  ......................................  111	  
3.4.2  Fgfbp1  knockdown  does  not  affect  the  autocrine  activity  of  FGF-­‐‑2  ....................  113	  
3.4.3  Fgfbp1  knockdown  induces  a  tip  cell-­‐‑like  phenotype  in  vitro  ..............................  114	  
3.4.4  Fgfbp1  knockdown  causes  the  upregulation  of  Plvap  in  vitro  .............................  116	  
3.4.5   Fgfbp1   knock   down   in   bMECs   causes   alterations   in   the   response   to   Wnt3a  
treatment  ...............................................................................................................................  119	  
4.  DISCUSSION  ............................................................................................................................  127	  
4.1   Fgfbp1a   and   b   expression   and   function   in   zebrafish:   different   specializations   after   the  
evolutionary  divergence  of  the  two  paralogues  ...........................................................................  128	  
4.2  The  glial  barrier:  an  astrocyte  reaction  to  endothelial  barrier  impairment  ...........................  131	  
4.3  Pericyte  decrease  and  BM  rearrangements:  a  “chicken  or  egg”  situation  ............................  132	  
4.5   Small   vessel   disease   (SVD):   a   link   between   FGFBP1,   Collagen   IV   and   increased   cerebral  
hemorrhage  susceptibility  ...........................................................................................................  135	  
4.6  FGFBP1:  a  novel  regulator  of  Wnt  activity?  ........................................................................  136	  
4.7  Concluding  remarks  ..............................................................................................................  138	  
BIBLIOGRAPHY  ..........................................................................................................................  139	  






LIST  OF  ABBREVIATIONS  
     
ABC:  ATP-­‐‑binding  cassette  
ADAM-­‐‑TS:  a  disintegrin-­‐‑like  and  metalloproteinase  with  thrombospondin  motif  
AJ:  adherens  junction  
Alk:  activin  receptor-­‐‑like  kinase  
AMT:  adsorptive-­‐‑mediated  transcytosis  
APC:  adematous  poliposis  coli  
Aqp4:  aquaporin  4  
β-­‐‑TrCP:  β-­‐‑transducin  repeat  containing  protein  
BBB:  blood  brain  barrier  
BM:  basament  membrane  
bMEC:  brain  murine  endothelial  cell  
BMPR1A:  bone  morphogenetic  protein  receptor  type  1  
CAM:  chorioallantoic  membrane  
Cer:  cerberus  
CK1:  casein  kinase  1  
CNS:  central  nervous  system  
CSF:  cerebrospinal  fluid  
CYP:  cytochrome  P450    





DLAV:  dorsal  longitudinal  anastomotic  vessel  
Dll4:  delta-­‐‑like  4  
dpc:  days  post  coitum  
dpn:  days  post  natal  
Dvl:  dishevelled  
EC:  endothelial  cell  
ECGS:  endothelial  cell  growth  supplement  
ECKO:  endothelial  cell-­‐‑specific  knock  out  
ECM:  extracellular  matrix  
ESM-­‐‑1:  endothelial  specific  molecule  1  
FCS:  fetal  calf  serum  
FGF:  fibroblast  growth  factor  
FGFBP1:  fibroblast  growth  factor  binding  protein  1  
FrzB:  frizzled-­‐‑related  protein  
Fw:  forward  
GFP:  green  fluorescent  protein  
GLUT1:  glucose  transporter  1  
GOF:  gain  of  function  
GSK3β:  glycogen  synthase  kinase  3  β  
HBp17:  heparin-­‐‑binding  protein  17  kDa  
hpf:  hours  post  fertilization  
HSPG:  heparan  sulfate  proteoglycan  
HRP:  horseradish  peroxidase  
11	  
	  
Icam1:  intercellular  adhesion  molecule  1  
ICH:  intracerebral  hemorrhage  
IF:  immunofluorescence  
IGFBP3:  insulin  growth  factor  binding  protein  3  
ISV:  intersomitic  vessel  
LAM:  leukocyte  adhesion  molecule  
LEF:  lymphocyte  enhancer  factor  
LMP:  low  melting  point  
LRP:  lipoprotein  receptor-­‐‑related  protein  
MMP:  matrix  metalloprotease    
MO:  morpholino  
MS:  multiple  sclerosis  
NC1:  non-­‐‑collagenous  domain  1  
NSDT-­‐‑1:  N-­‐‑deacetylase/N-­‐‑sulfotransferase  1  
N-­‐‑cadherin:  neuronal  cadherin  
NVU:  neurovascular  unit  
Plvap:  plasmalemmal  vesicle-­‐‑associated  protein  
PDGF-­‐‑B:  platelet  derived  growth  factor  B  
PDGFRβ:  platelet  derived  growth  factor  receptor  β  
PFA:  paraformaldehyde  
qRT-­‐‑PCR:  quantitative  reverse  transcriptase  polimerasi  chain  reaction  
RMT:  receptor-­‐‑mediated  transcytosis  




SCC:  squamous  cell  carcinoma  
SLC:  small  solute  carrier  
Shh:  sonic  hedgehog  
SNP:  single  nucleotide  polymorphism  
SVD:  small  vessel  disease  
TCF:  T-­‐‑cell  factor  
TEER:  transendothelial  electrical  resistance  
TGFβ:  transforming  growth  factor  β  
TJ:  tight  junction  
Vcam1:  vascular  cell  adhesion  molecule  1  
VE-­‐‑cadherin:  vascular  endothelial  cadherin  
VEGF:  vascular  endothelial  growth  factor  
VEGFR:  vascular  endothelial  growth  factor  receptor  
vSMC:  vascular  smooth  muscle  cell  
WB:  western  blot  
WIF-­‐‑1:  Wnt  inhibitory  factor  1  
WT:  wild  type  
ZO:  zonula  occludens  





Figure  1.  Barriers  of  the  brain  .......................................................................................................  20	  
Figure  2.  Tight  Junctions  and  Adherens  Junctions  in  Endothelial  Cells  ................................  23	  
Figure  3.  Routes  for  permeation  and  transport  across  the  BBB  ...............................................  25	  
Figure  4.  Organization  of  the  neurovascular  unit  (NVU)  ........................................................  27	  
Figure  5.  Pericyte  ultrastructure  ..................................................................................................  28	  
Figure   6.   Molecular   pathways   regulating   pericyte   recruitment,   differentiation   and  
vascular  stabilization  .....................................................................................................................  32	  
Figure  7  -­‐‑  Development  of  the  BBB  .............................................................................................  38	  
Figure  8.  The  canonical  Wnt/β-­‐‑catenin  pathway  .....................................................................  41	  
Figure  9.  Structure  of  the  human  FGFBP1  ..................................................................................  44	  
Figure  10.  Mechanism  of  action  of  FGFBP1  ...............................................................................  46	  
  
RESULTS  
Figure  11.  Analysis  of  Fgfbp1  and  Axin-­‐‑2  expression  in  lung  and  brain  ECs  in  a  β-­‐‑catenin  
gain-­‐‑of-­‐‑function  model  ..................................................................................................................  65	  
Figure  12.  Analysis  of  Fgfbp1  expression  in  lung  and  brain  ECs  of  1  week  old  and  3  weeks  
old  mice  ...........................................................................................................................................  66	  
Figure  13.  Analysis  of  Fgfbp1a  and  b  expression  upon  Wnt  signaling  activation  ...............  68	  
Figure  14.  Kinetics  of  expression  of  Fgfbp1a  and  b  in  zebrafish  during  development  .......  69	  
Figure  15.  Localization  of  Fgfbp1a  and  b  during  zebrafish  development  .............................  70	  
Figure  16.  Design  and  testing  of  morpholinos  targeting  Fgfbp1a  and  b  ...............................  72	  
Figure  17.  Quantification  of  the  hemorrhagic  phenotype  in  Fgfbp1a  and  b  morphants  .....  73	  
Figure   18.  Analysis   of   the   trunk  vascular   development   in   zebrafish  upon  Fgfbp1   knock  
down  ................................................................................................................................................  75	  
Figure   19.   Analysis   of   the   head   vascular   development   in   zebrafish   upon   Fgfbp1   knock  
down  ................................................................................................................................................  76	  
Figure   20.   Time   lapse   confocal  microscopy   analysis   of   the   brain   vascular   phenotype   of  
Fgfbp1a  and  Fgfbp1b  morphants  .................................................................................................  77	  
Figure  21.  In  vivo  permeability  assay  on  Tg(fli1a:EGFP)  morphants  ....................................  79	  
Figure  22.  Design  of  the  Fgfbp1flox/flox/VEC-­‐‑PAC  transgenic  mouse  model  ...........................  80	  
14	  
	  
Figure  23.    Analysis  of  Fgfbp1  expression  in  brain  ECs  of  Fgfbp1  WT  and  ECKO  mice  at  1  
and  3  weeks  of  age  .........................................................................................................................  81	  
Figure  24.  Analysis  of  FGFBP1  protein  localization  in  brain  vasculature  .............................  82	  
Figure   25.  Analysis   of   EYFP   expression   in   Fgfbp1flox/flox/VEC-­‐‑PAC/R26-­‐‑EYFP   1  week   old  
mice  upon  tamoxifen  injection  .....................................................................................................  83	  
Figure  26.  Vascular  phenotype  of  Fgfbp1  WT  and  ECKO  embryos  .......................................  84	  
Figure   27.   Analysis   of   brain   vasculature   in   Fgfbp1   WT   and   ECKO   mice   at   different  
postnatal  ages  .................................................................................................................................  85	  
Figure   28.   Analysis   of   retinal   vasculature   in   Fgfbp1   WT   and   ECKO   mice   at   different  
postnatal  ages  .................................................................................................................................  87	  
Figure   29.   Electron   microscopy   analysis   of   ultrastructural   organization   of   the   NVU   in  
Fgfbp1  WT  and  ECKO  mice  .........................................................................................................  89	  
Figure  30.  Quantification  of  pericytes  number  in  Fgfbp1  WT  and  ECKO  mice  at  different  
ages  ...................................................................................................................................................  90	  
Figure  31.  Analysis  of  the  pericyte  phenotype  in  Fgfbp1  WT  and  ECKO  mice  at  different  
ages  ...................................................................................................................................................  92	  
Figure  32.  Analysis  of  astrocyte  endfeet  polarization  by  aquaporin  IV  immunostaining  ..  93	  
Figure  33.  Analysis  of  collagen  IV  expression  and  coverage  in  Fgfbp1  WT  and  ECKO  mice  
at  different  ages  ..............................................................................................................................  95	  
Figure  34.  Analysis  of  collagen  IV  α1  chain  (Col4a1)  expression  and  coverage  in  Fgfbp1  
WT  and  ECKO  mice  at  different  ages  .........................................................................................  96	  
Figure  35.  Analysis  of  collagen  IV  α2  chain  (Col4a2)  expression  and  coverage  in  Fgfbp1  
WT  and  ECKO  mice  at  different  ages  .........................................................................................  97	  
Figure  36.  Analysis  of  laminin  α4  expression  and  coverage  in  Fgfbp1  WT  and  ECKO  mice  
at  different  ages  ..............................................................................................................................  98	  
Figure  37.  Analysis  of  laminin  α5  expression  and  coverage  in  Fgfbp1  WT  and  ECKO  mice  
at  different  ages  ............................................................................................................................  100	  
Figure  38.  Analysis  of  laminin  α2  expression  and  coverage  in  Fgfbp1  WT  and  ECKO  mice  
at  different  ages  ............................................................................................................................  101	  
Figure   39.  Analysis   of   expression  of   endothelial-­‐‑derived  BM  components   in   1  week  old  
and  3  weeks  old  Fgfbp1  WT  and  ECKO  mice  .........................................................................  103	  
Figure  40.  Analysis  of  BBB  permeability  by  quantification  of  Alexa555-­‐‑cadaverine  leakage
  ........................................................................................................................................................  104	  
15	  
	  
Figure   41.   Analysis   of   correlation   between   increased   BBB   permeability   and   TJs  
organization  ..................................................................................................................................  105	  
Figure   42.   Analysis   of   correlation   between   increased   BBB   permeability   and   TJs  
organization  ..................................................................................................................................  106	  
Figure  43.  Analysis  of  IgG  leakage  in  Fgfbp1  WT  and  ECKO  brains  ...................................  108	  
Figure  44.  Correlation  between  IgG  leakage  and  Plvap  expression  in  Fgfbp1  ECKO  mice
  .........................................................................................................................................................  109	  
Figure  45.  Analysis  of  BBB  molecular  signature  in  1  week  old  and  3  weeks  old  Fgfbp1  WT  
and  ECKO  mice  ............................................................................................................................  110	  
Figure  46.  Analysis  of  Fgfbp1  expression  in  bMECs  upon  transfection  with  three  different  
siRNAs  ...........................................................................................................................................  112	  
Figure   47.   Analysis   of   FGFBP1   protein   expression   and   localization   in   bMECs   upon  
transfection  with  siFGFBP1#2  ....................................................................................................  113	  
Figure   48.  Analysis   of   FGF-­‐‑2-­‐‑   induced   p42/p44  MAPK  phosphorylation   in   bMECs   after  
Fgfbp1  siRNA  treatment  .............................................................................................................  114	  
Figure   49.   Analysis   of   tip-­‐‑cell   markers   expression   in   bMECs   upon   transfection   with  
Fgfbp1  siRNA  ...............................................................................................................................  115	  
Figure  50.  Analysis  of  Wnt3a-­‐‑treated  bMECs  morphology  in  a  wound-­‐‑healing  assay  upon  
Fgfbp1  siRNA  ...............................................................................................................................  116	  
Figure   51.   Analysis   of   claudin-­‐‑5,   claudin-­‐‑3   and   Plvap   expression   and   localization   in  
bMECs  upon  Fgfbp1  siRNA  transfection  .................................................................................  118	  
Figure   52.   Graphical   representation   of   the   differential   response   to   Wnt3a   treatment   in  
siCTRL-­‐‑treated  cells  and  siFgfbp1#2-­‐‑treated  cells  ..................................................................  120	  
  
DISCUSSION  
Figure   53.   Proposed   model   for   pericyte   deficiency   and   BM   impairment   in   brain  
vasculature  of  Fgfbp1  ECKO  mice  .............................................................................................  135	  
	  
	  




The  Blood  Brain  Barrier  (BBB)  is  a  highly  specialized  vascular  structure  whose  aim  
is   to   tightly   regulate   the   permeability   between   the   blood   flow   and   the   Central  
Nervous  System  (CNS).  To  this  purpose,  the  ECs  in  the  brain  need  to  present  some  
peculiar   features:   the   presence   of   high-­‐‑resistance   tight   junctions   (TJs)   to   block  
paracellular   permeability,   the   lack   of   fenestrations,   and   the   expression   of   some  
specific  transmembrane  transporters  to  selectively  allow  the  entrance  of  nutrients  
and   the   exit   of   toxic   metabolites.   The   high   level   of   specialization   of   the   brain  
microvasculature   is   obtained   as   a   result   of   the   interaction   of   the   endothelial  
compartment   with   the   other   components   of   the   so-­‐‑called   NeuroVascular   Unit  
(NVU),  such  as  the  Basement  Membrane  (BM),  pericytes  and  astrocyte  end-­‐‑feet.    
The  canonical  Wnt/β-­‐‑catenin  pathway,  that  is  specifically  activated  in  CNS  vessels  
during   development,   regulates   BBB   initiation   and   maintenance.   Moreover,  
inactivation  of  this  pathway  in  vivo  leads  to  angiogenic  defects  in  the  CNS  and  not  
in  other  vascular  regions.    
Affymetrix   analysis  previously  performed   in  our  group  provided  a   list   of   genes  
whose   transcription   is   selectively   regulated   upon  Wnt3a   stimulation   in   murine  
primary  ECs  isolated  from  brain  (bMEC).  One  of  the  most  upregulated  transcripts  
is  that  of  Fibroblast  Growth  Factor  Binding  Protein  1  (FGFBP1)  gene.    
FGFBP1   is   a   cargo   protein   that,   after   being   secreted   in   the   extracellular   matrix  
(ECM),   is   able   to   non-­‐‑covalently   bind   the   FGF   immobilized   in   the   ECM   and   to  
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mobilize   it,   protecting   it   from   degradation   and   presenting   it   to   FGF   tyrosine-­‐‑
kinase  receptor  on  the  cell  membrane.  
Given  the  capability  of  Wnt3a  stimulation  to  selectively  induce  FGFBP1  expression  
in  brain  ECs,  we  hypothesized  that  this  protein  could  be  involved  in  the  process  of  
initiation  and/or  maturation  of  the  BBB.  
In   this  work,  we  demonstrate   in  vivo   in   the   zebrafish  model   that  FGFBP1  knock  
down   by   morpholino   presents   vascular   abnormalities   in   the   brain   and   in   the  
trunk,   together   with   cerebral   hemorrhages   and   impaired   permeability.   Taking  
advantage  of  the  endothelial-­‐‑specific  FGFBP1  knock  out  murine  model,  we  further  
demonstrate   that   inhibition   of   endothelial   FGFBP1   expression   affects   brain  
vascular   development,   causing   vascular   defects   and   increased   BBB  permeability  
and   also   influencing   the   number   of   pericytes   and   the   composition   of   the   BM.  
Finally,  we   show   in   vitro   that   FGFBP1   absence   promotes   a   “tip-­‐‑like”   phenotype  
and  an  increase  in  the  expression  of  Plvap  in  bMECs.  
In  conclusion,  our  work  proposes  a  novel  role  for  FGFBP1  in  the  maintenance  of  
the  properties  of  the  BBB  and  in  the  regulation  of  the  complex  interactions  of  the  





1.1  The  Blood  Brain  Barrier  (BBB)  
The   brain   is   the   most   complex   organ   of   the   human   body,   with   a   constant  
metabolic   request   of   oxygen   and   nutrients   corresponding   to   20%   of   the   whole  
metabolic   reserves   of   the   organism   [1].   Moreover,   the   central   nervous   system  
(CNS)  relies  for  its  function  on  a  complex  series  of  chemical  and  electric  signals  to  
modulate   cell-­‐‑to-­‐‑cell   communication   in   a   much   broader   and   intricate   network.  
Most   of   these   signals   require   changes   in   the   flux   of   ions   across   the   neuronal  
membrane,   generating   a   variation   in   the   electric   potential   of   the   cell   that   in  
absence  of   stimuli   is  maintained  stable  by  a  basal   ionic   current.  External   factors,  
such  as  food  intake  and  physical  activity,  can  physiologically  result  in  fluctuations  
of   blood   ionic   composition,   therefore   affecting   also   the   composition   of   the  
extracellular   fluids  bathing   the  neurons.  To   limit   the   extent  of   these   fluctuations  
and   to  guarantee   the   required  oxygen  and  nutrients   supply,   a   strict  homeostatic  
control   is   required   [2].   In   the   CNS,   this   homeostatic   regulation   is   provided   by  
three  different  layers,  acting  as  physical  barriers  to  the  passage  of  ions  and  other  
solutes   from   the   blood   to   the   cerebral   parenchyma:   a)   the   brain   microvascular  
endothelium;   b)   the   choroid   plexus,   the   ependymal   covering   of   the   brain  
ventricles,  responsible  for  the  secretion  of  the  cerebrospinal  fluid  (CSF);  and  c)  the  
arachnoid  epithelium,  the  middle   layer  of   the  meninges  forming  the  outer   lining  




Figure  1.  Barriers  of  the  brain  
Within  the  brain,  three  different  barrier  sites  exist:  a)  the  blood  brain  barrier  (BBB),  formed  by  the  
endothelial   cells   of   the   brain   microvasculature;   b)   the   blood-­‐‑CSF   barrier   at   the   choroid   plexus,  
formed   by   the   epithelial   cells   of   the   plexus   in   the   brain   ventricle;   and   c)   the   arachnoid   barrier,  
formed  by   the  arachnoid   cells   in   the   subdural   space.  ECF:   extracellular   fluid;  CSF:   cerebrospinal  
fluid.    
(Adapted  from  Abbott  N.J.,  J  Inherit  Metab  Dis  2013)  
  
Of  the  three  barriers,  the  endothelial  layer  (also  referred  to  as  blood  brain  barrier  -­‐‑  
BBB)  is  the  major  responsible  for  the  homeostatic  control  of  brain  permeability  and  
for   the   exchange  of  molecules  between   the  blood   flow  and   the  CNS:   indeed   the  
BBB  represents  the  broader  interface  between  the  vascular  system  and  the  nervous  
system,  with  an  average  surface  of  12-­‐‑20  m2  in  the  human  brain,  and  it  ensures  the  
21	  
	  
shortest  diffusion  distance  between   the  blood  and  neurons   (the  average  distance  
between  a  microvascular  branch  and  a  single  neuron  spans  from  8  to  25  µμm)  [4].  
Thanks  to  these  features,  the  BBB  stands  in  an  optimal  position  to  fulfill   its  main  
functions  that  are:  
1)   to   regulate   the   traffic   of   solutes,   allowing   the   entrance   of   nutrients   from   the  
blood  and  preventing  the  entrance  of  toxic  molecules;  
2)  to  maintain  the  ionic  homeostasis  necessary  for  a  proper  neuronal  function;  
3)  to  provide  immune  surveillance  and  to  limit  inflammation  and  cell  damage  [2].  
To  accomplish  these  tasks,  the  endothelial  cells  (ECs)  in  the  brain  need  to  present  
some  important  features:  organization  of  high-­‐‑resistance  cell-­‐‑to-­‐‑cell  tight  junctions  
(TJs)   to   block   the   paracellular   permeability,   lack   of   fenestrations   and   very   low  
rates   of   pinocytosis/transcytosis   to   limit   the   transcellular   passage   of   molecules,  
expression   of   specialized   transmembrane   transporters   to   provide   the   brain  
parenchyma  with  nutrients  and   low  expression  of   leukocyte  adhesion  molecules  
(LAMs)  to  avoid  the  passage  of  leukocytes  from  the  blood  flow  to  the  brain  tissue  
[5,  6].  
  
1.1.1  Endothelial  junctions  
One  of  the  most  distinctive  and  extensively  investigated  features  of  the  BBB  is  the  
presence   of   very   strong   and   well-­‐‑organized   cell-­‐‑to-­‐‑cell   endothelial   junctions  
(Fig.2).  Endothelial  junctions  are  formed  by  two  different  types  of  structures,    the  
tight   junctions  (TJs)  and  the  adherens   junctions  (AJs),  that  are  both  composed  by  
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transmembrane   proteins   tipically   engaged   in   homophilic   interactions   and  
connected  to  the  intracellular  actin  cytoskeleton  [7].    
The  major  components  of  the  TJs  are  the  claudins.  More  than  20  different  claudins  
exist   in  mammals,   but  only   few  of   them  seem   to  be   expressed  by  brain  ECs   [8].  
Claudin  5  is  the  most  abundant  claudin  in  endothelial  junctions;  although  claudin  
5   is   ubiquitously   expressed   along   the   vascular   tree,   it   appears   to  play   a   specific  
role  at  the  BBB:  indeed,  claudin  5  deficient  mice  die  at  birth  due  to  BBB  leakiness  
to   small   molecules   [9].   Claudin   3   and   claudin   12   have   also   been   identified   as  
specific   components   of   the   brain   endothelial   junctions,   but   their   contribution   to  
BBB   physiology   is   still   not   clear   [10,   11].   Together   with   the   claudins,   other  
transmembrane   molecules,   such   as   occludin   and   junctional   adhesion   molecules  
(JAMs),  contribute  to  the  formation  of  the  TJ  [12].  On  the  cytoplasmic  side,  these  
proteins  are  associated  to  other  proteins,  such  as  zonula  occludens  (ZO)  proteins  
ZO-­‐‑1   and   ZO-­‐‑2,   cingulin   and   ZO-­‐‑1-­‐‑associated   nucleic   acid-­‐‑binding   protein  
(ZONAB),  that  link  the  TJs  to  the  actin  cytoskeleton,  to  the  adherens  junctions  and  
to  the  polarity  complexes  [13].  
Cell-­‐‑to-­‐‑cell   adhesion   at   AJs   is   mediated   by   proteins   belonging   to   the   cadherin  
family:   in   particular,   in   the   BBB   (as   in   the   rest   of   the   vascular   tree)   the   main  
cadherin   present   is   the   endothelial   selective   vascular   endothelial   cadherin   (VE-­‐‑
cadherin),  that  form  the  AJs  between  endothelial  cells,  and  the  neuronal  cadherin  
(N-­‐‑cadherin),   that   mediates   the   EC-­‐‑pericyte   interaction   [7,   14].   Intracellularly,  
these  proteins  bind  to  members  of  the  catenin  family,  such  as  β-­‐‑catenin,  p120  and  
plakoglobin,   that   link   them   to   actin-­‐‑binding   proteins,   like   α-­‐‑catenin,   finally  
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mediating   the   interaction   between  AJs   and   the   cytoskeleton   that   is   necessary   to  
maintain  the  cell  shape  and  polarity  [7].    
In   the   context   of   brain   endothelium,   the   strict   control   of   permeability   is  mainly  
operated  by  TJs,  that  can  restrict  the  paracellular  flux  of  small  molecules  and  ions;  
however,  AJs   have   an   important   role   in   TJ   assembly,   since   it   has   been   reported  
that  VE-­‐‑cadherin   expression   and   clustering   between   neighboring   cells   is   able   to  
induce  the  upregulation  of  the  TJ  component  claudin-­‐‑5  [15].  
  
Figure  2.  Tight  Junctions  and  Adherens  Junctions  in  Endothelial  Cells  
TJs   are  mainly   formed  by  members  of   the   claudin   family   (in   the  BBB  endothelium,   claudin-­‐‑3,   -­‐‑5  
and   -­‐‑12),   associated   to   some   intracellular   partners   like   ZO   proteins.   AJs   in   the   endothelium   are  
formed   by   the   transmembrane   VE-­‐‑cadherin,   whose   intracellular   domain   binds   members   of   the  
catenin   protein   family,   such   as   β-­‐‑catenin,   plakoglobin   and   p120,  mediating   the   interaction  with  
actin  binding  proteins  such  as  α-­‐‑catenin.    







1.1.2  Molecular  transport  
At  the  level  of  the  BBB  endothelium,  the  passage  of  gaseous  molecules,  such  as  O2  
and  CO2,  and  of  small  lipophilic  compounds  occurs  via  passive  diffusion  through  
the  lipidic  layers  of  the  cell  membrane.    
Transmembrane   transporters   belonging   to   the   family   of   solute   carrier   (SLC)  
proteins   are   embedded   in   both   apical   and   basal  membranes   of   the   ECs   and   are  
responsible   for   the   influx   of   ions,   glucose,   aminoacids   and   other   essential  
molecules,  and  for  the  efflux  of  waste  products  [16].  Among  these  carriers,  of  great  
relevance   is   the   glucose   transporter  GLUT1,   encoded  by   the  Slc2a1   gene,  whose  
expression   is   induced   by   Wingless-­‐‑Int   (Wnt)   signaling   [17,   18]   and   whose  
deficiency  leads  to  epilepsy  [19].    
In   addition,   members   of   another   class   of   transmembrane   proteins,   the   ATP-­‐‑
binding  cassette   (ABC)   transporters,  are  mainly   inserted   in   the  apical  membrane  
and  act  by  regulating  the  efflux  of  toxic  compounds  potentially  coming  from  the  
environment.   This   line   of   defense   is   completed   by   the   presence   of   a   series   of  
metabolizing  enzymes,  mainly  belonging   to   the   cytochrome  P450   family   (CYPs),  
that  are  able  to  metabolize  any  toxic  molecule  that  eventually  escapes  the  efflux  by  
the  ABC  transporters  [20].  
Larger   molecules,   such   as   peptides   and   proteins,   gain   access   to   the   brain  
parenchyma   mainly   by   vesicular   mechanisms   of   transcytosis,   both   receptor-­‐‑
mediated   (RMT)   and   adsorptive-­‐‑mediated   (AMT).   The   number   of   endocytic  
vesicles  in  the  brain  ECs  is  normally  kept  quite  low  by  mechanisms  that  still  need  
to   be   clarified;   interestingly,   the   increase   in   transcytosis   rates   is   the   first   change  
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occurring   during   brain   hypoxia   and   one   of   the   first   hallmarks   of   endothelial  
damage  during  stroke,  brain  injury  and  other  pathological  conditions  [4].  
A  diagram  summarizing  the  possible  routes  of  access  across  the  BBB  is  reported  in  
Figure  3.  
  
Figure  3.  Routes  for  permeation  and  transport  across  the  BBB  
Non-­‐‑polar  solutes  and  small  lipidic  solutes  may  passively  cross  the  endothelium  and  eventually  be  
intercepted   by   active   efflux   carriers   that   will   pump   these   solutes   out   of   the   EC.   Small   polar  
molecules,   such   as   glucose   and   amino   acids,   can   enter   the  CNS   through   specific   influx   carriers.  
Macromolecules   like   peptides   and   proteins   are   transported   across   the   endothelium   by   receptor-­‐‑
mediated  transcytosis  (RMT),  while  the  adsorptive-­‐‑mediated  transcytosis  (AMT)  is  non-­‐‑specifically  
induced  by  positively  charged  macromolecules.  
(Adapted  from  Abbott  N.J.,  J  Inherit  Metab  Dis  2013)  
     
1.1.3  Leukocyte  adhesion  
Leukocyte   entry   into   tissues   is   a   multistep   process   largely   mediated   by   the  
expression  on  the  endothelium  of  specific  LAMs:  molecules  like  E-­‐‑selectin  and  P-­‐‑
selectin  mediate   the   initial   rolling  adhesion  of   the   leukocyte   to   the  endothelium,  
while   the   subsequent   firm   adhesion   step   is   mainly   mediated   by   intercellular  
adhesion   molecule   1   (Icam1)   and   vascular   cell   adhesion   molecule   1   (Vcam1),  
allowing  the  final  transmigration  of  the  leukocyte  [21].  While  these  molecules  are  
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highly  expressed  in  all  peripheral  vascular  districts,  their  expression  is  very  poor  
in  the  healthy  CNS  endothelium;  however,  during  the  inflammation  processes  that  
occur  in  the  CNS  when  affected  by  diseases  like  stroke  or  multiple  sclerosis  (MS),  
the  expression  of  these  molecules  can  be  upregulated  [21,  22].  
In   addition   to   LAMs,   also   plasmalemmal   vesicle-­‐‑associated   protein   (Plvap),   a  
protein   already   known   to   be   involved   in   fenestrae   formation   and   endocytic  
uptake,  has  been  reported   to  be  associated  with   leukocyte   trafficking   [23,  24];  as  
for   LAMs,   also   Plvap   expression   is   normally   low   in   the   brain   ECs   compared   to  
peripheral  ECs,  while  it  is  upregulated  in  the  BBB  in  pathological  conditions  [25].  
  
1.2  Cellular  and  extracellular  components  of  the  NeuroVascular  Unit  
Although  most  of  the  properties  of  the  BBB  are  manifested  within  the  endothelial  
compartment,   the   high   level   of   specialization   of   the   brain   microvasculature   is  
obtained   as   a   result   of   the   interaction   of   the   ECs   with   other   cell   types   (i.e.  
pericytes,  astrocytes)  and  with  the  basement  membrane  (BM)  [26].  Due  to  the  strict  
interaction   and   interdependency   of   all   these   cellular   and   extracellular   elements,  
they  are  often  referred   to  as  a  whole  anatomical  and  functional  complex,  named  
neurovascular  unit   (NVU)   [27].   The  different   components   of   the  NVU  and   their  
contribution   to   the   BBB   physiology   are   represented   in   Figure   4   and   will   be  




Figure  4.  Organization  of  the  neurovascular  unit  (NVU)  
In   the   CNS,   vessels   forming   the   BBB   interact  with   pericytes,   astrocytes   and   the   basal   lamina   to  
create  an  anatomically  and  functionally  integrated  platform  named  neurovascular  unit  (NVU).  
(Adapted  from  Abbott  NJ  et  al.,  Front.  Pharmacol.  Conference  2010)  
  
1.2.1  Pericytes  
The   currently   accepted   definition   of   pericyte   is   “a   cell   embedded   within   the  
vascular  BM”  [28].  Pericytes  are  not  to  be  confused  with  vascular  smooth  muscle  
cells   (vSMCs):   indeed,  despite   their   similar  perivascular   location  and   the   lack  of  
univocal   molecular   markers   to   clearly   distinguish   the   ones   from   the   others,  
pericytes   surround   the   endothelium   around   capillaries,   while   vSMCs   surround  
mainly  small  arteries,  arterioles  and  venules  [29].  
Pericytes  have  a  quite  rounded  soma,  generally  located  at  the  capillaries  branching  
points,   giving   rise   to  primary  processes   extending   in   the   length  of   the   capillary;  
from   the   primary   processes   and   perpendicularly   to   them,   some   secondary  
processes  rise  that  partially  encircle  the  vessel  [29].    
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From  an  ultrastractural  point  of  view,  most  of  the  endothelium-­‐‑pericyte  interface  
is   separated   by   the   BM,   except   at   some  points,  where   they   can  make   contact   in  
different   ways:   1)   through   “peg-­‐‑socket”   contacts,   where   pericytes   cytoplasmic  
protrusions,   called   “pegs”,   are   inserted   into   endothelial   invaginations,   called  
“sockets”  [30];  2)  through  the  “adhesion  plaques”,  ultrastructurally  similar  to  the  
AJ,  where  N-­‐‑cadherin-­‐‑based  connections  are  formed  [31];  3)  through  gap-­‐‑junction-­‐‑
like  structures  [32]  (Fig.5).  
  
Figure  5.  Pericyte  ultrastructure  
Pericytes  (P)  are  ensheathed  within  the  BM  (pink),  that  they  share  with  the  endothelial  cell  (E).  The  
BM  is  interrupted  at  some  points,  where  the  two  cell  types  get  directly  in  contact  through  the  “peg-­‐‑
socket”  contacts  or  through  the  adhesion  plaques.  
(Adapted  from  Armulik  A.  et  al.,  Dev  Cell  2011)  
  
With   a   1:1-­‐‑3:1   ratio   between   ECs   and   pericytes,   the   CNS   vasculature   is   the  
vascular   district   with   the   highest   pericyte   coverage   [28,   33].   Pericytes   enter   the  
brain  during  angiogenesis  at  the  same  time  as  ECs,  and  the  maturation  of  the  two  
cell   types   is  very  strongly   interdependent,  since  defects   in   the  maturation  of  one  
cell  type  is  able  to  cause  defects  in  the  other,  and  vice  versa  [34].    
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Pericyte   development   and   their   interaction   with   the   ECs   relies   on   several  
paracrine  and   juxtacrine  signaling  routes;  only   the  main  signaling  pathways  will  
be   discussed   below,   but   a   more   comprehensive   description   is   schematically  
represented  in  Figure  6:  
- Platelet   Derived   Growth   Factor   B   (PDGF-­‐‑B)/   Platelet   Derived   Growth  
Factor  Receptor  β  (PDGFRβ):  
PDGF-­‐‑B   is  released  by  ECs  and  binds   to  PDGFRβ  on  the  pericyte  surface.  
The  knockout  of  pdgfb  or  pdgfrb  genes  are  phenotipically  identical  and  lead  
to   perinatal   lethality   due   to   vascular   abnormalities   caused   by   mural   cell  
deficiency  [35,  36].  Different  studies  reported  that  PDGF-­‐‑B  is  not  uniformly  
expressed   by   the   endothelium   during   angiogenesis:   tip   cells,   the   ECs  
guiding  the  sprouting  by  standing  at  the  angiogenic  leading  front,  express  
higher   levels  of  PDGF-­‐‑B  compared  to  the  stalk  cells,   the  ECs  that  stand  at  
the  back  of  the  tip  cells.  In  this  way,  pericytes  are  immediately  recruited  to  
the   angiogenic   sprouts,   lagging   slightly   behind   the   tip   cell:   as   a  
consequence,  pericyte  recruitment  to  the  nascent  vessels  is  directly  coupled  
to  the  angiogenic  sprouting  process  [30].  
As   soon  as  PDGF-­‐‑B   is   secreted  by   the  EC,   it   is   bound   to   the   extracellular  
matrix  (ECM)  thanks  to  its  C-­‐‑terminal  retention  motif  with  high  affinity  for  
heparan   sulfate   proteoglycans   (HSPGs)   and   heparin   [37-­‐‑39].   Different  
studies   demonstrated   that   the   binding   of   PDGF-­‐‑B   to   HSPGs   is  
indispensable   for   a   proper   pericyte   recruitment:   indeed,   mice   with   a  
targeted   deletion   of   the   retention  motif   (pdgfbret/ret)   show   hypoplasia   and  
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partial   detachment   of   pericytes   [40],   suggesting   that   PDGF-­‐‑B   needs   to   be  
presented  as  a  matrix-­‐‑bound  factor  to  exert  its  function;  moreover,  a  critical  
contribution   is   given   by   endothelium-­‐‑derived   HSPGs,   since   the   global  
reduction   of   the   enzyme   N-­‐‑sulfated   heparin   sulfate,   due   to   the   total  
knockout  of  N-­‐‑deacetylase/N-­‐‑sulfotransferase  1  (NSDT-­‐‑1),  causes  a  delay  in  
pericyte   recruitment   and   an   impairment   in   their   attachment   to   the   vessel  
wall  [38],  while  pericyte-­‐‑specific  deletion  of  heparin  sulfates  does  not  cause  
any  similar  defect  [41].  
- Angiopoietin-­‐‑1   (Ang-­‐‑1)/   Tyrosine   kinase   with   immunoglobulin-­‐‑like   and  
EGF-­‐‑like  domains  2  (Tie-­‐‑2):  
This  pathway  modulates  endothelial  maturation  and  stability  and  it  goes  in  
the   opposite   direction   to   PDGF-­‐‑B/PDGFRβ   pathway:   indeed,   Ang-­‐‑1   is  
expressed  by  pericytes,  while  its  receptor  Tie-­‐‑2  is  mainly  expressed  by  ECs  
[42-­‐‑45].   Ang1   and   Tie2   null   mice   die   around   midgestation   because   of  
cardiovascular  defects  and  show  lack  of  mural  cells  [46-­‐‑48];  moreover,   the  
overexpression  of  Tie-­‐‑2  antagonist  Ang-­‐‑2  has  been  shown  to  cause  pericyte  
loss  [49].    
The  published  observations  that  ang-­‐‑1  conditional  knockout  does  not  affect  
pericyte  recruitment  [50]  and  that  pericytes  are  normally  recruited  to  Tie-­‐‑2  
negative   endothelium   in   a  mouse   chimera   of   normal   and   Tie-­‐‑2   null   cells  
[51]   suggest   that   Ang-­‐‑1/Tie-­‐‑2   signaling   is   required   to   stabilize   the  
vasculature  and  to  reduce  vascular  permeability,  but  not  to  recruit  pericytes  
to  the  endothelium.  
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- Transforming  Growth  Factor  β  (TGFβ):  
TGFβ-­‐‑mediated   interaction   between   ECs   and   pericytes   is   bidirectional,  
since  both  cell  types  express  both  TGFβ  ligand  and  its  receptors  [52].  
Both  ECs  and  pericytes  express  two  different  type  I  TGFβ  receptors,  activin  
receptor-­‐‑like   kinase   1   (Alk-­‐‑1)   and   Alk-­‐‑5,   that   trigger   different   cellular  
effects.   In   mural   cells,   Alk-­‐‑5   activation   promotes   mitotic   and   migratory  
quiescence   by   phosphorylation   of   Smad2/3,   leading   to   pericyte  
differentiation;   conversely,   Alk-­‐‑1   activation   leads   to   Smad1/5  
phosphorylation,  promoting  cell  proliferation  and  migration  and  opposing  
pericyte   differentiation   [53-­‐‑55].   On   the   other   hand,   in   ECs   a   complex  
interplay  between  Alk-­‐‑1  and  Alk-­‐‑5  exists,  with  Alk-­‐‑1  inhibiting  Alk-­‐‑5  that,  
at  the  same  time,  is  required  for  Alk-­‐‑1  signaling  [55,  56].  
Overall,  Alk-­‐‑5  and  Alk-­‐‑1  seem  to  have  quite  opposite  actions,  with  the  first  
promoting  vascular  stabilization  and  the  latter  opposing  it.  The  net  effect  of  
TGFβ  on  ECs  and  pericytes  may  depend  on  the  intensity  and  the  duration  
of   the   signal   and   on   the   balance   of   Alk-­‐‑1/5   expression   levels;   a   plausible  
possibility  is  that  Alk-­‐‑1  signaling  may  be  mainly  active  in  the  first  phases  of  
TGFβ  stimulation,  promoting  cell  proliferation  and  migration,  while  Alk-­‐‑5  





Figure   6.   Molecular   pathways   regulating   pericyte   recruitment,   differentiation   and   vascular  
stabilization  
EC-­‐‑pericytes   interactions   are   mediated   by   several   paracrine   and   juxtacrine   signaling   pathways,  
resulting   in   different   effects   on   both   cell   types.   Ligand-­‐‑receptor   pairs   are   indicated   in   the   same  
color.   In   the   case  of  N-­‐‑cadherin  and  Notch-­‐‑mediated   interactions,   the  direct   contact  between   the  
EC  and  the  pericyte  is  required.  
(Adapted  from  Armulik  A.  et  al.,  Dev  Cell  2011)  
  
The  role  of  pericytes   in  BBB  development   is  under  active   investigation.  Many   in  
vitro  studies  suggest  that  pericyte  may  regulate  the  BBB  at  the  level  of  endothelial  
junctions,   by   showing   that   the   transendothelial   electrical   resistance   (TEER)   is  
increased   in  endothelial   cell  monolayers  when  cocultured  with  pericytes   [57-­‐‑60].  
This  theory  was  challenged  by  in  vivo  studies  on  pericyte-­‐‑deficient  murine  models  
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[10,   61]   that   independently   demonstrated   that   pericyte   loss   does   not   alter   the  
endothelial  molecular  signature,  but   it   increases  the  endothelial   transcytosis  rate,  
resulting  in  increased  vessel  permeability.  
  
1.2.2  Astrocytes  
Astrocytes  are  microglial  CNS  cells.  They  take  part  to  the  NVU  by  sending  cellular  
processes  that  ensheath  the  abluminal  side  of  BBB  vessels:  these  processes,  called  
astrocyte   end-­‐‑feet,   are   very   rich   of  water   channels,   like   aquaporin4   (Aqp4),   and  
potassium  channels,  like  Kir4.1,  and  they  are  anchored  to  the  vascular  BM  via  the  
distroglycan  complex  [62].  
Astrocyte   specification   in   the   CNS   takes   place   quite   late   during   development,  
when  neuronal  differentiation   and  brain   angiogenesis   have   already  occurred   (in  
mice   this  happens  generally  around  birth)   [63];   later  on,  during  postnatal  stages,  
the   investment   of   BBB   vessels   with   the   astrocyte   end-­‐‑feet   starts,   and   it   is  
completed  around  two  weeks  after  birth  in  mice  [64].  
Astrocytes  are  reported  to  be  important  regulators  of  the  BBB  properties;  however,  
since   they   differentiate   relatively   late,   most   likely   they   do   not   act   in   the   early  
induction  phases  of  the  BBB  [65].      
The   current   knowledge   about   the   endothelium-­‐‑astrocyte   cross-­‐‑talk   and   the  
astrocyte-­‐‑derived  signals  regulating  BBB  physiology  is  relatively  limited:  the  bone  
morphogenetic   protein   receptor   type   1   (BMPR1A)   expression   and   signaling   in  
astrocytes  has  been  reported  to  be  necessary  for  the  astrocyte  end-­‐‑feet  to  properly  
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invest   the   BBB   vasculature   [66];   in   addition,   also   pericyte-­‐‑derived   signals   have  
been  shown  to  participate  in  the  regulation  of  end-­‐‑feet  polarization  [61].  
In   recent   years,   a   role   for   astrocytes   has   been   demonstrated   also   in   regulating  
endothelial   quiescence:   Alvarez   et   al.   showed   that   astrocyte-­‐‑derived   sonic  
hedgehog   (Shh)   is   necessary   for   the   maintenance   of   endothelial   immune  
quiescence,   an   observation   also   sustained   by   the   fact   that   Shh   pathway   is   often  
found  deregulated  in  MS  patients  [67].    
Finally,  some  works  suggested  that  astrocytes  may  regulate  brain  fluid  transport  
at  the  NVU.  While  the  lymphatic  system  provides  clearance  of  interstitial  fluids  in  
the   periphery,   this   does   not   happen   in   the   brain   since   it   completely   lacks  
lymphatic   vessels.   Recently,   a   so-­‐‑called   “glymphatic”   (derivative   of   glia   and  
lymphatic)   pathway   was   identified:   this   pathway   takes   advantage   of   the  
expression   of   Aqp4   on   astrocytes,   so   that   it   can   facilitate   the   drainage   and   the  
clearance  of  the  interstitial  fluids  by  exploiting  astrocytic  water  channels  [68].  
	  
1.2.3  Perivascular  macrophages  and  microglia  
Perivascular   macrophages   are   blood-­‐‑derived   immune   cells   with   phagocytic  
activity.  They  reside  in  the  perivascular  space  surrounding  arterioles  and  regulate  
the  immune  response  and  the  leukocyte  entry  into  the  brain  parenchyma  [69,  70].  
Microglial  cells  are  actually  misnamed  small  macrophages  that  reside  in  the  brain  
and   in   the   spinal   cord.   They   are  developmentally  distinct   from   the  perivascular  
macrophages,  since  they  derive  from  the  yolk  sac,  and  they  colonize  the  brain  very  
early,  before  the  CNS  vascularization  starts  [71,  72].  Even  though  their  function  in  
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BBB   development   is   still   largely   unknown,   they   are   reported   to   have   a   role   in  
maintaining  vessel  integrity  and  in  facilitating  damaged  vessels  repair  [73].  
  
1.2.4  Basement  membrane  
The  abluminal  side  of  vascular  tubes  in  all  different  tissues  is  covered  by  the  basal  
lamina,   or   basement   membrane   (BM),   a   layered   cell-­‐‑adherent   ECM   essential   to  
maintain   vessel   integrity   [74-­‐‑76].   The   BM   protects   the   tissue   from   mechanical  
stress  and  provides  an  interface  between  the  ECs  and  their  environment,  allowing  
the   binding  of   secreted   signal  molecules,   such   as   growth   factors,   and  mediating  
their   interaction   with   the   vessels   [74,   76].   The   main   BM   components   are  
fibronectin,   type   IV   collagen,   laminins,  HSPGs   (perlecan  or   agrin)   and  nidogens  
[77].  
Laminins  are  large  heterotrimeric  glycoproteins  formed  by  one  α,  one  β  and  one  γ  
chain;  they  have  been  shown  to  be  able  to  self-­‐‑assemble  into  large  networks  and  to  
interact   with   cellular   receptors,   such   as   integrins,   to   transmit   biological   signals  
[78].  While  laminins  mainly  account  for  the  BM  biological  activity,  collagen  IV  has  
been   shown   to   be   essential   to   confer   structural   stability   to   the   vascular   BM,  
although   it   is   not   required   to   initiate   its   assembly   during   development   [79];  
indeed,  mutations  in  the  human  genes  Col4a1  and  Col4a2,  encoding  for  collagen  IV  
α1  and  α2  chains  respectively,  have  been  found  to  be  associated  with  intracerebral  
hemorrhages  (ICH)  [80,  81].  
In   the   CNS,   vessels   are   surrounded   by   two   different   layers   of   BM,   an   inner  
endothelial  BM  (eBM)  and  an  outer  parenchymal  BM  (pBM),   that  differ   for  both  
36	  
	  
molecular   composition   and   cellular   origin:   the   first   is   deposited   by   ECs   and  
pericytes  and  is  characterized  by  the  presence  of  α1  and  α2  chains  of  collagen  IV,  
α4  and  α5  chains  of   laminin   (combined  with   laminin  β1  and  γ1   to   form  laminin  
411  and  511,  respectively)  and  perlecan;  the  second  is  produced  by  astrocytes  and  
is   defined   by   the   presence   of   α3   chain   of   collagen   IV,   α2   chain   of   laminin  
(combined  with  laminin  β1  and  γ1  to  form  laminin  211)  and  agrin.  At  the  level  of  
capillaries,  the  two  different  BM  fuse  to  form  a  composite  BM  with  characteristics  
intermediate  between  the  endothelial  BM  and  the  parenchymal  one  [82].    
ECs   are   known   to   be   able   to   synthesize   and   secrete  most   of   the  matrix  proteins  
involved   in   the   BM   formation;   however,   many   published   works   demonstrated  
that  pericytes  can  contribute  to  the  eBM,  also  by  secreting  some  BM  components  
like  laminin  and  collagen  IV  [83-­‐‑85].  Beside  the  direct  contribution  of  pericytes  in  
the   production   of   BM   proteins,   it   has   also   been   shown   that   an   effective   BM  
deposition  is   the  result  of   the  heterotypic   interaction  between  ECs  and  pericytes:  
many  groups  contributed  in  showing,  both  in  vitro  and  in  vivo,  that  ECs-­‐‑pericytes  
cross-­‐‑talk  increases  the  production  of  laminins  α5  and  β2,  fibronectin,  collagen  IV  
α1  chain,  nidogen-­‐‑1  and  perlecan  [86-­‐‑88].  
Not  only  the  different  cell  types  forming  the  NVU  contribute  in  the  deposition  of  
the  BM,  but  also   the  BM  composition   can  affect  both   the  vessel   angiogenic   state  
and   the   differentiation   of   pericytes   and   astrocytes.   In   particular,   recent   works  
showed  that  the  non-­‐‑collagenous  domain  1  (NC1)  of  collagen  IV  α1  chain  is  able  to  
inhibit  angiogenesis  by  binding  matrix  metalloprotease  2  (MMP-­‐‑2)  and  preventing  
its   activation,   thus   reducing   ECs   mobility   [89],   and   that   laminin   α4   is   able   to  
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induce   Delta-­‐‑like   4   (Dll4)/Notch   signaling,   thus   regulating   the   vascular   density  
and  tip-­‐‑cell  formation  [90].  Finally,  Yao  and  coworkers  demonstrated  that  the  loss  
of   astrocytic   laminins   causes   BBB   breakdown   by   decreasing   the   expression   of  
endothelial   TJs   proteins   and   of   the   astrocyte   end-­‐‑feet   marker   Aqp4   and   by  
converting   pericytes   from   a   BBB-­‐‑stabilizing   resting   state   to   a   BBB-­‐‑disrupting  
contractile  state  [91].  
  
1.3   BBB   development   and   specialization:   the   role   of   canonical   Wnt/β-­‐‑catenin  
pathway  
Vascularization  of  the  CNS  starts  between  embryonic  day  7.5  dpc  and  8.5  dpc  in  
mice,  with  the  formation  of  a  perineural  vascular  plexus  by  vasculogenesis.  Later  
on,   at   around   day   9.5   dpc,   capillary   sprouts   invade   the   neuroepithelium   by  
angiogenesis,  branching  from  the  pial  surface  to  the  periventricular  zone  [92,  93].  
The  acquisition  of  BBB  features  is  a  multi-­‐‑step  process,  whose  beginning  coincides  
with  the  blood  vessels  ingression  in  the  neural  tube:  it  has  been  shown  that,  at  day  
12   dpc,   brain   ECs   already   express   the   TJ   protein   occludin   and   the   glucose  
transporter   GLUT1   [94,   95].   Nonetheless,   at   this   stage   the   BBB   still   lacks   an  
effective  control  of  permeability,  as  shown  by  the  fact  that,  at  day  15  dpc,  the  fetal  
brain  is  permeable  to  horseradish  peroxidase  (HRP)  [96,  97].  At  late  gestation  and  
during  early  postnatal  life,  brain  ECs  start  showing  an  increase  in  TJ  organization  
and   in   efflux   transporters   expression,   together   with   a   decrease   in   the   vesicular  
transport   and   in   LAMs   expression   [94,   98].   All   these   developmental   steps   are  
mediated   by   molecular   signals   coming   from   the   interaction   with   different   cell  
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types:  first,  the  neural  progenitor  cells  induce  the  earliest  “tight”  properties,  such  
as   the   appearance   of   immature  TJs;   then  pericytes   inhibit   LAMs   expression   and  
suppress   the   transcytosis   pathways;   finally   astrocytes   definitively   “seal”   the  
barrier,   inducing   the   expression   of   efflux   transporters   and   cooperating   with  
pericytes  to  stabilize  the  TJs  [6,  65,  94]  (Fig.  7).  
  
Figure  7  -­‐‑  Development  of  the  BBB  
The  development  of  the  BBB  is  a  multistep  process  that  requires  the  acquisition  of  specific  proteins,  
including  TJ  molecules  and  specific  nutrient   transporters,  whose  expression   is   induced  by  neural  
progenitor  cells.  Pericytes  recruitment  allows  strengthening  of  the  endothelial  barrier  by  regulating  
TJ  structure,  limiting  transcytosis  rate  and  inhibiting  LAMs  expression.  Finally,  astrocytes  provide  
further  regulation  of  the  BBB  functions.    
(Adapted  from  Daneman  R.  et  al.,  Nature  2010)  
  
Many  molecular  pathways  are  involved  in  brain  vascular  development  and  in  the  
BBB  specification.  
The  vascular  endothelial  growth  factor  (VEGF)  is  the  main  growth  factor  to  induce  
vasculogenic   and   angiogenic   vascularization   both   in   CNS   and   non-­‐‑CNS   tissues  
[99].  The  abrogation  of  VEGF  signaling  pathway,  by  deleting  either  the  ligand  or  
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its  receptor   (VEGF  receptor  2  –  VEGFR2),  cause  early  embryonic   lethality  due  to  
compromised   blood   vessel   formation   [100,   101].   In   embryo   brain,   VEGF   is  
produced   by   cells   in   the   subventricular   ectoderm,   so   that   sprouting   vessels   are  
directed  along  the  VEGF  gradient  [102];  reductions  of  neural  VEGF  levels  result  in  
vascular   malformations   and   abnormal   vessel   density   in   the   retina   and   in   the  
cerebral  cortex  [103].  
While  VEGF  signaling   supervises   the   initial  vasculogenic  and  angiogenic  phases  
of  CNS  and  non-­‐‑CNS  vascular  development,  other  molecular  pathways  have  been  
shown  to  act  specifically  on  brain  vessel  to  establish  the  BBB.    
The  main  pathway  reported  to  be  involved  in  CNS-­‐‑specific  vascularization  is  the  
canonical  Wnt/β-­‐‑catenin  pathway.  
Wnts  are  secreted  glycoproteins  produced  by  different  cell  types  [104];  19  different  
Wnt   ligands   exist   in   humans   and   mice,   but   the   ones   reported   to   activate   the  
canonical  β-­‐‑catenin-­‐‑mediated  pathway  are  Wnt1,  Wnt3a,  Wnt7a/b  and  Wnt8   [11,  
18,  105].  Reception  and  transduction  of  these  signals  relies  on  the  binding  of  Wnt  
ligands  to  two  different  classes  of  cell-­‐‑surface  receptors:  the  seven-­‐‑transmembrane  
G-­‐‑protein-­‐‑coupled   receptors   Frizzled,   and   the   lipoprotein   receptor-­‐‑related  
proteins   (LRPs),   in   particular   LRP5/6   [106-­‐‑110].   Some   secreted   molecules   can  
interfere   with   Wnt   signal   activation,   both   by   binding   and   antagonizing   Wnt  
ligands,  as   in  the  case  of  Frizzled-­‐‑related  proteins  (FrzB),  Wnt-­‐‑inhibitory  factor  1  
(WIF-­‐‑1)   and  Cerberus   (Cer),   or   by  blocking  Wnt   access   to  LRP   co-­‐‑receptors   and  
inducing  LRP  endocytosis,  as  in  the  case  of  Dickkopf  (Dkk)  proteins  [111,  112].  In  
particular,  Dkk-­‐‑1   is  one  of   the  best  characterized   inhibitors  of   the  canonical  Wnt  
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pathway  and  is  itself  a  Wnt/β-­‐‑catenin  target  gene,  thereby  establishing  a  negative-­‐‑
feedback  loop  [113].    
In  the  absence  of  Wnt,  β-­‐‑catenin  is  associated  to  a  cytoplamic  multimeric  protein  
complex,   called   destruction   complex,   formed   by   Axin2,   adenomatous   poliposis  
coli  (APC),  casein  kinase  1  (CK1)  and  glycogen  synthase  kinase  3β  (GSK3β):  CK1  
phosphorylates  β-­‐‑catenin  on  Ser45,  then  GSK3β  adds  further  phosphorylations  on  
Ser33,   Ser37   and   Thr41[114].   These   phosphorylations   address   β-­‐‑catenin   to  
ubiquitination  by  β-­‐‑transducin  repeat-­‐‑containing  protein  (β-­‐‑TrCP)  and  subsequent  
proteosomal  degradation  [105].  Deletions  or  point  mutations  of  all  the  amino  acid  
residues   targeted   by   phophorylation   result   in   β-­‐‑catenin   stabilization:   for   this  
reason,   one   of   the   genetic   strategies   used   to   create   transgenic   models   with  
increased  β-­‐‑catenin  stability  is  to  conditionally  delete  the  exon  3  of  the  gene,  that  
encodes  for  all  the  phosphorylated  residues  [115].    
In  the  presence  of  Wnt,  a  cascade  of  events  starts  that  leads  to  inactivation  of  the  
destruction  complex  by  the  protein  Dishevelled  (Dvl)  (with  a  mechanism  still  not  
well  understood):  β-­‐‑catenin  is  therefore  free  to  accumulate  in  the  cytoplasm  and  is  
translocated  to  the  nucleus,  where  it  can  serve  as  a  transcriptional  co-­‐‑activator  of  
the   transcription   factors   T-­‐‑cell   factor(TCF)/lymphocyte   enhancer   factor   (LEF),  
replacing   the   transcriptional   co-­‐‑repressor   Groucho   that   was   binding   TCF/LEF  




Figure  8.  The  canonical  Wnt/β-­‐‑catenin  pathway  
In   the   absence   of   Wnt   ligands,   β-­‐‑catenin   is   sequestered   in   the   cytoplasm   by   the   destruction  
complex,  phophorylated  and  addressed  to  proteosomal  degradation.  When  Wnt  is  present,  it  binds  
to  Frizzled  receptor  inducing  the  disassembly  of  the  destruction  complex,  so  that  β-­‐‑catenin  is  free  
to  migrate   to   the   nucleus   and   to   act   as   a   transcriptional   co-­‐‑activator   of   the   transcription   factors  
TCF/LEF.  
(Adapted  from  Roberts  D.M.  et  al.,  Nat  Struct  Mol  Biol  2007)    
  
In   the   last   years,   different   groups   independently   (and   almost   simultaneously)  
demonstrated   the   influence   of   Wnt/β-­‐‑catenin   pathway   on   CNS   vascularization  
and  BBB  development  [11,  17,  18].  
Brain  angiogenesis   is   regulated  by  the  canonical  Wnt   ligands  Wnt7a  and  Wnt7b,  
that  are  produced  by  the  neuroepithelial  cells  and  act  in  a  paracrine  way  on  ECs  in  
the   CNS   [17].   The   genetic   loss   of   function   of   canonical  Wnt   pathway,   either   by  
abrogating   Wnt7a/b   in   the   neuroepithelium   or   by   inactivating   β-­‐‑catenin   in   the  
endothelium,   lead   to   angiogenic   defects   and   vascular   hemorrhages   [11,   17]:  
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however   these  defects   are   restricted   to   the  CNS,   confirming   that  Wnt/  β-­‐‑catenin  
signaling   is  activated  specifically   in  brain  ECs  and  not   in  other  vascular  districts  
[18].  
Beside  inducing  CNS  angiogenesis,  Wnt  signaling  (and  in  particular  the  canonical  
Wnt   ligand  Wnt3a)   has   also   been   demonstrated   to   upregulate   the   expression   of  
BBB   components,   such   as   GLUT1   and   Claudin-­‐‑3,   and   to   downregulate   the  
expression  of  Plvap  [11,  17,  18].  
Finally,  Liebner  and  coworkers   showed   that   canonical  Wnt  signaling   is  active   in  
ECs   during   brain   angiogenesis,  with   a   peak   of   activation   during   embryonic   life  
(10.5  dpc   –   15.5  dpc);   then,   starting   from  day   17.5  dpc,  Wnt   signaling  decreases  
and  finally  it  is  maintained  to  very  low  level  in  the  adult  brain  [11,  116].    
All   these  observations  underline  that  CNS  vascularization  and  BBB  development  
are  two  tightly  coupled  processes  that  occur  simultaneously  and  under  the  control  
of   the   same   signaling   pathways.   Whether   canonical   Wnt   signaling   can   also  
intervene  in  the  final  steps  of  maturation  of   the  NVU,  for  example  by  regulating  
the  interaction  of  ECs  with  astrocytes  and  pericytes,  is  still  to  be  determined  [99].  
  
1.4  Fibroblast  Growth  Factor  Binding  Protein  1  (FGFBP1)  
The  fibroblast  growth  factor  (FGF)  family  consists  of  at  least  23  structurally  related  
members   regulating   a   plethora   of   biological   functions,   including   angiogenesis,  
embryonic  development  and  cell  migration,  proliferation  and  differentiation  [117].  
In  particular,  FGF-­‐‑1  (or  acidic  FGF  –  aFGF)  and  FGF-­‐‑2  (or  basic  FGF  –  bFGF)  are  
tightly  bound  to  HSPGs  in  the  ECM,  which  inhibits  their  biological  activity  [118].  
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Two  different  mechanisms  have  been  proposed  for  FGFs  release  from  the  ECM:  1)  
an   enzymatic   cleavage   of   HSPGs   by   heparanase,   or   2)   the   action   of   a   carrier  
protein  called  FGF  binding  protein  1  (FGFBP1)  [117].    
FGFBP1  was  first  isolated  in  1991  from  the  culture  medium  of  human  epidermoid  
carcinoma  A431  cells  and  was   initially  designated  as  heparin-­‐‑binding  protein  17  
kDa  (HBp17)  [119].    
The  primary  structure  of  the  protein  consists  of  234  amino  acids.  At  the  N-­‐‑terminal  
there   is   a   33-­‐‑residues   signal   sequence   that   addresses   the   protein   to   secretion,  
which   is   cleaved   in   the  mature  protein;  an  additional  cleavage  site  prior   to  Met-­‐‑
168  confers  the  protein  its  apparent  molecular  weight  of  17  kDa  [119].    
FGFBP1   is   well   conserved   among   different   species,   with   the   human   protein  
showing   84,   57   and   49%   amino   acid   identities   with   bovine,   rat   and   mouse  
proteins,  respectively  [120,  121].    
Mass  spectrometry  analysis  of   the  protein   isolated   from  bovine  mammary  gland  
secretion   determined   the   presence   of   five   disulfide   bonds   (Cys71-­‐‑Cys88;   Cys97-­‐‑
Cys130;   Cys106-­‐‑Cys142;   Cys198-­‐‑Cys234;   Cys214-­‐‑222)   between   all   the   ten   Cys  
residues   present   in   the   bovine   sequence;   importantly,   these   residues   are  
positionally   conserved   also   in   human   and   mouse   proteins.   The   analysis   of   the  
bovine   protein   also   revealed   the   presence   of   N-­‐‑   and  O-­‐‑glycosylation   at   Asn155  
and   Ser172,   respectively,   that   may   explain   the   discrepancies   between   the  
estimated  and  the  observed  molecular  weight  [121].  
The  domain  of  the  human  protein  responsible  for  the  interaction  with  heparin  has  
been  localized  between  residues  Arg110  and  Phe143  and  is  characterized  by  a  high  
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content   of   basic   amino   acids   [122].   Moreover,   two   additional   heparin-­‐‑binding  
consensus  sequences  have  been  localized:  one  is  located  at  residues  Lys163-­‐‑Ser169,  
while  the  other,  located  at  Lys25-­‐‑His32,  is  positioned  within  the  N-­‐‑terminal  signal  
sequence   that   is   cleaved   during   the   secretion   process   [123].   Finally,   the   FGF  
binding  site  has  been  described  to  be  located  at  the  C-­‐‑terminal,  between  residues  
Lys193  and  Cys234  [124]  (Fig.  9).    
  
Figure  9.  Structure  of  the  human  FGFBP1  
The  disulfide  bonds   are   conserved   among  different   species.  The   functional  domains   (N-­‐‑terminal  
signal  sequence,  inner  heparin-­‐‑binding  site  and  C-­‐‑terminal  binding  site)  and  the  glycosilation  sites  
are  reported  in  the  figure.  
(Adapted  from  Abuharbeid  S.  et  al.,  Int  J  Biochem  Cell  Biol.  2006)  
  
Immunohistochemical   studies   at   different   stages   of   mouse   embryogenesis  
demonstrated   that  FGFBP1   is  normally  expressed   in  a  broad  spectrum  of   tissues  
during   development   and   that   its   expression   also   correlates   with   the   specific  
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developmental   stage   [125];   conversely,   it   was   demonstrated   that   FGFBP1   is   not  
expressed  in  most  adult  tissues  [120,  126,  127].    
Besides   some   studies   on   the   physiological   expression   of   FGFBP1,   most   of   the  
research  on  the  topic  is  focused  on  its  role  in  tumor  development:  indeed,  FGFBP1  
was   found   to   be   highly   expressed   in   cells   and   tissues   from   head   and   neck  
squamous  cell  carcinoma  (SCC),  invasive  human  breast  cancer,  some  human  colon  
cancer   cell   lines   and   tissues   and   prostate   carcinoma   cell   lines   [126-­‐‑129].  
Interestingly,   FGFBP1   positive   SCC   showed   the   highest   vascular   density,  
suggesting  that  FGFBP1  could  serve  as  an  angiogenic  switch  in  cancer  [128].    
The  described  mechanism  of  action  of  FGFBP1  involves  FGFBP1  binding  to  FGF-­‐‑2,  
that  cause  FGF-­‐‑2  release  from  the  ECM  due  to  a  reduction  in  its  affinity  to  HSPGs  
[118]  (Fig.  10).  FGFBP1  interaction  with  FGF-­‐‑2  is  reported  to  be  specific  and  dose-­‐‑
dependent,  and   it   is   inhibited  by  FGF-­‐‑1,  heparansulphate  and  heparinoids   [130].  
Many   works   demonstrated   that   this   mechanism   is   able   to   positively   modulate  
FGFs   activity.   The   exogenous   administration   of   FGFBP1   stimulates   FGF-­‐‑2-­‐‑
dependent   growth   of   different   tumor   cell   lines   and   promotes   ECs   growth   and  
chemotaxis  [118].  In  addition,  and  further  confirming  the  role  of  FGFBP1  in  tumor  
angiogenesis,   it   has   been   shown   that   FGFBP1   addition   can   increase   FGF-­‐‑2-­‐‑
mediated   blood   vessel   growth   in   a   chicken   chorioallantoic   membrane   (CAM)  
assay,  and  that  early  embryonic  death  due  to  hemorrhages  and  increased  vascular  




Figure  10.  Mechanism  of  action  of  FGFBP1  
Secreted   FGFBP1   binds   to   immobilized   FGF-­‐‑2   and   releases   it   from   the   HSPGs   in   the   ECM.  
Solubilized  FGF-­‐‑2  is  presented  by  FGFBP1  to  its  receptor  and  activates  the  downstream  signaling.  
(Adapted  from  Abuharbeid  S.  et  al.,  Int  J  Biochem  Cell  Biol.  2006)  
  
1.5  Aim  of  the  work  
The  relevance  of  the  canonical  Wnt/β-­‐‑catenin  pathway  in  the  determination  of  the  
BBB   features   in   the   CNS   vasculature   has   been   extensively   investigated   by   our  
group   and  by  others.   In   addition   to   this,   our   group   also   obtained  data   showing  
that   FGFBP1,   a   protein   known   to   be   involved   in   physiological   and   pathological  
angiogenic   processes   and   whose   expression   is   strictly   regulated   during  
development,  is  upregulated  by  activation  of  Wnt/β-­‐‑catenin  signaling  specifically  
in  brain  ECs.    
Stemming  from  these  observations,  our  works  aims  at  elucidating  a  possible  role  
for   FGFBP1   in   the   development   and/or   in   the   maintenance   of   the   BBB,   in  
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particular   trying   to   define   both   FGFBP1   effects   on   endothelium   per   se   and   its  




2.  MATERIALS  AND  METHODS  
  
2.1  Sequence  aligments  and  phylogenetic  tree  construction  
FGFBP1  protein   sequences   in  human,  mouse  and  zebrafish  were   retrieved  using  
BLAST,  then  aligned  with  ClustalW  to  determine  the  homology.  The  phylogenetic  
tree  was  constructed  using  ClustalW.  
  
2.2  Animals  
All   animal   procedures   were   approved   by   the   Italian   Ministry   of   Health   and  
carried   out   in   accordance   with   the   guidelines   established   in   the   directive  
2010/63/EU  on  the  protection  of  animals  used  for  scientific  purposes.  
The  following  zebrafish  lines  were  used:    
-­‐‑AB,  purchased  from  Zebrafish  International  Resource  Center  (ZIRC);  
-­‐‑Tg(fli1a:EGFP),   kindly  donated  by  Dr.  B.  Weinstein   (National   Institute   of  Child  
Health  and  Development,  Bethesda,  US)  
-­‐‑Tg(gata1a:dsRed),   kindly   provided   by   Dr.   L.   Zon   (Harvard   Medical   School,  
Boston,  US).  
The  following  mouse  strains  were  used:    
-­‐‑  FGFBP1flox/flox,  generated  by  Taconic  Artemis  (Koeln,  Germany)  on  a  C57/Black6N  
background  according  to  the  knock-­‐‑in  procedures;  
-­‐‑   Cdh5(PAC)-­‐‑CreERT2   (VEC-­‐‑PAC)   [132],   kindly   provided   by   Dr.   R.H.   Adams  
(University  of  Munster,  Munster,  Germany);    
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-­‐‑  Rosa  26-­‐‑Enhanced  Yellow  Fluorescent  Protein   (R26-­‐‑EYFP)  [133],  kindly  donated  by  
Dr.  S.  Casola  (IFOM,  Milan,  Italy);  
-­‐‑  β-­‐‑catlox(ex3)/lox(ex3)   [134],  generously  provided  by  Dr.  M.  Taketo   (Kyoto  University,  
Kyoto,  Japan).  
-­‐‑  BAT-­‐‑gal  [135],  kindly  gifted  by  Dr.  S.  Piccolo  (University  of  Padua,  Padua,  Italy).  
For   primary   brain   ECs   (bMECs)   preparation,   C57Bl6   (Charles   River)   wild   type  
animals  were  used.  
  
2.3  Mouse  genotyping  
To   determine   the   genotype   of   the   mice,   tail   biopsies   were   collected   and   the  
genomic   DNA  was   extracted   by   incubating   the   biopsies   O/N   at   56°C   in   a   “tail  
buffer”  made  of   0.5  mg/ml  Proteinase  K   (Sigma),   0.5%  Triton  X-­‐‑100   in  Gitschier  
Buffer  1X;  then  the  Proteinase  K  was  inactivated  by  keeping  the  sample  at  95°C  for  
10  minutes.  The  genomic  PCR  was  performed  with  specific  primer  pairs  (reported  
in  Table  1)  to  amplify  the  desired  sequences  and  then  loaded  on  a  1%  agarose  gel  
for  amplicons  detection.  
PCR  






insertion  of  the  5’  
LoxP  sequence  
LOXP1  Fw:    
TCCACCCTGTTTCAAGTTGG;  
LOXP1  Rv:    
GACCACCTGTTGGGAAAGG  
WT:  210  bp  
Tg:  367  bp  

















WT:  209  bp  
Tg:  357  bp  



















































WT:  600  bp  
Tg:  320  bp  
Het:  320  +  
600  bp  
Exon3/DEL  
Identifies  exon  3  







WT:  690  bp  
Del:  490  bp  




2.4  Preparation  and  culture  of  bMECs  
Mouse   brain   microvascular   fragments   were   processed   as   described   previously  
[136,  137].  Capillary  fragments  were  resuspended  in  culture  medium  composed  of  
DMEM  (GIBCO),  20%  North  American  Fetal  Calf  Serum  (FCS-­‐‑NA)  (HyClone),  EC  
growth  supplement   (ECGS)   (50  µμg/ml;  made   in  our   lab   from  calf  brain),  heparin  
(100   µμg/ml,   from   porcine   intestinal   mucosa;   Sigma),   glutamine   (2   mM;   Sigma),  
sodium  pyruvate  (1  mM;  Sigma)  and  penicillin/streptomycin  (100  units/l;  Sigma),  
then   seeded   on  wells   coated  with   collagen   I   solution   from   rat   tail   (Sigma).   ECs  
were  selected  for  puromycin  (4  µμg/ml;  Sigma)  resistance  for  2  days  and  grown  in  
presence   of   either   murine   Wnt3a   recombinant   protein   (100   ng/ml.;   315-­‐‑20,  
Peprotech)  or  control  vehicle  (1%BSA  in  PBS).  When  required  by  the  experiment,  
cells  were  treated  with  recombinant  murine  FGF-­‐‑2  (100  ng/ml;  450-­‐‑33,  Peprotech).  
All  cells  were  cultured  at  37°C  in  a  humidified  atmosphere  with  5%  CO2.  
  
2.5  Morpholino  microinjections  
Morpholinos   were   injected   at   one   cell-­‐‑stage   in   the   different   strains   and   the  
phenotype  was   assayed   between   48-­‐‑72   hpf   as   described.   The  morpholinos  were  
synthetized   by   GeneTools   and   dissolved   in   nuclease-­‐‑free   water;   5   nl   of  
morpholino  solution  were  injected  in  each  egg.  The  sequences  of  the  morpholinos  
used  and  the  final  concentrations  are  reported  in  Table  2.  A  p53  morpholino  was  
coinjected   in   all   the   experiments   to  minimize   the   toxic   effects.   All  morpholinos  
were  injected  at  the  highest  concentration  that  did  not  cause  embryo  lethality.  
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Name   Sequence  
Final  
concentration  
MO-­‐‑CTRL   CCTCTTACCTCAGTTACAATTTATA   0.15  mM  
MO-­‐‑Dkk1   AATTGTAGGATGTATTCCCTGGGTG   0.1  mM  
MO-­‐‑Fgfbp1a   CATGTCCTTCAGTCCTACAAATAGC   0.3  mM  
MO-­‐‑Fgfbp1b   CGCATCATGGCTGCATTGGAAATAC   0.2  mM  
MO-­‐‑p53   GCGCCATTGCTTTGCAAGAATTG   0.15  mM  
Table   2.  Nucleotidic   sequences   and   final   concentrations   of   the   morpholinos   used   for   in   vivo  
knockdown  experiments  
  
2.6  Cell  dissociation  and  sorting  from  zebrafish  embryos  
For   cell   dissociation   and   sorting   experiments   on   zebrafish   samples,   40  
Tg(fli1a:eGFP)  embryos  at  72  hpf  were  used;  in  addition,  the  same  number  of  AB  
(GFP  negative)  embryos  was  used  as  negative  control.  Embryos  were  put  into  1.5  
ml   tubes   (Eppendorf)  and  washed  with  PBS  1x   twice   (5  minutes  each),   then  PBS  
was  replaced  with  1  ml  of  deyolking  solution  (NaCl  50  µμM,  KCl  2  µμM,  CaCl2  1  µμM  
and  NaHCO3  1  µμM   in  distilled  water)  and  pipetted  with  a  200  µμl   tip.  Deyolked  
embryos  were   incubated  at  28°C   in  5  ml  of  protease  solution   (1  µμM  EDTA  pH8,  
0.25%  Trypsin  in  PBS  1x)  until  embryos  were  completed  dissociated,  then  1  ml  of  
stop  solution   (300  µμl  FBS  plus  3  µμl  CaCl2  2M   in  PBS  1x)  was  added   to  block  cell  
dissociation.   The   suspension   was   centrifuged   at   3000   rpm   for   3   minutes,   the  
supernatant   was   discarded   and   the   cell   pellet   was   resuspended   in   suspension  
medium  (1%  FBS,  CaCl2  0.08  µμM  in  PBS  1x).  Cells  were  sorted  in  two  populations  
(GFP  +  and  GFP  -­‐‑)  with  a  Facsaria  Cell  Sorter   (BD  Biosciences)  and   immediately  
processed  for  mRNA  extraction.  
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2.7  Semiquantitative  RT-­‐‑PCR  
Total  RNA  from  zebrafish  embryos  was  extracted  using  Trizol  (Qiagen)  and  then  
purified  with  RNeasy  Kit   (Qiagen)   according   to  manufacturer’s   instruction.   The  
desired  amount  of  RNA  (usually  1  µμg)  was  retrotranscribed  with  random  examers  
using  the  High  Capacity  cDNA  Archive  Kit  (Applied  Biosystems).  
5  ng  of  cDNA  were  used  as   template   for   the  RT-­‐‑PCR  reaction.  The  sequences  of  
the  primer  pairs  used  to  amplify  the  desired  regions  are  reported  in  Table  3.  The  
PCR  conditions  used  for  the  amplification  were:  94°C  for  2  min,  35  cycles  of  94°C  
for  40  sec,  57°C  for  40  sec  and  72°C  for  1  min,  then  72°C  for  10  min.  The  samples  
were  loaded  on  1%  agarose  gel  in  TAE  1X  for  amplicons  detection.  
Fgfbp1a  
Forward   GAAGGACATGTCTCTCCGCGGAA  
Reverse   GCTCAGCAGTCTCCACTCTGGATT  
Fgfbp1b  
Forward   ATGATGCGCGCGACAGGCATCGC  
Reverse   CATGAGCATTCATCATTCTCCAGC  
β-­‐‑actin  
Forward   ACCTCATGAAGATCCTGACC  
Reverse   TAATCCACATCTGCTGCTGG  
Table  3.  Primers  used  for  the  amplification  of  the  mRNAs  of  interest  in    semiquantitative  RT-­‐‑PCR  
experiments.  
	  
2.8  Whole-­‐‑mount  In  Situ  Hybridization  
Whole-­‐‑mount  In  Situ  Hybridization  (ISH)  on  zebrafish  embryos  at  different  stages  
was  performed  as  previously  described  [138].    
The  full-­‐‑coding  sequence  of  Fgfbp1  cDNAs  was  cloned  into  pCR2.1-­‐‑TOPO  vector,  
using   TOPO   TA  Cloning   kit   (Invitrogen);   the   sequence   of   the   primers   used   are  
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reported   in   Table   4.   cDNA-­‐‑containing   vectors   were   cut   with   BamHI   and  
transcribed  with  T7  RNA  Polimerase  using  a  digoxigening-­‐‑labebled  NTPs  mixture  
in  order  to  obtain  dig-­‐‑labeled  antisense  RNA  probes.  
Fgfbp1a  
Forward   CGGAATTCGCTATTTGTAGGACTGAAGGACATG  
Reverse   CGTCTAGAGCAGTCTCCACTCTGGATTACA  
Fgfbp1b  
Forward   CGGAATTCTATTTCCAATGCAGCCATGATGCGCGCG  
Reverse   CGTCTAGATTCATCATTCTCCAGCATCAAGAAGAG  
Table  4.  Primers  used  for  Fgfbp1a  and  Fgfbp1b  cloning  into  pCR2.1-­‐‑TOPO  vector  
  
2.9  O-­‐‑dianisidine  staining  
For  histochemical  staining  of  haemoglobin,  embryos  at  48  hpf  were  incubated  with  
o-­‐‑dianisidine  stain  solution  (40%  ethanol,  0.01  M  sodium  acetate,  0.65%  H2O2,  0.6  
mg/ml  o-­‐‑dianisidine  Sigma)  for  15  minutes  and  then  washed  in  water.  
    
2.10  In  vivo  permeability  assays  
72  hpf  zebrafish  embryos  were  anesthetized  with  0.2%  Tricaine  (Sigma)  and  were  
positioned  ventral  side  up  in  a  1%  agarose  injection  mold.  Using  a  microinjection  
device  (Picospritzer  III,  Parker  Instrumentation)  fitted  with  a  pulled  glass  capillary  
needle,   5nl   of   DAPI   or   rhodamine-­‐‑labeled   lysine-­‐‑fixable   10kDa   dextran  
(Invitrogen)  were   injected   into   the  cardiac  venous  sinus.  Embryos  were  returned  
to  egg  water  to  recover  and  then  fixed  in  4%  paraformaldehyde  (PFA)  40  minutes  
after  the  tracer  injection.  
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For  permeability  assays  in  mice,  the  animals  were  injected  intraperitoneally  with  a  
solution   of  Alexa555-­‐‑Cadaverine   (10   µμg/g   of   body  weight)   (Invitrogen);   5   hours  
after   the   injection   the  animals  were  anesthetized  with  Avertin   (250  µμg/g  of  body  
weight)   (Sigma),   then   perfused  with   PBS   for   1  minutes   and  with   4%   PFA   for   5  
minutes.  After  dissection,  brain  and  eyes  were  fixed  O/N  in  4%  PFA  at  4°C,  then  
washed  twice  in  PBS.    
  
2.11  Tamoxifen  treatment  
A  stock  solution  of  Tamoxifen   (Sigma)  was  prepared  by  dissolving   it   in   corn  oil  
and  10%  ethanol  to  reach  a  10  mg/ml  concentration.  Tamoxifen  working  solutions  
were   prepared   immediately   before   the   injection   by  diluting   the  mother   solution  
1:5   in  corn  oil.  The  solution  was  administered  to  newborns  (0-­‐‑1  dpn)  by  a  single  
intragastric  injection  (35  µμg/g  of  body  weight).  Control  animals  were  injected  with  
the  same  vehicle  used  to  dissolve  tamoxifen  (corn  oil  plus  2%  ethanol).  
  
2.12  Immunofluorescence  (IF)  analysis  of  brains  and  retinas  
For  tissue  IF  analysis,  brains  and  retinas  were  dissected  from  the  mice  and  fixed  in  
4%   PFA   O/N   at   4°C.   Brains   were   embedded   in   4%   Low   Melting   Point   (LMP)  
agarose   in   PBS   and   100   µμm   sections  were   cut   at   the   vibratome   (1000   Plus,   The  
Vibratome   Company,   St.   Louis,   MO,   US).   Both   brain   sections   and   retinas   were  
incubated  O/N  at  4°C  in  a  blocking  solution  (1%  Fish  Skin  Gelatin,  0.5%  Triton-­‐‑X,  
5%  Normal  Donkey  Serum,   0.01%  Thimerosal),   then   incubated  O/N  at   4°C  with  
the   primary   antibodies   diluted   in   an   Ab   buffer   (1%   Fish   Skin   Gelatin,   0.25%  
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Triton-­‐‑X,   0.01%   Thimerosal).   The   samples  were  washed   three   times  with   PBS   +  
0.25%  Triton-­‐‑X,   then   incubated   for   4   hours   at  RT  with   the   secondary   antibodies  
diluted  in  Ab  buffer,  washed  again  with  PBS  +  0.25%  Triton-­‐‑X  for  three  times  and  
with   PBS   for   two   times.   The   samples   were   postfixed  with   4%   PFA   at   RT   for   5  
minutes,  then  washed  in  PBS  for  three  times  and  finally  mounted  on  glass  slides  
with  Vectashield  with  DAPI   (Vector  Labs).  For  ECM  proteins   staining,   an   initial  
step  of  unmasking  was  performed  by  preincubating   floating  sections   in  distilled  
water  at  37°C  for  5  minutes,  incubating  them  in  pepsin  solution  (1  mg/ml  in  0.2%  
HCl)   (Dako)  at  37°C  for  10  minutes  and  washing  them  with  PBS  once  at  37°C  (5  
minutes)  and  three  times  at  RT  (10  minutes  each).  
Samples  were   observed   at   a   confocal  microscope   (Leica)   using   10x,   20x   and   40x  
objectives.   Acquired   images   were   processed   with   ImageJ;   only   adjustments   of  
brightness   and   contrast   were   applied   in   the   preparation   of   the   figures.   For  
comparison  purposes,  different  sample  images  of  the  same  antigen  were  acquired  
under  constant  acquisition  settings.  
  
2.13  Transmission  electron  microscopy     
Animals   were   anesthetized   by   intraperitoneal   injection   of   Avertin   20mg/ml  
solution   (about   0.5   mg/g   of   body   weight).   Mice   were   intracardiacally   perfused  
with  1-­‐‑2  ml  of  heparin  0.025%  in  PBS,   followed  by  20  minutes  of  perfusion  with  
Fixative  solution  (2%  PFA  +  2.5%  Glutaraldehyde  in  0.2M  Sodium  Cacodylate)  at  a  
speed  of  5  ml/min.  Perfused  animals  were  kept  in  a  plastic  bag  for  90  minutes  and  
then  the  brains  were  dissected  and  stored  in  Fixative  solution  until  processing.    
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Brain  samples  were  treated  with  1%  reduced  osmium  tetroxide,  stained  with  0.3%  
thiocarbohydrazide   in  0.1  cacodylate  buffer   (pH  7.0),   treated  again  with  reduced  
osmium   tetroxide   for   30  minutes   and   then   dehydrated   using   increasing   ethanol  
concentrations.  The  samples  were  finally  embedded  in  Epon  resin  and    60nm-­‐‑thick  
sections  were  cut  and  observed  at  the  electron  microscope  (Tecnai  20).  
  
2.14  RNA  interference  
Three   different   Stealth   RNAi   Duplexes   (Invitrogen)   were   used   to   knockdown  
FGFBP1  mRNA.  The  sequences  of  the  siRNA  used  are  reported  in  Table  5.  Stealth  
RNAi   siRNA   Negative   Control   Med   GC   Duplex   #3   (Invitrogen)   was   used   as  
negative   control   in   all   the   experiments.   Transfection   was   performed   using  
Lipofectamine  2000  (Invitrogen)  following  manufacturer’s  instruction.  
   Name   Sequence  
siFgfbp1#1   NM_008009_stealth_201   CCTCGTTAGGGAAGGCCCAGAATAA  
siFgfbp1#2   NM_008009_stealth_235   CAGGACATCTAAATCTCTGACGCAT  
siFgfbp1#3   NM_008009_stealth_406   CGACAAAGACCAGATCTACTGGAAA  
Table  5.  Nucleotidic  sequences  of  the  siRNAs  used  for  in  vitro  FGFBP1  knockdown.  
  
2.15  Affymetrix  analysis  
Total   mRNA   was   extracted   by   primary   bMECs,   treated   with   either   vehicle   or  
recombinant  Wnt3a   and   with   either   siCTRL   or   siFgfbp1#2,   and   analyzed   using  
Affymetrix  GeneChip  arrays  Gene  ST  1.0  covering  29000  murine  genes.  For  each  
condition,  total  mRNA  extracts  from  three  different  experiments  were  analyzed  to  
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measure  biological  variability.  In  order  to  identify  the  modulated  genes,  an  initial  
filter   was   applied   to   select   transcripts   with   at   least   a   2-­‐‑fold   change   and  with   a  
statistical  significance  lower  than  0.05.  
  
2.16  Immunofluorescence  (IF)  analysis  of  cells  
For   cell   IF   analysis,   cells  were   fixed   and   permeabilized   in   1%  PAF/0.1%  Triton-­‐‑
X/0.1%  NP40  for  30  minutes  at  RT  or  with  ice-­‐‑cold  100%  methanol  for  3  minutes.  
Fixed   cells  were   incubated  with   blocking   solution   (PBS   +   5%  BSA  +   5%  Normal  
Donkey   Serum)   for   at   least   1   hour   at   RT   and   then   with   the   primary   antibody  
(diluted  in  PBS  +  5%  BSA)  O/N  at  4°C;  after  3  washes  in  PBS  +  1%  BSA,  the  cells  
were   incubated   with   the   appropriate   secondary   antibody   (diluted   in   PBS   +   1%  
BSA)  for  1  hour  at  RT,  then  washed  in  PBS,  postfixed  in  1%  PFA  for  3  minutes  at  
RT,  washed  again  and  finally  mounted  in  Vectashield  with  DAPI.    
Samples  were   observed   at   a   confocal  microscope   (Leica)   using   20x,   40x   and   63x  
objectives.   Acquired   images   were   processed   with   ImageJ;   only   adjustments   of  
brightness   and   contrast   were   applied   in   the   preparation   of   the   figures.   For  
comparison  purposes,  different  sample  images  of  the  same  antigen  were  acquired  
under  constant  acquisition  settings.  
  
2.17  Quantitative  Real  Time  RT-­‐‑PCR  (qRT-­‐‑PCR)  
Total  RNA  from  cultured  cells  was  extracted  with  RNeasy  Kit  (Qiagen)  following  
manufacturer’s   instructions.   The   desired   amount   of   RNA   (usually   500   ng)   was  
retrotranscribed  with  random  examers  using  the  High  Capacity  cDNA  Archive  Kit  
60	  
	  
(Applied  Biosystems).  cDNA  (5  ng)  was  amplified   in   triplicate  with   the  TaqMan  
Gene   Expression   Assay   (Applied   Biosystems)   and   the   I/Prism   7900   HT  
Thermocycler.  For  each   sample,   the  expression   level  was   first  normalized   to  18S  
housekeeping   gene   and   then   determined   with   the   comparative   threshold   cycle  
(Ct)  method  as  previously  described.    
	  
2.18  Western  blot  analysis  
Total  proteins  were  extracted  by  solubilizing  cells  in  boiling  Laemli  buffer.  Lysates  
were  incubated  for  10  minutes  at  100°C  and  then  spinned  for  5  minutes  at  13000  
rpm   to   discard   cell   debris.   The   supernatants   were   collected   and   the   protein  
concentration  was  determined  using  a  BCA  Protein  Assay  Kit  (Pierce)  according  to  
the  manufacturer’s  instructions.  Equal  amounts  of  protein  were  loaded  on  gel  and  
separated   by   SDS-­‐‑PAGE,   transferred   to   a   Protran   Nitrocellulose   Hybridization  
Transfer   Membrane   0,2   µμm   pore   size   and   blocked   for   1h   at   RT   in   TBS-­‐‑T   1X  
containing  5%  BSA.  The  membranes  were   then   incubated   for   1  hour   at  RT  with  
primary   antibodies   diluted   in   TBS-­‐‑T   1X   containing   5%   BSA.   Membranes   were  
rinsed  at   least  three  times  in  TBS-­‐‑T  1X  and  then  incubated  for  1  hour  at  RT  with  
secondary  antibodies  diluted  in  TBS-­‐‑T  1X  containing  5%  BSA.  After  three  washes,  
membranes  were  incubated  with  ECL  for  1  min  and  exposed  for  the  required  time.  
2.19  Antibodies  and  reagents  
The   following   antibodies   were   used   for   IF:   FGFBP1   (R&D   AF1413,   dil.   1:400),  
FGFBP1   (Bioss,  bs-­‐‑1768R,  dil.1:150),  GFP   (Invitrogen,  A-­‐‑21311dil.   1:300),  PECAM  
(Millipore   MAB1398Z,   dil.   1:200),   VE-­‐‑cadherin   (BD,   550548,   dil.   1:200),  
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podocalyxin   (R&D,   AF1556,   dil.   1:200),   GLUT1   (Thermo   Scientific   #RB-­‐‑9052-­‐‑P0,  
dil.  1:300),  NG2  (Millipore  AB5320,  dil.  1:200),  desmin  (Abcam  ab15200,  dil.  1:200),  
PDGFRβ   (R&D   AF1042,   dil.   1:200),   laminin   α2   (Abcam   ab11576,   dil.   1:200),  
collagen  IV  α1  chain  (Chondrex  #7070,  dil.  1:200),  collagen  IV  α2  chain  (Chondrex  
#7071,  dil.  1:200),  aquaporin  IV  (Millipore  AB3594,  dil.  1:200),  collagen  IV  (Serotec  
2150-­‐‑1470,   dil.   1:200),   appropriate   secondary   antibodies   conjugated   with   Alexa  
488,  Alexa  555  and  Alexa  647   (Invitrogen,  dil.   1:200).  Antibodies  against   laminin  
α4   and   laminin   α5   were   kindly   provided   by   Prof.   Lydia   Sorokin   (Institute   of  
Physiological  Chemistry  and  Pathobiochemistry,  Münster  University,  Germany).  
To   enhance   FGFBP1   signal,   the   Tyramide   Signal   Amplification   kit   (TSA   kit#12,  
Life  Technologies)  was  used  on  vibratome  sections.  
The   following   primary   antibodies   were   used   for  WB:   total   p42/44   MAPK   (Cell  
Signaling,  dil.  1:1000),  phosphorylated  p42/44  MAPK  (Cell  Signaling,  dil.  1:1000).  
  
2.20  Quantifications  
In   zebrafish   experiments,   at   least   10   animals   per   group   were   analyzed.   The  
number  of  ISVs  and  of  ISVs-­‐‑DLAV  connections,  the  number  of  hemorrhages  and  
the   number   of   DAPI   positive   nuclei   in   the   permeability   assay   were   manually  
counted.  
In  mice  experiments,   at   least   2  WT  and  3  KO  animals   from   the   same   litter  were  
analyzed  for  each  stage  of  development.  At  least  3  confocal  z-­‐‑projection  (about  15  
µμm  thickness)  images  were  used  for  each  quantification.    
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To  quantify  the  vascular  density,  whole-­‐‑mount  retinas/brain  sagittal  sections  were  
stained   for   PECAM;   the   images   were   thresholded   and   binarized   and   the  
percentage  of  PECAM-­‐‑positive  pixels  was  determined  with  ImageJ.    
To   quantify   the   vessel   coverage   by   BM   proteins   (collagen   IV,   Col4a1,   Col4a2,  
laminin  α2,  laminin  α4,  laminin  α5),  the  images  were  thresholded  and  binarized;  
the  respective  binarized  PECAM  image  was  then  used  as  selection  mask  and  the  
percentage   of   BM/pericyte   marker   positive   pixels   within   the   selection   was  
calculated  using  ImageJ.  
To  quantify  the  fluorescence  intensity  of  Plvap  and  of  BM/pericyte  markers  (as  a  
measure  of  their  expression),  the  respective  binarized  PECAM  image  was  used  as  
selection  mask  and  the  mean  fluorescence  intensity  of  BM/pericyte  markers  within  
the  selection  was  determined  using  ImageJ.  
The   number   of   branching   points   and   the   number   of   PDGFRβ  positive   pericytes  
were  manually  counted.  
All  images  acquisitions  and  all  quantifications  were  carried  out  blind.  
  
2.21  Statistical  analysis  
Data   are   presented   as   mean   ±   standard   deviation.   Statistical   significance   was  
determined   by   performing   2-­‐‑tailed   unpaired   Student’s   t-­‐‑test   (Excel).   A   P   value  





3.1   Fgfbp1   expression   is   regulated   by   canonical  Wnt/β-­‐‑catenin   pathway  both   in  
vitro  and  in  vivo  
3.1.1  Fgfbp1  expression  is  upregulated  by  Wnt3a  treatment  in  primary  brain  ECs  
In  the  perspective  of  better  understanding  the  effect  of  the  canonical  Wnt  pathway  
on   brain  microvasculature,  we   performed   an  Affymetrix   screening   to   determine  
the   modifications   in   the   transcriptional   program   of   murine   primary   brain   ECs  
when   treated   with   the   canonical   Wnt   ligand   Wnt3a.   Among   the   genes   that  
resulted   to   be   modulated   by   Wnt   pathway   activation,   one   of   the   genes   that  
showed   the   strongest   upregulation   was   Fgfbp1,   that   in  Wnt3a-­‐‑treated   cells   was  
2.646   fold   higher   than   in   control   cells   (p<0.001).   As   an   internal   control   of   an  
effective   Wnt3a   treatment,   also   the   canonical   Wnt/β-­‐‑catenin   target   genes  Axin2  
and  Slc2a1  resulted  to  be  upregulated  in  Wnt3a-­‐‑treated  cells  (Axin2:  fold  change  =  
2.781,  p  value  <0.001;  Slc2a1:  fold  change  =  1.218;  p  value  <0.005).  
  
3.1.2  Fgfbp1  expression  is  upregulated  in  brain,  but  not   lung,  ECs  in  a  murine  
model  of  β-­‐‑catenin  gain-­‐‑of-­‐‑function  
To   verify   in   vivo   the   effect   of   Wnt   activity   on   FGFBP1   expression,   we   took  
advantage   of   a  murine  model   of   β-­‐‑catenin   gain   of   function   (β-­‐‑catlox(ex3)/wt).   After  
crossing   these  mice  with   the   transgenic   strain   (Cdh5(PAC)-­‐‑CreERT2),  where  CRE  
recombinase   is  under   the   transcriptional   control  of   the  endothelial   specific  Cdh5  
64	  
	  
promoter,   the   recombinase   is   expressed   only   in   ECs,   where   it   targets   for  
recombination   the   LoxP   sites.   Indeed,   the   CRE   protein   is   fused   to   a   tamoxifen-­‐‑
responsive   ERT2   domain,   that   translocates   the   recombinase   to   the   nucleus   to  
induce  the  deletion  only  upon  tamoxifen  treatment.  This  approach  allowed  us  to  
obtain  an  endothelial-­‐‑specific  β-­‐‑catenin  gain  of  function  (GOF)  model.  
The  recombination  was  induced  in  the  progeny  by  injecting  tamoxifen  soon  after  
birth  (0  dpn)  and  ECs  from  brain  and  lungs  were  isolated  at  day  8  dpn.  Real-­‐‑Time  
PCR   (qRT-­‐‑PCR)   analysis   of   Ffgbp1   gene   expression   showed   that   Fgfbp1  mRNA  
was  significantly  higher  in  brain  ECs  isolated  from  GOF  mice  compared  to  those  
isolated  from  WT  mice  (p<0.05),  while  it  was  not  induced  by  β-­‐‑catenin  activity  in  
the  ECs  isolated  from  the  lung  (Fig.  11a).  The  absence  of  Fgfbp1  induction  in  lung  
ECs  isolated  from  GOF  mice  was  not  dependent  on  the  eventual  lack  of  activation  
of  Wnt/β-­‐‑catenin   pathway   in   these   cells,   since   the   transcription   of   the   canonical  
Wnt  target  gene  Axin-­‐‑2  was  strongly  upregulated  in  lung  ECs  isolated  from  GOF  
mice  compared  to  those  isolated  from  control  animals  (Fig.  11b).  
Finally,   in   GOF   8   dpn   pups   Fgfbp1   levels   are   significantly   higher   in   brain   ECs  





Figure  11.  Analysis  of  Fgfbp1  and  Axin-­‐‑2  expression  in  lung  and  brain  ECs  in  a  β-­‐‑catenin  gain-­‐‑
of-­‐‑function  model  
qRT-­‐‑PCR  analysis  of   (a)  Fgfbp1  and   (b)  Axin-­‐‑2  expression   in  ECs   freshly   isolated   from  the  brain  
and   the   lungs   of   WT   and   β-­‐‑catlox(ex3)/wtx   Cdh5(PAC)-­‐‑CreERT2   (GOF)   8   dpn   pups.   The   levels   of  
mRNA  are  normalized  on  18S.  Data  are  presented  as  mean  ±  standard  deviation  of   the  analyzed  
samples  (WT:  n=2;  GOF:  n=6).  *:  p<0.05;  **:p<0.001.  
  
Lastly,   we   confirmed   that   the   expression   of   Fgfbp1   was   lower   in   lung   ECs  
compared  to  brain  ECs  also   in  older  mice,  as  shown  by  the  qRT-­‐‑PCR  analysis  of  
Fgfbp1  mRNA  levels   in  microvascular  fragments  isolated  from  the  brain  and  the  






Figure  12.  Analysis  of  Fgfbp1  expression  in  lung  and  brain  ECs  of  1  week  old  and  3  weeks  old  
mice  
qRT-­‐‑PCR  analysis  of  Fgfbp1  expression   in  ECs  freshly   isolated  from  the  brain  and  the   lungs  of  1  
week   old   and   3   weeks   old   WT   mice.   The   levels   of   mRNA   are   normalized   on   18S.   Data   are  
presented  as  mean  ±  standard  deviation  of  the  analyzed  samples  (WT:  n=2;  GOF:  n=6).  *:  Lung  vs.  
Brain:  p<0.05.  ^:  3  weeks  vs.  1  week:  p<0.05.  
  
	  
3.1.3  Fgfbp1  is  upregulated  by  Wnt  pathway  activation  in  a  zebrafish  model  
To   further   confirm   these   in   vivo   observations,   we   decided   to   analyze   a   second  
animal   model:   zebrafish.   The   preparatory   bioinformatics   analysis   performed   to  
search   for   FGFBP1   homologues   in   human,   mouse   and   zebrafish   showed   that  
FGFBP1   belongs   to   a   family   of   proteins,   that   includes   three   different  members:  
FGFBP1,   2   and   3.   Both   FGFBP1   and   2   are   present   in   zebrafish   as   two   different  
paralogues:  a  and  b.  Despite  a  quite  low  total  sequence  homology  of  FGFBP1a  and  
b   with   both   human   and   mouse   protein   sequences   (23%   and   24%   amino   acid  
identities   to   human   and   mouse,   respectively),   the   functional   domains   of   the  
protein   (the   C-­‐‑terminal   FGF-­‐‑binding   domain   and   the   intermediate   heparin-­‐‑
binding   domain)   resulted   to   be   very   conserved   among   the   three   species.   In  
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addition,  FGFBP1b  is  the  zebrafish  paralogue  with  the  highest  homology  with  the  
murine  and  human  proteins.    
To   study   the   effect   of   Wnt   signaling   activation   on   zebrafish   Fgfbp1a   and   b  
expression,  we  took  advantage  of  the  transgenic  line  Tg(fli1a:EGFP),  in  which  ECs  
are  marked   in  green  by  the  expression  of  GFP,   that   is  driven  by  the  endothelial-­‐‑
specific  promoter  fli1a.  Tg(fli1a:EGFP)  eggs  were  collected  and  injected  with  either  
a  control  or  a  Dkk1  morpholino   to  specifically  enhance  Wnt  activity.  Three  days  
after  the  morpholino  injection,  embryos  were  disaggregated  and  cells  were  sorted  
for  GFP  fluorescence  in  order  to  obtain  two  subpopulations:  GFP  positive  (GFP+,  
mainly   endothelial)   and   GFP   negative   (GFP-­‐‑,   mainly   non-­‐‑endothelial).   Total  
mRNA  was  extracted  from  sorted  cells  and  analyzed  by  semiquantitative  RT-­‐‑PCR  
for   the   expression   of   Fgfbp1a,   Fgfbp1b   and  Axin-­‐‑2   (as   an   internal   control   of   an  
effective  Wnt  activity  enhancement  by  Dkk1  morpholino   injection).  As  expected,  
Axin-­‐‑2  was   significantly   increased   upon  MO-­‐‑Dkk1   injection   in   both   endothelial  
and   non   endothelial   cells   (p<0.05),   indicating   that   the   treatment   effectively  
induced  Wnt  signaling  activation.   In  ECs,  both  Fgfbp1a  and  b  were  significantly  
upregulated   by  Wnt   activity   (p<0.05);   conversely,   in   non   endothelial   cells   MO-­‐‑
Dkk1  injections  resulted  to  be  able  to  increase  only  Fgfbp1a  mRNA  levels  (p<0.05),  
while  Fgfbp1b  was  not  significantly  modulated.  Finally,  the  analysis  showed  that  
already   in   basal   conditions   (i.e.   in   control-­‐‑injected   samples)   Fgfbp1a   expression  
was  lower  in  non-­‐‑endothelial  cells  compared  to  ECs,  and  vice  versa  Fgfbp1b  was  
lower  in  ECs  than  in  non-­‐‑endothelial  cells,  suggesting  a  different  cell  specificity  of  




Figure  13.  Analysis  of  Fgfbp1a  and  b  expression  upon  Wnt  signaling  activation  
(a)   Semiquantitative   RT-­‐‑PCR   analysis   of   GFP+   and   GFP-­‐‑   cells   isolated   and   sorted   from  
Tg(fli1a:EGFP)   3   dpf   zebrafish   embryos   after   injection   with   either   a   control   morpholino   (MO-­‐‑
CTRL)  or  a  Dkk1  morpholino  (MO-­‐‑Dkk1)  and  (b)  its  quantification.  Data  are  presented  as  mean  ±  
standard   deviation   of   replicates   of   a   representative   experiment   (n=2).   *:   ECs  MO-­‐‑Dkk1   vs.  MO-­‐‑
CTRL;  non  ECs  MO-­‐‑Dkk1  vs.  MO-­‐‑CTRL:  p<0.05.  ^:  MO-­‐‑CTRL  non-­‐‑ECs  vs.  EC:  p<0.05  
  
3.2  Characterization  of  Fgfbp1  expression  and  function  in  the  zebrafish  model  
3.2.1  Fgfbp1a  and  b  are  differentially  expressed  during  zebrafish  development  
To   evaluate   Fgfbp1a   and   b   expression   during   zebrafish   development,   we  
performed   a   semiquantitative   RT-­‐‑PCR   on   whole   embryo   mRNA   extracts,   with  
primer   pairs   specifically   designed   to   amplify   each   of   the   two   transcripts,   at  
different   embryonic   stages:   2  hours  post   fertilization   (hpf),   9   hpf,   24  hpf,   48  hpf  
and   72   hpf.   The   results   showed   that   the   two   paralogues   were   differentially  
expressed   during   larvae   development:   Fgfbp1a   was   expressed   at   low   levels  
already  at  2  and  9  hpf,  it  was  strongly  upregulated  at  24  and  48  hpf  and  it  started  
decreasing  at  72  hpf;  Fgfbp1b  was  completely  absent  until  24  hpf,  when  it  started  
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being   expressed   at   low   levels,   and   then   gradually   increased   at   later   time  points  
(Fig.  14).  
  
Figure  14.  Kinetics  of  expression  of  Fgfbp1a  and  b  in  zebrafish  during  development  
Representative  image  of  a  semiquantitative  RT-­‐‑PCR  analysis  of  Fgfbp1a  and  b  expression  in  whole  
embryo  mRNA   extracts   at   different   developmental   stages.   β-­‐‑actin  was   used   as   internal   loading  
control.    
  
To  further  investigate  the  expression  pattern  of  Fgfbp1a  and  b  in  terms  of  spatial  
distribution,  we  performed  an   In  Situ  Hybridization   (ISH)  with  antisense  probes  
specific   for   each   of   the   two   transcripts.   The   ISH   revealed   an   almost   ubiquitous  
pattern  of  expression  for  both  paralogues,  confirming  the  reports  in  the  literature  
about   Fgfbp1   role   during   development   of   different   tissues   and   organs.  
Observation   at   high   magnification   also   revealed   the   presence   in   the   brain   of  
strongly  positive  structures  with  a  topology  very  similar  to  that  of  the  major  brain  
vessels   (Fig.   15,   arrows).   The   same   structures  were   also   visible   in   100   µμm-­‐‑thick  
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vibratome  sections  of  72  hpf  larvae,  where  it  was  possible  to  distinguish  also  the  
vascular  lumen  of  the  major  vessels  (Fig.  15,  arrowhead).  
  
Figure  15.  Localization  of  Fgfbp1a  and  b  during  zebrafish  development  
Representative  image  of  an  In  Situ  Hybridization  (ISH)  analysis  of  the  expression  of  Fgfbp1a  and  b  
in   zebrafish   embryos   at   different   developmental   stages.   Arrows   indicate   strongly   stained  
structures  with   a   vascular-­‐‑like   topology;   the   arrowhead   indicates   the   vascular   lumen  of   a  major  
brain  vessel.  
  
3.2.2  Fgfbp1a  and  b  knock  down  in  vivo  causes  brain  hemorrhages  in  zebrafish  
To   test   the   role   of   Fgfbp1a   and   b   during   zebrafish   development,  we  decided   to  
silence  them  using  specific  morpholinos.  The  designed  morpholinos  belong  to  the  
class  of  ATG-­‐‑blocking  morpholinos,  meaning  that   they  bind  to  ATG  sequence  of  
the   mRNA   and   block   its   translation   into   protein   (Fig.   16a).   For   this   reason,   to  
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check   for   the   efficacy   of   the   designed   morpholinos   in   blocking   their   specific  
targets,  we  used  two  DNA  constructs  (one  for  Fgfbp1a  and  the  other  for  Fgfbp1b)  
in   which   the  morpholino   target   sequence   is   tagged  with   GFP:   in   presence   of   a  
specific  and  effective  binding  of   the  morpholinos   to   their   respective   target  DNA  
construct,  the  GFP  signal  is  expected  to  be  switched  off  (Fig.  16b).  We  injected  the  
DNA  constructs  in  the  fertilized  eggs,  alone  or  in  combination  with  the  respective  
morpholino,  and  subsequently  analyzed  GFP  expression  in  8  hpf  embryos  with  a  
fluorescence  microscope.  As  shown  in  Fig.  16c,  GFP  was  clearly  expressed  when  
the  construct  was   injected  alone,  but   it  was  switched  off  when  the  construct  and  
the  morpholino  were  coinjected,  indicating  that  each  morpholino  was  effective  in  
blocking  its  specific  target  sequence.  Importantly,  the  turning  off  of  the  GFP  was  
not   an   aspecific   effect   due   to   the   coinjection   of   both   construct   and  morpholino,  
since  the  eggs  that  received  the  morpholino  together  with  the  empty  vector  were  




Figure  16.  Design  and  testing  of  morpholinos  targeting  Fgfbp1a  and  b  
(a)  Mechanism  of  action  of  the  designed  ATG-­‐‑blocking  morpholinos.  (b)  Design  of  the  constructs  
for  the  test  of  efficacy  of  the  morpholinos.  Two  different  DNA  constructs,  with  either  Fgfbp1a  or  b  
sequence  fused  to  GFP,  were  designed  in  order  to  be  coinjected  with  the  respective  morpholino.  (c)  
Test   of   efficacy   of   the   designed   morpholinos.   The   DNA   constructs   were   injected   alone   or   in  
combination  to  the  respective  morpholino  in  order  to  check  for  the  expression  of  GFP.  
  
The  morpholinos  were  injected  into  a  wild  type  zebrafish  strain  to  search  for  gross  
morphological  alterations.  The  morphological  analysis  did  not  show  any  evident  
difference   in   size   and   overall   development,   but   it   displayed   the   presence   of  
hemorrhagic  events  in  both  Fgfbp1a  and  Fgfbp1b  morphants.  In  particular,  more  
than   half   of   the   animals   treated   with   MO-­‐‑Fgfbp1a   (51,65%;   p<0.001)   presented  
large  hemorrhagic  areas  in  the  brain  and  15,38%  (p<0.001)  of  them  presented  small  
hemorrhages   in   other   body   regions;   conversely,   a   much   smaller,   but   still  
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statistically  significant,  proportion  of  MO-­‐‑Fgfbp1b-­‐‑injected  animals  (brain:  4,55%;  
other:  4,55%;  p<0.001)  displayed  hemorrhages  in  the  brain  and  in  other  regions.  In  
addition,  brain  hemorrhages  of  Fgfbp1b  morphants  were  much  smaller  compared  
to  those  of  MO-­‐‑Fgfbp1a-­‐‑injected  animals,  and  most  of  the  time  they  were  so  small  
that   they  could  not  be  detected  by  direct  stereomicroscope  observation  but  were  
revealed  only  after  O-­‐‑dianisidine  staining  to  detect  hemoglobin  (Fig.  17).  
  
Figure  17.  Quantification  of  the  hemorrhagic  phenotype  in  Fgfbp1a  and  b  morphants    
(a)  Morphological   observation   and   (b)   hemorrhages   quantification   after   injection   of   either  MO-­‐‑
FGFBP1a  or  MO-­‐‑FGFBP1b.  All  animals  were  injected  at  1-­‐‑cell  stage  and  analyzed  48  hours  later  by  
simple   stereomicroscope   observation   or   by   O-­‐‑dianisidine   staining.   At   least   40   animals   were  
analyzed  for  each  condition.  Scale  bar:  500  µμm.  
  
3.2.3   Fgfbp1a   and   b   knock   down   in   vivo   causes   defects   in   zebrafish   vascular  
development  
To   determine   whether   the   occurrence   of   the   hemorrhages   was   due   to   vascular  
defects,  we  took  advantage  again  of  Tg(fli1a:eGFP)  line  to  visualize  blood  vessels  
morphology   after   morpholino   injections.   During   normal   zebrafish   vascular  
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development,   as   well   as   in   MO-­‐‑CTRL   treated   animals,   the   intersomitic   vessels  
(ISVs)   start   sprouting   from   the  dorsal   aorta   (DA)   towards   the  dorsal   side  of   the  
trunk,   where   they   finally   fuse   perpendicularly   to   form   the   dorsal   longitudinal  
anastomotic   vessel   (DLAV).   Upon   injection   of   MO-­‐‑Fgfbp1a   the   normal   trunk  
vascular  development  looked  affected:  the  number  of  ISVs  that  started  sprouting  
from   the   DA   was   strongly   reduced   at   all   analyzed   stages   (24,   48   and   72   hpf)  
(p<0.001),   and  most   of   them   failed   to   efficiently   form   connections   at   the   DLAV  
(p<0.001).   Conversely,   the   ISVs   sprouting   process   occurred   normally   in   MO-­‐‑
Fgfbp1b   injected   animals,   but   the   process   of   DLAV   formation   was   impaired:  
indeed,  while  at  48  hpf  there  was  a  higher  number  of  ISVs  forming  connections  at  
the   DLAV   compared   to   age-­‐‑matched   controls   (p<0.025),   this   number   did   not  
increase   at   later   stages   (72   hpf),   remaining   lower   than   in   MO-­‐‑CTRl   animals  
(p<0.05),   indicating   that   the   vascular   development   was   accelerated   in   the   first  
phases,   but   then   it   slowed   down   and   failed   to   form   a   completely   developed  




Figure  18.  Analysis  of  the  trunk  vascular  development  in  zebrafish  upon  Fgfbp1  knock  down  
(a)   Representative   images   of   confocal  Z-­‐‑stacks   of   trunk  vascular  phenotype   in  Tg(fli1a:EGFP)   72  
hpf   animals   after   injection   with   either   MO-­‐‑Fgfbp1a   or   MO-­‐‑Fgfbp1b.   Scale   bar:   250   µμm.   (b)  
Quantification  of  the  number  of  ISVs  sprouting  from  the  DA  in  MO-­‐‑CTRL,  MO-­‐‑Fgfbp1a  and  MO-­‐‑
Fgfbp1b   animals   at   24,   48   and   72   hpf.   For   each   group,   at   least   30   animals   were   analyzed.   **:  
p<0.001.  (c)  Quantification  of  the  number  of  ISVs  forming  connections  at  the  DLAV  in  MO-­‐‑CTRL,  
MO-­‐‑Fgfbp1a   and  MO-­‐‑Fgfbp1b   animals   at   24,   48   and   72  hpf.   For   each  group,   at   least   30   animals  
were  analyzed.  *:  p<0.05;  **:  p<0.001.  
  
Besides   the   defects   in   the   development   of   the   ISVs   and   of   the   DLAV,   some  
vascular   abnormalities   were   also   found   in   the   head   vasculature.   Indeed,   while  
control   animals   had   a   regular   and   organized   brain   vasculature,   Fgfbp1a  
morphants  showed  the  lack  of  some  vessels  (Fig.  19,  arrows),  possibly  indicating  a  
defective   sprouting   activity;   conversely,   Fgfbp1b   morphants   showed   some  
76	  
	  
tortuous   and   irregular   vessels   (Fig.   19,   arrowhead)  with   hyperbranching   events  
(Fig.  19,  asterisk).  
  
Figure  19.  Analysis  of  the  head  vascular  development  in  zebrafish  upon  Fgfbp1  knock  down  
Representative   images  of   confocal  Z-­‐‑stacks  of  head  vascular  phenotype   in  Tg(fli1a:EGFP)   72  hpf  
animals  after  injection  with  either  MO-­‐‑Fgfbp1a  or  MO-­‐‑Fgfbp1b.  Scale  bar:  250  µμm.  Arrows:  lacking  
vessels;  arrowhead:  tortuous  vessel;  asterisk:  extrabranching.  
  
To   clarify   the   dynamics   of   uprising   of   the   vascular   defects   in   the   head,   we  
performed   the   morpholino   injections   in   the   double   transgenic   strain  
Tg(fli1a:EGFP)xTg(gata1a:dsRed),   in  which  ECs  are  highlighted   in  green  by  GFP  
and  erythrocytes  are  highlighted  in  red  by  dsRed.  We  then  performed  in  vivo  time  
lapse  confocal  microscopy  of  48  hpf  animals  to  follow  the  vascular  development  of  
the  brain  for  at  least  5  hours  (see  Fig.  20  and  movies  1-­‐‑2-­‐‑3).    
The   time   lapse   of   control-­‐‑injected   animals   showed   a   normal   vascular  
development,  with   the   typical   sprouting   vessel   (Fig.   20,   circle)   that   searches   the  
surrounding   region,   fuses   with   another   proximal   vessel   and   finally   opens   its  
lumen  allowing  the  blood  flow  to  start  (movie  1).  
Conversely,  the  time  lapse  on  MO-­‐‑Fgfbp1a  animals  showed  an  impairment  in  the  
sprouting   process,   resulting   in   the   inability   of   the   brain   vasculature   to   develop  
77	  
	  
properly.  Moreover,   also   the   arising   of   the   hemorrhagic   phenotype   was   clearly  
visible  as  the  accumulation  of  dsRed  positive  erythrocytes  (movie  2;  Fig.  20,  dotted  
circle).  
Finally,   in   the  Fgfbp1b  morphants   the   time   lapse   showed   that,  despite   a  normal  
and  effective  sprouting  process,  the  developing  vessels  had  difficulties  in  defining  
their  correct  growing  trajectory.  As  a  result  of  this  impairment  in  the  path-­‐‑finding,  
the  vessel  alternated  phases  of  growth  and  regression  to  constantly  search  for  the  
correct  orientation  (movie  3  and  Fig.  20;  the  arrow  indicates  the  growing  vessels,  
the  dotted  lines  represent  the  former  trajectories  of  the  vessel).  
  
Figure  20.  Time  lapse  confocal  microscopy  analysis  of  the  brain  vascular  phenotype  of  Fgfbp1a  
and  Fgfbp1b  morphants  
Time  lapse  microscopy  of  Tg(Fli1a:EGFP)xTg(gata1a:dsRed)  animals  injected  with  MO-­‐‑CTRL,  MO-­‐‑
Fgfbp1a  or  MO-­‐‑Fgfbp1b.  Anestethized  48  hpf  embryos  were  immobilized  in  4%  LMP  agarose  and  
12  µμm  Z-­‐‑stacks  were  acquired  every  15  minutes  for  at  least  5  hours.  Circle:  area  of  sprouting  of  a  
new  brain  vessel;  dotted  circle:  area  of  hemorrhage;  arrow:  brain  vessel  with  impaired  path-­‐‑finding  




3.2.4   Fgfbp1a   knock   down   in   vivo   causes   increased   vascular   permeability   in  
zebrafish  brains  
Finally,   to   analyze   the   effect   of   Fgfbp1   knock   down   on   brain   vascular  
permeability,  we  performed  a  functional  assay  by  injecting  rhodamine-­‐‑labeled  10  
kDa  dextran   into   the   venous   sinus   of   72   hpf  morphants   and   analyzing   them   40  
minutes   after   the   injection.  We  observed   that   the   tracer  was   retained  within   the  
brain   vessels   both   in   control   animals   and   in   Fgfbp1b   morphants,   indicating   an  
effective   control   of   permeability;   conversely,   in   Fgfbp1a   morphants   the   vessels  
were  no  longer  able  to  retain  the  tracer,  indicating  that  Fgfbp1a  loss  causes  defects  
in   the   control   of   brain   vascular   permeability   (Fig.   21a).   To   get   quantitative  
information   from   this   functional   assay,   we   also   performed   the   injection   with  
DAPI,   in   order   to   count   the   number   of   DAPI   positive   cells   in   the   brain  
parenchyma,   that   is   proportional   to   the   amount   of   dye   that   leaks   out   of   the  
vessels.   The   quantification   confirmed   a   massive   increase   in   brain   vascular  
permeability  in  Fgfbp1a  morphants,  while  MO-­‐‑Fgfbp1b  injected  animals  showed  a  
number   of   DAPI   positive   brain   nuclei   comparable   to   that   of   control-­‐‑injected  







Figure  21.  In  vivo  permeability  assay  on  Tg(fli1a:EGFP)  morphants  
(a)  Representative  confocal  Z-­‐‑stack  images  of  the  in  vivo  permeability  assay.  Rhodamine-­‐‑labeled  10  
kDa  dextran  was  injected  in  the  venous  sinus  of  72  hpf  Tg(fli1a:EGFP)  morphants  and  the  animals  
were  fixed  in  4%  PFA  40  minutes  after  the  injection.  At  least  10  animals  were  injected  and  analyzed  
per  each  group.  (b)  Quantification  of  the  in  vivo  permeability  assay.  DAPI  was  injected  in  the  same  
way  as  rhodamine-­‐‑labeled  10  kDa  dextran,  larvae  were  fixed  40  minutes  after  the  injection  and  the  
number   of   DAPI   positive   cells   in   brain   parenchyma   was   quantified.   At   least   10   animals   were  
injected  and  quantified  per  each  group.  p<0.01.  
  
3.3   Characterization   of   Fgfbp1   expression   and   function   in   the   murine   brain  
vasculature  
3.3.1  FGFBP1  is  expressed  age-­‐‑dependently  and  is  localized  perivascularly  
Given   the   vascular   phenotype   observed   in   zebrafish   when   performing   the  
ubiquitous  knock  down  of  Fgfbp1,  we  decided  to  further  investigate  whether  the  
mechanism   by   which   FGFBP1   absence   causes   vascular   defects   might   be  
attributable  to  the  fraction  of  the  protein  that  is  of  endothelial  origin.  In  particular,  
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we  decided   to   focus   our   attention   on   the   analysis   of   the   brain   since,   as   already  
discussed   in   the   introduction  and   in   the  previous  results  sections,  Wnt/β-­‐‑catenin  
pathway  has  a  particular   relevance   in   the  differentiation  of   the  CNS  vasculature  
and   Fgfbp1   was   shown   to   have   a   higher   expression   in   brain-­‐‑derived   ECs  
compared   to   lung-­‐‑derived   ECs,   both   in   basal   conditions   and   in   β-­‐‑catenin  
overactivation  conditions  (GOF).  
For  our  purpose,  we  took  advantage  of  the  murine  transgenic  line  Fgfbp1flox/flox,  in  
which   the   exon   2   of   Fgfbp1   gene   is   included   between   two   LoxP   sites,   that   are  
recognized   and   cleaved   by   CRE   recombinase.   We   crossed   this   strain   with   the  
transgenic  Cdh5(PAC)-­‐‑CreERT2   (VEC-­‐‑PAC)   strain   to  obtain   the  Fgfbp1flox/flox/VEC-­‐‑
PAC   line,   that   allows   us   to   temporally   control   the   knock-­‐‑out   of   Fgfbp1   gene   to  
achieve  a  conditional  Fgfbp1  endothelial  cell-­‐‑specific  knock-­‐‑out  (ECKO)  (Fig.  22).  
  
Figure  22.  Design  of  the  Fgfbp1flox/flox/VEC-­‐‑PAC  transgenic  mouse  model  
Exon   2   of   Fgfbp1   gene   is   surrounded   by   LoxP   sites   in   Fgfbp1flox/flox  mice;   after   crossing  with   the  
VEC-­‐‑PAC   strain,   CRE   recombinase   is   expressed   only   in   ECs.  When   tamoxifen   is   injected   at   the  
desired  age,  ERT2  tamoxifen-­‐‑responsive  sequence  allows  to  translocate  CRE  recombinase  into  the  




To   determine   the   extent   of   recombination   achievable   with   this   system   and   to  
establish   a   time-­‐‑dependent   expression   curve   of   Fgfbp1   mRNA   in   the   brain  
endothelium,  we   isolated  microvascular   fragments   from   the  brain  of   1  week  old  
and  3  weeks  old  mice  that  received  tamoxifen  soon  after  birth  (0  dpn).  From  the  
qRT-­‐‑PCR   analysis   emerged   that   Fgfbp1   expression   levels   were   significantly  
different  also  when  comparing  brain  ECs  at  different  ages:  indeed,  Fgfbp1  mRNA  
isolated   from   brain   ECs   of   3   weeks   old   mice   was   60%   less   compared   to   that  
isolated   from   brain   ECs   of   1  week   old  mice   (p<0.05).  Moreover,   one  week   after  
tamoxifen   injection   in   Fgfbp1flox/flox/VEC-­‐‑PAC   mice,   Fgfbp1   mRNA   levels   were  
reduced  to  15%  of  age-­‐‑matched  control  mice  (p<0.05)  (Fig.  23).  
  
Figure  23.    Analysis  of  Fgfbp1  expression  in  brain  ECs  of  Fgfbp1  WT  and  ECKO  mice  at  1  and  3  
weeks  of  age  
qRT-­‐‑PCR  analysis  of  Fgfbp1expression  in  ECs  freshly  isolated  from  the  brain  of  1  week  old  and  3  
weeks  old  Fgfbp1flox/flox/VEC-­‐‑PAC  mice  injected  (ECKO)  or  not  (WT)  with  tamoxifen.  The  levels  of  
mRNA  are  normalized  on  18S.  Data  are  presented  as  mean  ±  standard  deviation  of   the  analyzed  
samples  (1  week  WT:  n=7,  ECKO:  n=4;  3  weeks  WT:  n=4;  ECKO:  n=6).  *:  p<0.05.  
  
To   further   evaluate   the   efficiency   of   the   recombination   and   to   assess   the  
localization  of  FGFBP1  protein,  we  performed  an  immunostaining  for  FGFBP1  on  
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brain  sections.  As  expected,  the  protein  was  not  endothelial-­‐‑specific,  but  a  strong  
and   intense   perivascular   staining   indicated   that   a   fraction   of   the   protein  
accumulated  around   the  vessels,  detected  by  PECAM  staining,   in  WT  mice.  The  
perivascular   staining   of   FGFBP1  was  massively   reduced   in   Fgfbp1   ECKO  mice,  
indicating   that   the   FGFBP1   fraction   that   resided   in   the   perivascular   area   was  
indeed  of  endothelial  origin  (Fig.  24).    
  
Figure  24.  Analysis  of  FGFBP1  protein  localization  in  brain  vasculature  
Representative   immunostaining   of   FGFBP1   (green)   and   PECAM   (red)   in   brain   sections   from   1  
week   old   animals.   Endothelial-­‐‑derived   FGFBP1  protein   is   localized  perivascularly   in  WT  brains,  
while  it  is  strongly  reduced  in  Fgfbp1  ECKO  brains.  Scale  bar:  100  µμm.    
  
Finally,   by   further   crossing   Fgfbp1flox/flox/VEC-­‐‑PAC   animals   with   the   Rosa   26-­‐‑
Enhanced   Yellow   Fluorescent   Protein   (R26-­‐‑EYFP)   reporter   strain,   that   expresses  
EYFP  only  after  CRE-­‐‑mediated  deletion  of  a  LoxP-­‐‑flanked  stop  codon,  we  verified  
that  in  our  model  system  CRE  recombinase  was  homogeneously  active  in  all  brain  
vasculature   (Fig.   25),   strongly   suggesting   that   also  Fgfbp1  deletion  might   follow  




Figure   25.   Analysis   of   EYFP   expression   in   Fgfbp1flox/flox/VEC-­‐‑PAC/R26-­‐‑EYFP   1   week   old  mice  
upon  tamoxifen  injection  
Representative   confocal   Z-­‐‑stack   images   of   brain   sections   of   1   week   old   Fgfbp1   ECKO   mice.  
Sections  were  immunostained  for  EYFP  and  for  the  endothelial  marker  PECAM.  Scale  bar:  100  µμm.  
  
3.3.2   Fgfbp1   endothelial-­‐‑specific   knock   out   causes   vascular   abnormalities   in  
brain  and  retinas  
To   understand   if   endothelial   FGFBP1   has   a   role   during   embryonic   vascular  
development,   we   crossed   a   Fgfbp1flox/flox/VEC-­‐‑PAC   animal   with   a   Fgfbp1flox/flox  
animal  and  intraperitoneally  injected  tamoxifen  in  the  pregnant  female  at  day  13.5  
post   coitum   (13.5  dpc).   The   female  was   then   sacrificed   at   17.5  dpc,   the   embryos  
were   fixed   and   the   brains  were   dissected   for   immunofluorescence   analysis.   The  
immunostaining  for  the  EC  marker  PECAM  showed  that  the  brain  vasculature  of  
FGFBP1   ECKO   embryos   was   irregular   and   disorganized   compared   to   control  
animals.  In  particular,  in  the  cortex  region  vessels  were  straight  and  regular  in  the  
control  animals,  while  they  were  shorter,  more  branched  and  discontinuous  in  the  
ECKO   animals;   in   addition,  many   vessels   appeared   to   be   “curly”   and   tortuous,  




Figure  26.  Vascular  phenotype  of  Fgfbp1  WT  and  ECKO  embryos  
Representative   PECAM   immunostainings   on   brain   sections   (100  µμm   thickness)   from  Fgfbp1  WT  
and  ECKO  embryos  at  17.5  dpc.  Recombination  was  induced  by  intraperitoneal  tamoxifen  injection  
in  the  mother  at  day  13.5  dpc.  Scale  bar:  200  µμm.  
  
We   further   analysed   the   vascular   phenotype   by   performing   PECAM  
immunostaining   on   brain   sections   from   WT   and   ECKO   animals   at   different  
postnatal  ages:   1  week,  2  weeks  and  3  weeks.  Again,  as  already  observed   in   the  
embryos,  many  abnormal  “curly”  vascular  structures  were  present  (Fig.  27a).  The  
impairment   in   the   vascular   development   was   clear   also   from   vascular   density  
quantification:  while  during   the   first  postnatal  week  ECKO  mice  show  a  slightly  
less  dense  brain  vasculature  compared  to  WT  animals,  the  vascular  density  tends  
to  increase  later  on,  becoming  significantly  higher  compared  to  control  animals  at  
3  weeks  of  age  (Fig.27b;  p<0.05).  In  addition,  as  shown  by  the  confocal  images  and  
by   the   related   quantifications,   brain   vessels   of   ECKO   mice   showed   an   higher  





Figure   27.  Analysis   of  brain  vasculature   in   Fgfbp1  WT  and  ECKO  mice   at   different  postnatal  
ages  
(a)  Representative  images  of  confocal  Z-­‐‑stacks  of  brain  sections  (100  µμm  thickness)  of  Fgfbp1  WT  
and   ECKO  mice   at   1,   2   and   3   weeks   of   age.   Sections   were   immunostained   for   the   endothelial  
marker  PECAM.  Scale  bar:  200  µμm.  (b)  Quantification  of  the  vascular  density  (percentage  of  area  
covered  by  PECAM  positive  vessels)  of  Fgfbp1  WT  and  ECKO  mice  at  1,  2  and  3  weeks  of  age.  For  
each  age  group,  2  WT  and  3  ECKO  mice  were  analyzed.  *:  p<0.05  (c)  Quantification  of  the  number  
of  branching  points  per  20x  magnification  field  of  Fgfbp1  WT  and  ECKO  mice  at  1,  2  and  3  weeks  
of  age.  For  each  age  group,  2  WT  and  3  ECKO  mice  were  analyzed.  *:  p<0.05  
  
Finally  we   investigated   retinal   vasculature   as   a  model   system   for   BBB   vascular  
development.  Whole  mount  retinas  from  Fgfbp1  WT  and  ECKO  mice  at  different  
ages  were  immonostained  for  PECAM  and  analysed  by  confocal  microscopy  (only  
images  corresponding   to  1  week  old  mice  are   reported   in  Fig.  28a).  The  analysis  
confirmed  the  same  abnormal  and  atypical  features  that  has  been  already  shown  
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for   both   embryonic   and   postnatal   brain   vasculature,   with   the   curly   phenotype  
interesting   mainly   the   big   vessels   (both   arteries   and   veins)   departing   from   the  
centre   of   the   retina.   Although   vessel   density   did   not   result   to   be   significantly  
different  between  WT  and  ECKO  animals  at  all  analysed  stages  (Fig.  28b),  Fgfbp1  
ECKO  presented  an  accelerated  vascular  growth  during  the  initial  phases  of  retina  
vascularization,  as  shown  by  the  quantification  of  the  radial  growth  of  angiogenic  
area   from   the   retina   centre   towards   the   periphery   (Fig.   28c;   newborn:   p<0.05;   1  
week:   p<0.01).   Consistently,   the   observation   of   the   angiogenic   leading   front   at  
retina  periphery   revealed  an   increased  number  of   filopodia  protruding   from   the  
tip-­‐‑cells,   the   endothelial   cells   responsible   for   migration,   in   1   week   old   Fgfbp1  
ECKO   mice   compared   to   age-­‐‑matched   control   animals   (Fig.   28a,   asterisks).   In  
addition,   1   week   after   birth   also   the   number   of   vessel   branching   points   at   the  
periphery  was  increased  in  ECKO  animals,  while  the  number  of  branches  from  the  
big  arteries  and  veins  departing  from  the  centre  of  the  retina  remained  unchanged  
(Fig.   28d).   Interestingly,   both   arterial/venous   and   peripheral   branching   points  
tended   to   decrease   at   2   and   3   weeks   of   age,   possibly   as   a   result   of   a   vascular  
remodeling  process;  this  process  mainly  seemed  to  occurr  to  equal  extents  both  in  
WT   and  ECKO  animals,   except   for   a   significative   reduction   of   branching  points  




Figure  28.  Analysis  of  retinal  vasculature  in  Fgfbp1  WT  and  ECKO  mice  at  different  postnatal  
ages  
(a)  Representative   images  of   confocal  Z-­‐‑stacks  of  whole  mount   retinas  of  Fgfbp1  WT  and  ECKO  
mice  at  1week  of  age.  Retinas  were  immunostained  for  the  endothelial  marker  PECAM.  Scale  bars:  
200  µμm,  100  µμm  and  30  µμm.  (b)  Quantification  of  the  vascular  density  (percentage  of  area  covered  
by  PECAM  positive  vessels)  of  Fgfbp1  WT  and  ECKO  mice  at  1,  2  and  3  weeks  of  age.  For  each  age  
group,   4   WT   and   6   ECKO   mice   were   analyzed.   (c)   Quantification   of   vascular   radial   growth  
(measured   as   distance   between   retina   centre   and   angiogenic   leading   front)   of   Fgfbp1   WT   and  
ECKO  mice  soon  after  birth  (1  dpn)  and  at  1,  2  and  3  weeks  of  age.  For  each  age  group,  4  WT  and  6  
ECKO   mice   were   analyzed.   *:   p<0.05;   **:   p<0.01   (d)   Quantification   of   the   number   of   vessel  
branching  points  of  Fgfbp1  WT  and  ECKO  mice  at  1,  2  and  3  weeks  of  age.  For  arteries  and  veins,  
the  number  of  branching  points  per  250  µμm  vessel  length  is  reported;  for  the  peripheral  vessels,  the  
number  of  branching  points  per  field  (250  µμm  x  250  µμm    area)  is  indicated.  For  each  age  group,  4  





3.3.3  Fgfbp1  ECKO  mice  show  alterations  in  the  ultrastructural  organization  of  
the  NVU  
To  deeply  investigate  the  origin  of  the  vascular  abnormalities  observed  in  Fgfbp1  
ECKO   mice   and   to   evaluate   the   overall   organization   of   the   NVU   after   Fgfbp1  
deletion,  we  performed  electron  microscopy  on  brain  cortexes  of  Fgfbp1  WT  and  
ECKO  1  month  old  mice.    
In  control  animals,  blood  capillaries   in   the  cortex  exhibited   typical   features:   they  
contained  rather  few  caveolae,  their  TJs  were  well  developed  and  almost  around  
each   profile   it   was   possible   to   find   the   processes   of   pericytes,   that   were  
surrounded  by  the  same  BM  of  endothelial  cells  (eBM).  
Conversely,   some  obvious   alterations  were   found   in   the   cortex  of  Fgfbp1  ECKO  
animal.   The   section   of   capillaries   was   not   roundish   as   in   control   animals,   but  
mostly  oval  or  oblong,  with  a  reduction  in  the  thickness  of  the  endothelial  wall;  on  
the   other   hand,   both   the   structure   of   the   TJs   and   the   number   of   caveolae  were  
unchanged.  
Not  only  the  endothelial  layer  was  altered  in  Fgfbp1  ECKO  animals,  but  also  the  
other  components  of  the  NVU  resulted   to  be  impaired:  pericyte  processes  (Fig.  29,  
asterisks)   around   capillary   sections   were   quite   rare   and   the   BM   (Fig.   29,  
arrowheads)  was  much  thinner  than  in  control  animals;  moreover,  in  many  cases  
the   layer   of   astrocytes   surrounding   the   capillary   and   adjacent   to   the   BM   was  
swollen   (Fig.   29,   arrows)   and   the   contacts   between   neighboring   perivascular  
astrocytes  (Fig.  29,  boxed  area)  were  tighter  compared  to  WT  animals.    
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Overall,   the   data   collected   from   the   electron   microscopy   analysis   indicate   that  
alterations   in   the   organization   of   the  NVU  were   present   in   Fgfbp1   ECKO  mice  
compared  to  control  animals.  
	  
Figure   29.   Electron  microscopy   analysis   of   ultrastructural   organization   of   the  NVU   in   Fgfbp1  
WT  and  ECKO  mice  
Representative   images   of   electron  microscopy   (EM)   analysis   of   the   brain   cortex   of   1  month   old  
Fgfbp1  WT  and  ECKO  mice.   60  nm   thick   sections   from   three   animals  per  group  were   analyzed.  
Asterisks:   pericyte   processes;   arrowheads:   basement   membrane;   arrows:   astrocyte   swollening;  
boxed  areas:  inter-­‐‑astrocytic  junctions.  Scale  bars:  2  µμm,  1  µμm  ad  500  nm.  
  
3.3.4  Fgfbp1  ECKO  brain  vasculature  displays  defects  in  pericyte  coverage  and  
BM  composition  
Starting   from   the   information   obtained  by   the   electron  microscopy   experiments,  
we  decided  to  further  investigate  the  organization  of  the  NVU  in  Fgfbp1  WT  and  
ECKO  mice  at  different  postnatal  ages.  
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The   observation   that   cortex   blood   capillaries   of   ECKO   animals   were   rarely  
associated   to   pericyte   processes   suggested   the   possibility   that   the   number   of  
pericytes  might  be  reduced  in  ECKO  mice  compared  to  control  mice.  To  test  this  
hypothesis  we  performed  an  immunostaining  for  the  pericyte  marker  PDGFRβ  on  
brain  sections  (Fig.  30a)  and  quantified  the  number  of  PDGFRβ  positive  pericyte  
cell   bodies;  we   found   that,   at   all   analyzed   ages   (1,   2   and   3  weeks)   the  pericytes  
number   was   at   least   30%   lower   in   Fgfbp1   ECKO   mice   compared   to   their   age-­‐‑
matched  controls  (Fig.  30b,  p<0.05).  
	  
Figure  30.  Quantification  of  pericytes  number  in  Fgfbp1  WT  and  ECKO  mice  at  different  ages  
(a)  Representative  images  of  confocal  Z-­‐‑stacks  of  brain  sections  (100  µμm  thickness)  of  Fgfbp1  WT  
and   ECKO  mice   at   1,   2   and   3   weeks   of   age.   Sections   were   immunostained   for   the   endothelial  
marker  VE-­‐‑cadherin  and  for  the  pericyte  marker  PDGFRβ.  Scale  bar:  200  µμm.  (b)  Quantification  of  
the  number  of  PDGFRβ  positive  pericytes   (measured  as  number  of  pericytes  per   500  µμm2  vessel  
area)  of  Fgfbp1  WT  and  ECKO  mice  at  1,  2  and  3  weeks  of  age.  For  each  age  group,  2  WT  and  3  
ECKO  mice  were  analyzed.  *:  p<0.05.  
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To  further  investigate  the  pericyte  phenotype,  we  checked  also  for  the  expression  
of  two  other  pericyte  markers:  NG2,  a  proteoglycan  mainly  expressed  by  pericyte  
precursors,   and   desmin,   an   intermediate   filament   component   commonly  
expressed  by  quiescent  pericytes  [29].    
As  shown  by  Fig.  31,  1  week  old  ECKO  mice  display  an   increased  expression  of  
NG2  compared  to  WT  controls,  suggesting  that  pericyte  precursors  are  even  more  
recruited  to  blood  capillaries.  However  at  later  ages  both  NG2  and  desmin  are  less  
expressed   in   the   ECKO   mice   compared   to   WT,   possibly   indicating   that   the  
reduction  of  the  number  of  pericytes  might  be  due  to  a  defect  in  their  capability  to  
maintain  their  interaction  with  the  endothelium  and/or  in  their  maturation  rather  




Figure  31.  Analysis  of  the  pericyte  phenotype  in  Fgfbp1  WT  and  ECKO  mice  at  different  ages  
Representative  images  of  confocal  Z-­‐‑stacks  of  brain  sections  (100  µμm  thickness)  of  Fgfbp1  WT  and  
ECKO  mice  at  1,  2  and  3  weeks  of  age.  Sections  were   immunostained  for   the  endothelial  marker  
PECAM  and  for  the  pericyte  markers  NG2  and  desmin.  Scale  bar:  200  µμm.  
  
To  investigate  possible  defects  in  astrocyte  organization  and  more  in  particular  in  
astrocyte   endfeet   polarization,   we   immunostained   the   sections   for   the   astrocyte  
endfeet  marker  aquaporin  IV,  that  resulted  to  be  equally  expressed  and  correctly  




Figure  32.  Analysis  of  astrocyte  endfeet  polarization  by  aquaporin  IV  immunostaining  
Representative  images  of  confocal  Z-­‐‑stacks  of  brain  sections  (100  µμm  thickness)  of  Fgfbp1  WT  and  
ECKO  mice  at  1,  2  and  3  weeks  of  age.  Sections  were   immunostained  for   the  endothelial  marker  
VE-­‐‑cadherin  and  the  astrocyte  endfeet  marker  aquaporin  IV.  Scale  bar:  100  µμm.  
  
Finally,   taking   into   account   the   reduction   of   the   BM   thickness   detected   by   EM  
experiments,   we   sought   to   investigate   in   depth   the   composition   of   the   BM   by  
analyzing   one   by   one   the   expression   and   the   vessel   coverage   of   the   main   BM  
proteins:  Collagen  IV,  both  in  the  trimeric  form  and  the  single  chains  α1  (Col4a1)  
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and  α2  (Col4a2),  and  Laminins,  both  the  eBM-­‐‑specific  laminin  α4  and  α5  and  the  
pBM-­‐‑specific  laminin  α2.    
By   immunostaining   analysis,   Collagen   IV   resulted   to   be   decreased   in   brain  
sections  of  Fgfbp1  ECKO  mice  at  1,  2  and  3  weeks  compared  to  their  age-­‐‑matched  
controls  (Fig.  33a);  after  quantification  of  the  confocal  images  we  found  that  both  
vessel  coverage  (measured  as  the  percentage  of  collagen  IV  positive  endothelium)  
(Fig.  33b)  and  overall  expression  levels  (measured  as  mean  fluorescence  intensity)  
(Fig.   33c)  were   reduced,   even   though   the   reduction   in   overall   expression   levels  
resulted  to  be  statistically  significative  only  in  3  weeks  old  mice  (Fig.  33c;  p<0.05).  




Figure   33.  Analysis   of   collagen   IV  expression   and   coverage   in  Fgfbp1  WT  and  ECKO  mice   at  
different  ages  
(a)  Representative  images  of  confocal  Z-­‐‑stacks  of  brain  sections  (100  µμm  thickness)  of  Fgfbp1  WT  
and   ECKO  mice   at   1,   2   and   3   weeks   of   age.   Sections   were   immunostained   for   the   endothelial  
marker  PECAM  and  the  BM  protein  collagen  IV.  Scale  bar:  100  µμm.  (b)  Quantification  of  collagen  
IV  vessel   coverage   (measured   as   percentage   of   collagen   IV  positive   endothelium)   in   Fgfbp1  WT  
and  ECKO  mice   at   1,   2   and   3  weeks   of   age.   For   each   age   group,   2  WT   and   3   ECKO  mice  were  
analyzed.   *:   p<0.05.   (c)  Quantification   of   collagen   IV   expression   (measured   as  mean   collagen   IV  
fluorescence   intensity)   in   Fgfbp1  WT   and   ECKO  mice   at   1,   2   and   3  weeks   of   age.   For   each   age  
group,  2  WT  and  3  ECKO  mice  were  analyzed.  *:  p<0.05.  
	  
Given   the   alterations   in   Collagen   IV   expression   and   coverage,   we   went   on  
analyzing   the   single   collagen   IV   chains,   α1   and   α2,   that   are   known   from   the  
literature  to  be  produced  and  secreted  by  ECs.  
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Collagen   IV  α1  chain   (Col4a1)   staining   revealed  some  small  differences  between  
Fgfbp1  WT   and   ECKO   at   different   stages   (Fig.   34a);   however   by   quantification  
none  of  these  differences  resulted  to  be  statistically  significant,  neither  in  terms  of  
vessel  coverage  nor  expression  levels  (Fig.  34b-­‐‑c).  
	  
Figure  34.  Analysis  of  collagen  IV  α1  chain  (Col4a1)  expression  and  coverage  in  Fgfbp1  WT  and  
ECKO  mice  at  different  ages  
(a)  Representative  images  of  confocal  Z-­‐‑stacks  of  brain  sections  (100  µμm  thickness)  of  Fgfbp1  WT  
and   ECKO  mice   at   1,   2   and   3   weeks   of   age.   Sections   were   immunostained   for   the   endothelial  
marker  PECAM  and  the  BM  protein  Col4a1.  Scale  bar:  100  µμm.  (b)  Quantification  of  Col4a1  vessel  
coverage  (measured  as  percentage  of  Col4a1  positive  endothelium)  in  Fgfbp1  WT  and  ECKO  mice  
at   1,   2   and   3   weeks   of   age.   For   each   age   group,   2   WT   and   3   ECKO   mice   were   analyzed.   (c)  
Quantification  of  Col4a1   expression   (measured  as  mean  Col4a1   fluorescence   intensity)   in  Fgfbp1  





Regarding   collagen   IV   α2   chain   (Col4a2)   (Fig.   35a),   no   major   differences   were  
detectable   except   a   small   and   non   statistically   significant   decrease   in   vessel  
coverage  in  Fgfbp1  ECKO  mice  at  3  weeks  (Fig.  35b),  and  a  substantial  increase  in  
expression  in  ECKO  animals  at  1  week  (Fig.  35c;  p<0.05).    
	  
Figure  35.  Analysis  of  collagen  IV  α2  chain  (Col4a2)  expression  and  coverage  in  Fgfbp1  WT  and  
ECKO  mice  at  different  ages  
(a)  Representative  images  of  confocal  Z-­‐‑stacks  of  brain  sections  (100  µμm  thickness)  of  Fgfbp1  WT  
and   ECKO  mice   at   1,   2   and   3   weeks   of   age.   Sections   were   immunostained   for   the   endothelial  
marker  PECAM  and  the  BM  protein  Col4a2.  Scale  bar:  100  µμm.  (b)  Quantification  of  Col4a2  vessel  
coverage  (measured  as  percentage  of  collagen  IV  α2  chain  positive  endothelium)  in  Fgfbp1  WT  and  
ECKO  mice  at  1,  2  and  3  weeks  of  age.  For  each  age  group,  2  WT  and  3  ECKO  mice  were  analyzed.  
(c)   Quantification   Col4a2   expression   (measured   as   mean   collagen   IV   α2   chain   fluorescence  
intensity)  in  Fgfbp1  WT  and  ECKO  mice  at  1,  2  and  3  weeks  of  age.  For  each  age  group,  2  WT  and  3  




The   analysis   of   laminins   started   from   the   characterization   of   the   components   of  
the  eBM  laminin  α4  and  laminin  α5.  
Laminin   α4   was   found   to   be   expressed   more   or   less   equally,   both   in   terms   of  
vessel  coverage  and  expression   levels,   in  Fgfbp1  WT  and  ECKO  mice  at  2  and  3  
weeks,  with   a   slightly   lower   expression   in   1  week  old  ECKO  mice   compared   to  
age-­‐‑matched  controls  (Fig.  36).  
  
Figure   36.  Analysis   of   laminin  α4   expression   and   coverage   in   Fgfbp1  WT   and  ECKO  mice   at  
different  ages  
(a)  Representative  images  of  confocal  Z-­‐‑stacks  of  brain  sections  (100  µμm  thickness)  of  Fgfbp1  WT  
and   ECKO  mice   at   1,   2   and   3   weeks   of   age.   Sections   were   immunostained   for   the   endothelial  
marker  PECAM  and  the  BM  protein  laminin  α4.  Scale  bar:  100  µμm.  (b)  Quantification  of  laminin  α4  
vessel  coverage   (measured  as  percentage  of   laminin  α4  positive  endothelium)   in  Fgfbp1  WT  and  
ECKO  mice  at  1,  2  and  3  weeks  of  age.  For  each  age  group,  2  WT  and  3  ECKO  mice  were  analyzed.  
(c)  Quantification   of   laminin   α4   expression   (measured   as   mean   laminin   α4   chain   fluorescence  
intensity)  in  Fgfbp1  WT  and  ECKO  mice  at  1,  2  and  3  weeks  of  age.  For  each  age  group,  2  WT  and  3  
ECKO  mice  were  analyzed.    
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Conversely,  regarding  laminin  α5,  the  immonostaining  analysis  (Fig.  37a)  and  its  
related  quantifications  (Fig.  37b-­‐‑c)  revealed  a  higher  vessel  coverage  (p<0.05)  and  
expression  level  of  laminin  α5  in  Fgfbp1  ECKO  mice  compared  to  control  animals;  
however,   while   at   later   stages   (2   and   3   weeks)   both   the   coverage   and   the  
expression   tended   to   increase   time-­‐‑dependently   in  WT   animals,   they   remained  
roughly  unchanged  in  ECKO  mice,  finally  resulting  in  an  overall  decrease  in  both  
vessel  coverage  and  expression  of  laminin  α5  in  Fgfbp1  ECKO  mice  compared  to  
controls.  




Figure   37.  Analysis   of   laminin  α5   expression   and   coverage   in   Fgfbp1  WT   and  ECKO  mice   at  
different  ages  
(a)  Representative  images  of  confocal  Z-­‐‑stacks  of  brain  sections  (100  µμm  thickness)  of  Fgfbp1  WT  
and   ECKO  mice   at   1,   2   and   3   weeks   of   age.   Sections   were   immunostained   for   the   endothelial  
marker  PECAM  and  the  BM  protein  laminin  α5.  Scale  bar:  100  µμm.  (b)  Quantification  of  laminin  α5  
vessel  coverage   (measured  as  percentage  of   laminin  α5  positive  endothelium)   in  Fgfbp1  WT  and  
ECKO  mice  at  1,  2  and  3  weeks  of  age.  For  each  age  group,  2  WT  and  3  ECKO  mice  were  analyzed.  
*:   p<0.05   (c)   Quantification   of   laminin   α5   expression   (measured   as   mean   laminin   α5   chain  
fluorescence   intensity)   in   Fgfbp1  WT   and   ECKO  mice   at   1,   2   and   3  weeks   of   age.   For   each   age  
group,  2  WT  and  3  ECKO  mice  were  analyzed.    
  
Finally,  we  analyzed  the  pBM  component   laminin  α2,   that  did  not  result   to  vary  
remarkably  between  Fgfbp1  WT  and  ECKO  animals,  except  for  a  slight  increase  in  
coverage   in   2   weeks   old   ECKO   mice   and   a   slight,   not   statistically   significant,  




Figure   38.  Analysis   of   laminin  α2   expression   and   coverage   in   Fgfbp1  WT   and  ECKO  mice   at  
different  ages  
(a)  Representative  images  of  confocal  Z-­‐‑stacks  of  brain  sections  (100  µμm  thickness)  of  Fgfbp1  WT  
and   ECKO  mice   at   1,   2   and   3   weeks   of   age.   Sections   were   immunostained   for   the   endothelial  
marker  PECAM  and  the  BM  protein  laminin  α2.  Scale  bar:  100  µμm.  (b)  Quantification  of  laminin  α2  
vessel  coverage   (measured  as  percentage  of   laminin  α2  positive  endothelium)   in  Fgfbp1  WT  and  
ECKO  mice  at  1,  2  and  3  weeks  of  age.  For  each  age  group,  2  WT  and  3  ECKO  mice  were  analyzed.  
(c)  Quantification   of   laminin   α2   expression   (measured   as   mean   laminin   α2   chain   fluorescence  
intensity)  in  Fgfbp1  WT  and  ECKO  mice  at  1,  2  and  3  weeks  of  age.  For  each  age  group,  2  WT  and  3  
ECKO  mice  were  analyzed.    
  
The   overmentioned   immunostaining   results   were   obtained   by   performing   an  
initial   unmasking   with   pepsin   (see   “Materials   and   methods”)   to   exclude   the  
possibility   that   the   observed   differences   might   be   due   to   the   presence   of   other  
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molecules   masking   the   antigen   of   interest;   importantly,   however,   the   same  
differences  were  detectable  also  in  non-­‐‑pepsin  treated  samples  (data  not  shown).      
Overall,  as  shown  by  the  analysis  of  the  BM  composition  (summarized  in  Table  6),  
the  results  point  out  to  the  possibility  that  endothelial-­‐‑specific  deletion  of  Fgfbp1  
gene   might   cause   a   collective   rearrangement   of   the   BM,   due   to   changes  
(sometimes  also  rather  subtle)  in  the  balance  of  the  single  BM  components.  
   Fgfbp1  ECKO  vs.  WT  
Coverage   Expression  
1  week   2  weeks   3  weeks   1  week   2  weeks   3  weeks  
Collagen  IV  (trimeric)   -­‐‑-­‐‑   -­‐‑-­‐‑   -­‐‑-­‐‑   -­‐‑   -­‐‑   -­‐‑-­‐‑  
Collagen  IV  α1  chain  (Col4a1)   =   -­‐‑   -­‐‑   -­‐‑   +   =  
Collagen  IV  α2  chain  (Col4a2)   =   =   -­‐‑   ++   =   =  
Laminin  α4   -­‐‑   =   =   -­‐‑   =   =  
Laminin  α5   ++   -­‐‑   -­‐‑   +   -­‐‑   -­‐‑  
Laminin  α2   =   ++   -­‐‑   -­‐‑   =   =  
Table  6.  Summary  table  of  the  modification  detected  in  the  BM  of  Fgfbp1  ECKO  mice  
++:  increase  (statistically  significant);    
+:  increase  (not  statistically  significant);    
-­‐‑-­‐‑:  decrease  (statistically  significant);    
-­‐‑:  decrease  (not  statistically  significant);    
=:  unchanged.  
  
To   determine   whether   the   modifications   in   the   BM   composition   were   due   to  
alterations   in   the   production   by   the   ECs,   we   isolated   brain   microvascular  
fragments   from   1   week   old   and   3   weeks   old   Fgfbp1  WT   and   ECKO  mice   and  
checked,   by   qRT-­‐‑PCR,   the   expression   of   genes   encoding   for   the   endothelial-­‐‑
derived  BM  components  Col4a1,  Col4a2,  laminin  α4  and  laminin  α5.  
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The  analysis  showed  that,  except   for  a  reduction   in   laminin  α4  expression   in   the  
endothelium   of   1   week   old   Fgfbp1   ECKO  mice,   neither   collagen   IV   chains   nor  
laminin   α5   were   significantly   modified,   indicating   that   the   alterations   in   BM  
deposition  were  not  attributable  to  a  defective  production  by  brain  ECs  (Fig.  39).  
	  
Figure  39.  Analysis  of  expression  of  endothelial-­‐‑derived  BM  components   in  1  week  old  and  3  
weeks  old  Fgfbp1  WT  and  ECKO  mice  
qRT-­‐‑PCR  analysis  of  the  endothelial-­‐‑derived  BM  components  (a)  Col4a1,  (b)  Col4a2,  (c)  laminin  α4  
and   (d)   laminin   α5   in   ECs   freshly   isolated   from   the   brain   of   1   week   old   and   3   weeks   old  
Fgfbp1flox/flox/VEC-­‐‑PAC  mice  injected  (ECKO)  or  not  (WT)  with  tamoxifen.  The  levels  of  mRNA  are  
normalized  on  18S.  Data  are  presented  as  mean  ±  standard  deviation  of   the  analyzed  samples   (1  
week  WT:  n=7,  ECKO:  n=4;  3  weeks  WT:  n=4;  ECKO:  n=6).  *:  p<0.05	  
  
These   data,   together   with   the   observation   that   Fgfbp1   ECKO   animals   show   a  
decreased  number  of  vessel-­‐‑associated  pericytes,  suggest  that  endothelial-­‐‑derived  
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FGFBP1   might   be   involved   in   the   regulation   of   the   cell-­‐‑cell   and   cell-­‐‑BM  
interactions  within  the  NVU.  
  
3.3.5  Fgfbp1  ECKO  mice  present  increased  BBB  permeability  
To   functionally   characterize   the   phenotype   of   Fgfbp1   ECKO   animals,   we  
investigated   the   status   of   BBB   permeability   by   injecting   10   dpn   mice   with  
Alexa555-­‐‑labeled   cadaverine   (molecular   weight:   ~950   Dalton)   and   searching   for  
areas  of  tracer  extravasation  within  the  brain.  
Since   after   extravasation   Alexa555-­‐‑cadaverine   is   intercepted   by   neurons,   that  
absorb   it   acquiring   a   red   staining   (example   in   Fig.   40a)   [61],   we   quantified   the  
number   of   Alexa555-­‐‑cadaverine   positive   neurons   per   field   as   a   measure   of   the  
amount   of   dye   that   extravasated   and   found   out   a   strong   increase   in   BBB   vessel  
permeability  in  Fgfbp1  ECKO  animals  compared  to  controls  (Fig.  40b;  p<0.05).  
	  
Figure  40.  Analysis  of  BBB  permeability  by  quantification  of  Alexa555-­‐‑cadaverine  leakage  
(a)  Representative  image  of  a  brain  section  were  Alexa555-­‐‑cadaverine  leakage  is  detected.  Sections  
(100   µμm   thickness)   were   immunostained   for   the   BBB   marker   GLUT1.   (b)   Quantification   of  
Alexa555-­‐‑cadaverine   leakage   (measured   as   number   of   cadaverine   positive   neurons   per   20x  




To  determine  whether   this   increase   in  permeability  was  due  to  alterations   in   the  
organization   of   TJs,   we   performed   an   immunostaining   for   claudin-­‐‑5;   however  
from   this   analysis   we   could   not   detect   any   sign   of   junctional   disorganization,  
leading   us   to   exclude   the   possibility   that   the   impairment   in   the   control   of   BBB  
permeability  in  Fgfbp1  ECKO  might  be  due  to  TJs  dismantling  (Fig.  41).  
	  
Figure  41.  Analysis  of  correlation  between  increased  BBB  permeability  and  TJs  organization  
Representative   images  of   confocal  Z-­‐‑stack   images  of  brain   sections   (100  µμm   thickness)  of  Fgfbp1  
WT  and  ECKO  mice  at  10  dpn  after  Alexa555-­‐‑cadaverine  injection.  Sections  were  immunostained  
for  the  TJ  marker  claudin-­‐‑5.  Scale  bar:  200  µμm.  
  
Opposite   to   what   we   observed   regarding   claudin-­‐‑5,   we   found   a   correlation  
between   the   increased  BBB  permeability   and   the   already  described   reduction   in  
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collagen   IV   coverage.   Indeed   we   detected   a   strong   reduction   in   collagen   IV  
coverage   in   the  areas  of   increased  vessel  permeability  were  Alexa555-­‐‑cadaverine  
extravasation   occurred,   while   collagen   IV   coverage   was   normal   in   both   control  
animals  and  ECKO  animals  in  the  areas  with  a  normal  permeability  (no  Alexa555-­‐‑
cadaverine  extravasation)  (Fig.  42).  
	  
Figure  42.  Analysis  of  correlation  between  increased  BBB  permeability  and  TJs  organization  
Representative   images  of   confocal  Z-­‐‑stack   images  of  brain   sections   (100  µμm   thickness)  of  Fgfbp1  
WT  and  ECKO  mice  at  10  dpn  after  Alexa555-­‐‑cadaverine  injection.  Sections  were  immunostained  




To  further  characterize   the  phenotype  of  Fgfbp1  ECKO  animals,  we   investigated  
the  status  of  the  BBB  permeability  by  checking  for  the  leakage  of  high  molecular  
weight  molecules.  To  this  purpose,  we  performed  an  immunostaining  for  IgG  on  
brain  sections  of  Fgfbp1  WT  and  ECKO  mice  at  1,  2  and  3  weeks  of  age  and  adult  
mice   (4  months)   and   then  quantified   the  number  of   IgG   leakage  areas  per  brain  
sagittal  section.    
As  for  Alexa555-­‐‑cadaverine,  we  could  not  detect  massive  IgG  leakage  all  over  the  
brain   sections,   but   only   small   areas   of   IgG   extravasation   (Fig.   43a).   The  
quantifications  of  these  “IgG  spots”  displayed  a  significant  increase  in  the  number  
of   IgG   leakage   areas   at   2   and   3  weeks   in   Fgfbp1   ECKO  mice   compared   to   age-­‐‑
matched  controls  (p<0.05);   in  addition,  this  phenotype  resulted  to  be  exacerbated  
in  adult  Fgfbp1  ECKO  mice,  even  though  some  IgG  spots  were  detectable  also  in  






Figure  43.  Analysis  of  IgG  leakage  in  Fgfbp1  WT  and  ECKO  brains  
(a)  Representative  confocal  Z-­‐‑.stacks  and  (b)  quantifications  of  IgG  leakake  spots   in  sagittal  brain  
sections  (100  µμm  thickness)  from  Fgfbp1  WT  and  ECKO  mice  at  1,  2  and  3  weeks  and  adult  mice  (4  
months).  Sections  were  immunostained  for  the  endothelial  marker  PECAM  and  for  IgG.  At  least  2  
WT  and  3  ECKO  animals  were  analyzed  per  each  stage.  *:  p<0.05;  **:  p<0.01.  
  
With   the   intention   of   clarifying   the   mechanism   responsible   for   the   increase   in  
permeability,  we  decided  to  analyze  the  expression  of  Plvap,  a  protein  known  to  
be   downregulated   in   brain   ECs   by   Wnt   signaling   activation   during   the  
establishment   of   the   BBB   and   already   reported   to   be   associated   to   poor   BBB  
differentiation  [139].  
From  Plvap  immunostaining  (Fig.  44a)  and  its  related  quantification  (Fig.  44b),  we  
detected   an   increase   in   Plvap  protein   levels   in   Fgfbp1  ECKO  mice   compared   to  
controls   at   all   analyzed   stages,   reflecting   a   defect   in   protein   downregulation   at  
later   stages   of   development   in   comparison   to   WT   animals.   Moreover,   we   also  
found   that   Plvap   overexpression   could   justify   the   increase   in   IgG   permeability,  
109	  
	  
since  we  observed  a   correlation  between   the  areas  of  high  Plvap  expression  and  
the  presence  of  extravasated  IgG  (Fig.  44a).  
	  
Figure  44.  Correlation  between  IgG  leakage  and  Plvap  expression  in  Fgfbp1  ECKO  mice  
(a)  Representative  images  of  confocal  Z-­‐‑stack  images  of  brain  sections  (100  µμm  thickness)  of  Fgfbp1  
WT  and  ECKO  mice  at  1,  2  and  3  weeks  of  age.  Sections  were  immunostained  for  the  endothelial  
marker  PECAM,  for  IgGs  and  for  Plvap.  Scale  bar:  100  µμm.  (b)  Quantification  of  the  expression  of  
Plvap  in  the  brain  endothelium  of  Fgfbp1  WT  and  ECKO  mice  at  1,  2  and  3  weeks  of  age.  *:  p<0.05.  
  
3.3.6  Endothelial  Fgfbp1  knock  out  does  not  alter  BBB  molecular  signature  
To   determine   whether   endothelial-­‐‑specific   deletion   of   FGFBP1   could   affect   the  
expression  of  other   typical  molecular   components  of  ECs  at   the  BBB  besides   the  
NVU   components   reported   in   the   previous   sections,   we   isolated   brain  
microvascular  fragments  from  1  week  old  and  3  weeks  old  Fgfbp1  WT  and  ECKO  
mice;   we   then   checked,   by   qRT-­‐‑PCR,   the   expression   of   genes   encoding   for  
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endothelial-­‐‑specific   BBB   transporters   and   markers,   as   well   as   for   junctional  
components.  
The  analysis  showed  that  neither  1  week  old  (Fig.  45a)  nor  3  weeks  old  (Fig.  45b)  
Fgfbp1   ECKO  mice   presented   a  molecular   signature   significantly   different   from  
the  one  of  age-­‐‑matched  control  animals,  indicating  that  FGFBP1  deletion  does  not  
affect   in   general   the   transcriptional   profile   of   the   endothelial   components   of   the  
BBB.  
	  
Figure  45.  Analysis  of  BBB  molecular  signature  in  1  week  old  and  3  weeks  old  Fgfbp1  WT  and  
ECKO  mice  
qRT-­‐‑PCR  analysis  of  BBB  molecular  components  in  ECs  freshly  isolated  from  the  brain  of  1  week  
old  and  3  weeks  old  Fgfbp1flox/flox/VEC-­‐‑PAC  mice  injected  (ECKO)  or  not  (WT)  with  tamoxifen.  The  
levels  of  mRNA  are  normalized  on  18S.  Data  are  presented  as  mean  ±   standard  deviation  of   the  
analyzed  samples  (1  week  WT:  n=7,  ECKO:  n=4;  3  weeks  WT:  n=4;  ECKO:  n=6).  	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3.4  Characterization  of  FGFBP1  expression  and  function  in  murine  primary  brain  
ECs  (bMECs)  
3.4.1  FGFBP1  is  effectively  downregulated  in  vitro  by  siRNA  
The   analysis   of   the   phenotype   arising   from   both   the   global   (zebrafish)   and   the  
endothelial-­‐‑specific   (mouse)   ablation   of   FGFBP1   highlighted   the   possibility   that  
the   responses   mediated   by   FGFBP1   could   be   either   directed   towards   the  
endothelium  itself,  to  regulate  cell-­‐‑autonomous  activities,  or  to  different  cell  types  
interacting  with  endothelium,  namely  the  components  of  the  NVU.  
To  discriminate  between  these  two  types  of  responses,  and  in  particular  to  identify  
the  endothelial-­‐‑cell  autonomous  activities  of  FGFBP1,  we  started  taking  advantage  
of  the   in  vitro  cultures  of  primary  ECs  isolated  from  murine  brains  (bMECs).     To  
study   the   effect   of   FGFBP1   absence   in   this   in   vitro  model,   we   designed   three  
different   siRNAs   and   tested   their   efficacy   by   checking   for   Fgfbp1   mRNA  
expression  by  Real  Time  PCR.  All  the  three  siRNA  tested  (siFGFBP1#1,  #2  and  #3)  
resulted   to   be   effective   in   this   in   vitro   setting,   but   the   strongest   Fgfbp1  mRNA  
downregulation  was  achieved  by  siFGFBP1#2  (Fig.  46;  p<0.01),  that  was  therefore  




Figure   46.   Analysis   of   Fgfbp1   expression   in   bMECs   upon   transfection   with   three   different  
siRNAs  
qRT-­‐‑PCR   analysis   of   Fgfbp1   expression   in   bMECs   treated   or   non-­‐‑treated   with   Wnt3a   upon  
transfection   with   three   different   siRNAs   targeting   Fgfbp1  mRNA   (siFGFBP1#1,   #2   and   #3).   The  
levels   of   mRNA   are   normalized   on   18S.   Data   are   presented   as   mean   ±   standard   deviation   of  
replicates  of  a  representative  expreriment  (n=3).  *:  p<0.05;  **:  p<0.01.  
  
The  downregulation  of  FGFBP1  was  effective  not  only  at  mRNA  level,  but  also  at  
protein  level.  Indeed,  as  shown  by  IF  analysis,  FGFBP1  protein.  that  is  localized  at  
EC  membrane,  is  upregulated  upon  treatment  with  Wnt3a  and  is  strongly  reduced  




Figure  47.  Analysis  of  FGFBP1  protein  expression  and  localization  in  bMECs  upon  transfection  
with  siFGFBP1#2  
Representative   confocal   images   of   FGFBP1   immunostaining   on   bMECs.   Cells  were   treated  with  
Wnt3a  and  with  siFGFBP1#2.  Scale  bar:  50  µμm.    
  
3.4.2  Fgfbp1  knockdown  does  not  affect  the  autocrine  activity  of  FGF-­‐‑2  
Since   it   has   been   reported   that   FGFBP1   has   a   role   in   presenting   FGF-­‐‑2   to   its  
receptor,  facilitating  its  signaling,  we  decided  to  test  whether  Fgfbp1  knockdown  
could  modify   the   signaling  pathway  downstream  of  FGF   receptor  activation.  To  
this   purpose,   besides   the   treatment   with  Wnt3a   and   with   siFGFBP1#2,   we   also  
added  a  treatment  with  FGF-­‐‑2  to  assess  the  impact  of  FGFBP1  absence  on  FGF-­‐‑2  
activity;   then,   we   checked   by   western   blot   (WB)   for   the   expression   and  
phosphorylation  of  p42/p44  MAP  kinases   (MAPK),   that  are  downstream  of  most  
signaling  routes  activated  by  FGF-­‐‑2.  The  WB  (Fig.  48a)  and  its  quantification  (Fig.  
48b)   showed   that   p42/p44   MAPK   phosphorylation   was   increased   upon   FGF-­‐‑2  
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treatment,  as  expected,  but  was  not  affected  by  the  presence  or  absence  of  FGFBP1,  
indicating  that  FGFBP1  is  not  able  to  influence  the  autocrine  activity  of  FGF-­‐‑2  on  
ECs  in  this  in  vitro  setting.  
	  
Figure  48.  Analysis  of  FGF-­‐‑2-­‐‑  induced  p42/p44  MAPK  phosphorylation  in  bMECs  after  Fgfbp1  
siRNA  treatment  
(a)  Western  blot  analysis  of  FGF-­‐‑2  induced  phosphorylation  of  p42/p44  MAPK  in  bMECs  treated  or  
non   treated  with  Fgfbp1  siRNA  and   (b)   its   related  quantification.  Both   total  and  phosphorylated  
p42/p44      were   normalized   on   tubulin,   then   the   ratio   of   the   two   was   calculated.   The   data   are  
presented  as  mean  ±  standard  deviation  of  replicates  of  a  representative  experiment  (n=2).  
  
3.4.3  Fgfbp1  knockdown  induces  a  tip  cell-­‐‑like  phenotype  in  vitro  
Given  the  in  vivo  observations  that  the  brain  vasculature  of  Fgfbp1  ECKO  animals  
is  more  branched  and  dense  than  the  one  of  control  animals  and  that  in  the  retina  
of  ECKO  animals  an  increased  number  of  tip  cells  is  present,  we  checked  in  vitro,  
by   RT-­‐‑PCR   analysis,   for   the   expression   of   some   tip-­‐‑cell   markers,   such   as   Dll4,  
VEGFR2   and   Neuropilin   1   (Nrp1).   The   RT-­‐‑PCR   data   (Fig.   49)   showed   an  
upregulation  of   the  mRNAs  of  all   these  molecules   in  Fgfbp1  siRNA-­‐‑treated  cells  
compared  to  control  cells;  moreover,  this  upregulation  was  not  dependent  on  the  
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treatment  with  Wnt3a  and  FGF-­‐‑2,   indicating  that  FGFBP1  absence  is  sufficient  to  
induce  the  expression  of  these  tip-­‐‑cell  markers  in  vitro.  
	  
Figure   49.   Analysis   of   tip-­‐‑cell   markers   expression   in   bMECs   upon   transfection   with   Fgfbp1  
siRNA  
qRT-­‐‑PCR   analysis   of  Dll4,   VEGFR2   and  Nrp1   expression   in   bMECs   treated   or   non-­‐‑treated  with  
Wnt3a  upon  transfection  with  Fgfbp1  siRNA.  The  levels  of  mRNA  are  normalized  on  18S.  Data  are  
presented   as   mean   ±   standard   deviation   of   replicates   of   a   representative   expreriment   (n=3).   *:  
p<0.05.  
  
To  validate  this  observation,  we  also  performed  a  wound-­‐‑healing  assay  on  Wnt3a-­‐‑
treated  bMECs  upon  transfection  with  either  a  control  siRNA  or  Fgfbp1  siRNA  to  
see  if  FGFBP1  ablation  induced  a  morphological  change  in  the  cells  towards  a  tip-­‐‑
like  phenotype.   The   assay   showed   that   the   cells,   after   Fgfbp1   knockdown,  were  
more  oriented  towards  the  wound  area;  moreover,  an  increased  number  of  cellular  
protrusions   was   present,   indicating   that,   in   the   absence   of   FGFBP1,   cells   were  




Figure   50.   Analysis   of   Wnt3a-­‐‑treated   bMECs   morphology   in   a   wound-­‐‑healing   assay   upon  
Fgfbp1  siRNA  
Representative   confocal   images   of   a   wound   healing   assay   on   Wnt3a-­‐‑treated   bMECs   upon  
transfection   with   either   a   control   siRNA   or   Fgfbp1   siRNA.   Cells   were   immunostained   for   the  
endothelial  marker  VE-­‐‑cadherin.  Scale  bar:    50  µμm  
  
3.4.4  Fgfbp1  knockdown  causes  the  upregulation  of  Plvap  in  vitro  
Starting   from   the   in   vivo   observation   that   increased  BBB  permeability   correlated  
with  a  higher  expression  of  Plvap,  we  decided  to  test  whether  the  upregulation  of  
this   protein   following   Fgfbp1   gene   deletion   in   the   endothelium   was   cell-­‐‑
autonomous  or  not;  together  with  this,  we  also  wanted  confirm  that  the  increased  
permeability   was   not   due   to   TJ   dismantling.   To   answer   these   questions,   we  
analyzed   in   vitro   the   expression   of   Plvap,   Claudin-­‐‑5   and   the   BBB-­‐‑selective  
Claudin-­‐‑3,  both  at  mRNA  level  by  qRT-­‐‑PCR  and  at  protein  level  by  IF.  
The   qRT-­‐‑PCR   analysis   (Fig.   51a)   showed   a   significant   30%   increase   of   Plvap  
mRNA   expression   in   Fgfbp1   siRNA-­‐‑treated   cells   (p<0.05)   already   in   basal  
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conditions   (i.e.   non  Wnt3a-­‐‑treated);   however,  while   Plvap   expression  decreased,  
as  expected,  in  presence  of  Wnt3a  in  siCTRL-­‐‑treated  cells  (30%  decrease,  p<0.05),  
Wnt-­‐‑mediated  downregulation  of  Plvap  was  milder  (15%)  in  siFGFBP1#2-­‐‑treated  
cells  (p<0.05).  Consistently  to  what  observed  in  vivo,  the  increase  of  Plvap,  both  at  
mRNA  and  protein  level,  is  not  coupled  to  a  reduction  in  Claudin-­‐‑5,  that  resulted  
to   be  unchanged   in   control   and   siRNA-­‐‑treated   cells   both   in   terms   of   expression  
(Fig.  51a)  and  junctional  localization  (Fig.  51b).  Finally,  Claudin-­‐‑3  showed  a  slight  
increase   in  mRNA   expression   levels   in   Fgfbp1   siRNA-­‐‑treated   bMECs   (Fig.   51a,  




Figure   51.   Analysis   of   claudin-­‐‑5,   claudin-­‐‑3   and   Plvap   expression   and   localization   in   bMECs  
upon  Fgfbp1  siRNA  transfection  
(a)  qRT-­‐‑PCR  analysis  of  claudin-­‐‑5,  claudin-­‐‑3  and  Plvap  expression  in  bMECs  treated  or  non-­‐‑treated  
with  Wnt3a   upon   transfection  with   Fgfbp1   siRNA.  The   levels   of  mRNA  are   normalized   on   18S.  
Data   are   presented   as   mean   ±   standard   deviation   of   replicates   of   a   representative   expreriment  
(n=3).   *:   CTRL   siFGFBP1#2   vs.   siCTRL:   p<0.05.   ^:   siCTRL   Wnt3a   vs.   CTRL:   p<0.05.   °:   Wnt3a  
siFGFBP1#2  vs.  siCTRL:  p<0.05.  (b)  Representative  confocal  images  of  a  IF  analysis  on  bMECs  upon  
transfection  with  either  a  control  siRNA  or  Fgfbp1  siRNA.  Cells  were  immunostained  for  claudin-­‐‑




3.4.5  Fgfbp1  knock  down  in  bMECs  causes  alterations  in  the  response  to  Wnt3a  
treatment  
The  observation  that  Plvap,  a  gene  known  to  be  downregulated  by  canonical  Wnt  
pathway,   is  more  effectively  downregulated  by  Wnt3a   in  siCTRL-­‐‑treated  bMECs  
than   in   siFgfbp1#2-­‐‑treated   cells   (Fig.   51a)   raised   the   hypothesis   that   FGFBP1  
absence  might  change  the  overall  response  of  brain  ECs  to  Wnt3a  treatment.  
To   test   this  possibility  we  analyzed  the  Affymetrix  data  by  comparing  the   list  of  
genes   that   were   modulated   (either   upregulated   or   downregulated)   by   Wnt3a  
treatment  either  in  control  cells  or  in  interfered  cells  (i.e.  “Upregulated  by  Wnt3a  
in   siCTRL   vs.   upregulated   by   Wnt3a   in   siFgfbp1#2”   and   “Downregulated   by  
Wnt3a  in  siCTRL  vs.  downregulated  by  Wnt3a  in  siFgfbp1#2”).  
The   analysis   showed   that,   within   the   group   of   genes   that  were   upregulated   by  
Wnt3a   treatment,   37   of   them   showed   this   upregulation   only   in   control   cells,   51  
only  in  interfered  cells  and  117  in  both  conditions.  In  parallel,  within  the  group  of  
genes   that   were   downregulated   by   Wnt3a   treatment,   31   genes   were  
downregulated  only  in  control  cells,  39  only  in  siFgfbp1#2-­‐‑treated  cells  and  52  in  
both  (Fig.  52).  
Moreover,   within   the   group   of   genes   that   were   modulated   by   Wnt3a   in   both  
control  and  interfered  cells,  some  genes  presented  differences  in  the  extent  of  the  
upregulation/downregulation,   including   some   canonical   Wnt   targets:   in  
particular,  Axin-­‐‑2  upregulation  upon  Wnt3a  stimulation  was  more  than  40%  lower  
in  siFgfbp1#2-­‐‑treated  cells  compared  to  control,  while  Plvap  downregulation  was  
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more  that  15%  lower  in  interfered  cells  compared  to  control  cells,  confirming  our  
previous  observations  (see  Tables  7  and  8).  
	  
Figure  52.  Graphical  representation  of  the  differential  response  to  Wnt3a  treatment  in  siCTRL-­‐‑
treated  cells  and  siFgfbp1#2-­‐‑treated  cells  
Diagram   of   the   number   of   genes   whose   transcription   is   modulated   (upregulated   or  
downregulated)  upon  Wnt3a  stimulation  in  siCTRL-­‐‑treated  cells  and  siFgfb1#2-­‐‑treated  cells.  
  
To  determine  whether   the  differentially  modulated  transcripts  might  account   for  
some  specific  biological  process,  we  performed  a  Gene  Ontology  scan   to  classify  
them   according   to   the   biological   functions   in   which   they   are   involved.   We  
observed  that  most  of  the  genes  that  were  upregulated  specifically  in  siFgfbp1#2-­‐‑
treated  cells  and  most  of   those  who  were  specifically  downregulated   in   siCTRL-­‐‑
treated  cells  were  genes  that  participate  in  the  processes  of  vascular  development,  
vessel  morphogenesis  and  tissue  remodeling  (Table  7).    





Vasculature  development   GO:  0001944   13   6.085e-­‐‑08  
Blood  vessel  development   GO:0001568   11   3.699e-­‐‑06  
Blood  vessel  morphogenesis   GO:0048514   10   4.991e-­‐‑06  
Cardiovascular  system  development   GO:0072358   13   1.351e-­‐‑05  
Table  7.  Gene  Ontology  analysis  of  the  most  enriched  biological  processes   in  which  differentially  
Wnt-­‐‑modulated  genes  are  involved  
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The   observation   that   these   genes   were   specifically   downregulated   by  Wnt3a   in  
presence  of  FGFBP1  and  specifically  upregulated  by  Wnt3a  in  absence  of  FGFBP1,  
suggests   that   FGFBP1   might   act,   through   a   mechanism   that   is   still   to   be  
investigated,  as  a  molecular  mediator  of  Wnt  activity.    
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Upregulated  by  Wnt3a  
Only  in  siCTRL   Only  in  siFgfbp1#2   Both  
         %  of  siCTRL  
ACP6   ADRB2   2610019F03RIK   87.91  
ADM   AHRR   4933409K07RIK   97.50  
ALAS1   ANGPT2   5730469M10RIK   101.73  
ARL4A   ANGPTL4   A130022J15RIK   100.32  
ATP10A   ASB4   ABHD2   92.42  
BSG   B930036N10RIK   ACER2   99.69  
CACHD1   BC028528   ADH1   72.31  
CTLA2A   BGN   APCDD1   78.98  
DISP2   CCDC85A   APOD   80.10  
ERN1   CTHRC1   AQP11   95.09  
FBLN1   ELOVL7   AXIN2   57.88  
FGFBP1   GM6020   BEX1   66.20  
GPER   GM8174   BMP2   99.74  
GPM6A   GNAS   CACNA1E   91.37  
IFITM1   HMCN1   CADM1   106.48  
JAG1   KANK4   CAR2   85.87  
JUB   LCE1H   CCDC141   84.33  
LPCAT3   MAOB   CCL2   92.82  
LRG1   MCOLN2   CD24A   102.74  
LRP8   MRPS21   CDH2   93.63  
NGFRAP1   MT2   CHRM3   103.99  
NOMO1   PCDH7   CLDN5   98.04  
NRGN   PHLDA1   COL10A1   111.31  
ODC1   PTGS2   CRCT1   118.10  
PLAT   RAMP3   CSF1   96.70  
RET   RECK   CTSC   104.32  
RGS16   RERG   CTXN1   106.70  
RYBP   RNU2   CYP1B1   86.88  
SLC16A12   RNU73B   DARC   109.68  
SLC7A5   RNY1   DPP4   100.58  
SPRY1   RPL13   EDN1   107.81  
SUSD4   SCARNA17   EFEMP1   93.35  
SWAP70   SFRP1   ENPP2   106.34  
TMEM37   SLAIN2   ENTPD1   104.45  
TTYH2   SLC44A1   FAM102A   111.13  
ZFP703   SNHG1   FAM13A   90.00  
ZNRF3   SNORD32A   FAM163A   91.88  
   SNORD34   FHL1   101.82  
   SNORD35A   FLRT2   89.78  
   SNORD49B   FOXF2   107.42  
   SNORD82   FOXQ1   87.05  
   SRGN   FRZB   106.11  
123	  
	  
Upregulated  by  Wnt3a  
Only  in  siCTRL   Only  in  siFgfbp1#2   Both  
         %  of  siCTRL  
   ST3GAL6   GATM   89.87  
   STXBP4   GKN3   69.95  
   TIPARP   GLDN   107.42  
   TRP53I11   GLI3   98.44  
   UCP2   GM12824   110.49  
   USP46   GPR126   109.09  
   VAULTRC5   GSTA4   97.21  
   ZFP36L1   HTR2A   115.72  
   ZFP51   INSR   109.83  
      ISM1   101.30  
      ISYNA1   80.02  
      ITGA4   110.12  
      KBTBD11   95.80  
      KCNIP3   80.83  
      KCNJ2   106.21  
      LAMA1   83.28  
      LCN2   121.37  
      LEF1   107.84  
      LIPA   105.34  
      LPHN3   93.52  
      LRRC7   82.19  
      LSR   91.62  
      MAL   108.15  
      MAOA   98.34  
      MEIS2   108.51  
      MFSD7C   98.46  
      MMRN1   91.45  
      MOGAT2   90.44  
      MYH10   93.07  
      MYL4   99.71  
      NEFL   95.11  
      NOSTRIN   135.25  
      NPNT   105.91  
      NTS   96.21  
      OLFML2A   112.98  
      PARM1   97.05  
      PDE7B   107.22  
      PGLYRP1   100.77  
      PKNOX2   108.69  
      PLXNB1   90.05  
      RASSF9   119.32  
      REEP1   113.31  
124	  
	  
Upregulated  by  Wnt3a  
Only  in  siCTRL   Only  in  siFgfbp1#2   Both  
         %  of  siCTRL  
      RGS2   97.13  
      RHOBTB1   107.37  
      RNF183   97.77  
      SCN3B   96.01  
      SERPINB6B   87.27  
      SESN3   93.45  
      SLC16A4   96.67  
      SLC16A6   94.10  
      SLC19A3   88.57  
      SLC22A14   102.48  
      SLC22A8   90.46  
      SLC2A1   99.15  
      SLC35F2   100.96  
      SLC38A3   84.03  
      SLC38A5   87.92  
      SLC39A8   97.57  
      SLC40A1   110.66  
      SLCO1A4   107.91  
      SLCO1A5   113.59  
      SLCO1C1   75.69  
      SLCO2B1   119.62  
      SRPX2   102.82  
      ST3GAL5   106.18  
      STC2   102.16  
      TBX1   94.21  
      TCF7   103.86  
      TGFB2   100.69  
      TNFRSF19   100.52  
      TRF   99.07  
      VIL1   83.47  
      VWF   98.31  
      ZIC2   107.01  
      ZIC3   99.77  
Table  8.  List  of  genes  differentially  upregulated  by  Wnt3a   treatment   in   siCTRL-­‐‑treated  cells   and  
siFgfbp1#2  cells.  Color  code:  Red  =  genes  whose  decrease  in  upregulation  in  siFgfbp1#2  vs.  siCTRL  
cells   is  higher   that  15%.  Green  =     genes  whose   increase   in  upregulation   in  siFgfbp1#2  vs.  siCTRL  





Downregulated  by  Wnt3a  
Only  in  siCTRL   Only  in  siFgfbp1#2   Both  
         %  of  siCTRL  
4930523C07RIK   APOL9B   8430408G22RIK   90.514448  
ACVR1B   CBS   ABLIM3   96.49760224  
AHR   CDA   ACE   101.9551747  
ATP2B4   CMPK2   ADAM12   99.53873793  
CXCR7   CPNE7   ADAM19   105.5553718  
EDNRB   CX3CL1   ADARB1   97.14657243  
ENPP6   D8ERTD82E   APLNR   104.6585372  
ESM1   DDX60   CCDC88C   119.0786689  
FAM36A   FBXL7   CDC42EP2   100.7548998  
FAM70A   GM10081   CLIC6   98.0041672  
GDA   GM5970   COL15A1   110.8416429  
GJA1   GPR21   COL8A1   100.4271954  
IGF1   GPRIN3   CXCL10   87.85400738  
IGFBP3   GRP   CYP1A1   94.06044091  
ITGA8   HEY1   D4BWG0951E   96.06248269  
LRRC55   I830012O16RIK   DEPDC6   96.6991424  
MGP   IFI203   DOCK8   100.281119  
NPTX1   IFIT1   EFNB2   103.2398535  
NUDT4   IFIT2   EGFL8   121.4628394  
P2RY2   IRF7   EMP2   88.98598257  
PAPSS2   MTX2   ENPP3   86.19583113  
PIK3R3   MYH9   EPHB1   125.3020484  
PLXNA4   OASL1   F8   82.35482031  
RAPH1   OASL2   FBLN2   89.60710288  
RASA4   PHXR4   FMO2   105.7758295  
SELP   PRKCH   GALNTL2   99.54529267  
SNCG   PRRG3   GJA4   120.482616  
SYT15   RSAD2   GJA5   78.54220467  
TINAGL1   RTP3   GPC4   101.0745654  
TNFSF18   S100A10   GPIHBP1   106.1044379  
VMN2R22   SERPINA1C   GRIN2A   87.34396929  
   SLC43A3   KCNE3   105.0921566  
   TGTP1   LAMA3   98.33180291  
   TRDN   LIFR   88.79805612  
   TSPAN33   LTBP4   96.70383439  
   UBE2L6   MCAM   99.57117086  
   UBE2V1   MEST   105.1719514  
   USP18   MET   86.38603422  
   XAF1   MMP15   91.94703767  
      NOS2   108.5699614  
      NT5E   107.322681  
      PLAU   100.1977422  
126	  
	  
Downregulated  by  Wnt3a  
Only  in  siCTRL   Only  in  siFgfbp1#2   Both  
         %  of  siCTRL  
      PLVAP   84.51621127  
      PRKCC   105.322232  
      PTP4A3   101.9703698  
      RNF125   98.54878571  
      SEMA3G   111.6749029  
      SH3GLB2   101.5577262  
      SLC45A4   98.58567937  
      SULT5A1   104.2227336  
      TRPC3   95.56836222  
      UPP1   106.1423209  
Table  9.  List  of  genes  differentially  downregulated  by  Wnt3a  treatment  in  siCTRL-­‐‑treated  cells  and  
siFgfbp1#2   cells.   Color   code:   Red   =   genes   whose   decrease   in   downregulation   in   siFgfbp1#2   vs.  
siCTRL  cells  is  higher  that  15%.  Green  =    genes  whose  increase  in  downregulation  in  siFgfbp1#2  vs.  
siCTRL  cells  is  higher  that  15%.  
	  




The  BBB  has  a  critical  role  in  accurately  maintaining  the  stringent  homeostasis  of  
the   CNS   that   is   strictly   required   to   allow   a   proper   neuronal   function.   For   this  
reason,   a  perfectly   functional  BBB   is  needed   to   supply  nutrients   and   ions   to   the  
brain   parenchyma   and   to   block   any   possible   assault   by   toxins   and   pathogens  
coming  from  the  environment  [140].    
Many   groups   have   already   demonstrated   that   the   BBB   breakdown   is   an   event  
often   related   to   many   neurological   disorders,   including   stroke,   brain   trauma,  
multiple   sclerosis   (MS)   and   Alzheimer’s   disease   (AD)   [141-­‐‑143],   for   which   a  
resolving  therapy  is  still  to  be  found.  
On   the   other   hand,   the   BBB   also   represents   the   main   obstacle   to   the  
pharmaceutical  treatment  of  cerebral  pathologies,  for  example  brain  tumors,  since  
it  can  prevent  the  entrance  of  drugs  into  the  brain  parenchyma.    
In   this   perspective,   defining   the   molecular   mechanisms   that   regulate   the  
development  and  the  function  of  the  BBB  assumes  a  great  medical  relevance,  since  
it  would   allow   to   search   for   specific   therapeutic   tools   able   to   restore   the  proper  
functional  activity  of  the  BBB,  in  the  cases  of  BBB  breakdown,  or  to  selectively  and  
transiently   open   it   in   order   to   allow   the   entrance   of   specific   pharmacological  
compounds,   in   the   cases   in   which   an   enhanced   drug   delivery   to   the   brain   is  
required.  
In  this  study,  we  aimed  at  determining  the  role  of  FGFBP1  in  the  regulation  of  the  
BBB  properties.   Indeed,  FGFBP1   is  an  appealing  candidate   for  a   function   in  BBB  
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development,   since  we   found   that   its   expression   is  much  higher   in  ECs   isolated  
from   the   brain   compared   to   other   ECs   and   that   its   expression   is   strongly  
upregulated  by  the  activation  of  canonical  Wnt/β-­‐‑catenin  pathway,  a  well-­‐‑known  
molecular  determinant  of  the  BBB  phenotype  [11,  17,  18].    
In  order  to  clarify  FGFBP1  function,  we  took  advantage  of  different  in  vivo  and  in  
vitro  systems:  
-­‐‑   an  ubiquitous  Fgfbp1  knock  down  zebrafish  model,   to   investigate   the   effect   of  
Fgfbp1  ablation  in  the  whole  organism;  
-­‐‑  a  conditional  endothelial-­‐‑specific  Fgfbp1  knock-­‐‑out  murine  model,  to  specifically  
determine  the  role  of  endothelial-­‐‑derived  FGFBP1;  
-­‐‑  cultures  of  primary  brain-­‐‑derived  murine  ECs  (bMECs)   treated  with  a     specific  
siRNA   targeting   Fgfbp1,   to   characterize   the   endothelial   cell-­‐‑autonomous  
responses  of  brain  ECs  to  FGFBP1  absence.  
  
4.1  Fgfbp1a  and  b   expression  and   function   in  zebrafish:   different   specializations  
after  the  evolutionary  divergence  of  the  two  paralogues  
In   zebrafish,   FGFBP1   is   present   as   two   different   paralogues,   FGFBP1a   and  
FGFBP1b,   being   the   latter   the   paralogue   with   the   highest   homology   with   the  
murine  protein.   Both  proteins   show  a   low   (23-­‐‑25%)   total   sequence   identity  with  
the   murine   sequence,   but   with   the   presence   of   two   highly   conserved   regions,  
corresponding   to   the   functional   domains   of   the   protein:   an   internal   heparin-­‐‑
binding  domain  and  a  C-­‐‑terminal  FGF-­‐‑binding  domain.  
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In  this  study,  we  analyzed  the  expression  of  the  two  paralogues,  their  function  and  
their   capability   to   be   induced   by   Wnt   pathway   activation:   our   data   strongly  
underlined  that  many  differences  (summarized  in  Table  10)  exist  between  the  two  
proteins,  both  in  terms  of  regulation  and  activity.  
   Fgfbp1a   Fgfbp1b  
Peak  of  expression   24  hpf   72  hpf  
Cell  specificity   Mostly  ECs   Mostly  non-­‐‑ECs  
Hemorrhages   Many  and  large   Few  and  small  
Vascular  defects  
Brain  and  trunk;  






Increased   Normal  
Induction  by  Wnt   ECs  and  non-­‐‑ECs   ECs  
Table  10.  Schematic  summary  of  the  differences  between  Fgfbp1a  and  Fgfbp1b  
     
The   results   obtained   clearly   indicate   the   involvement   of   FGFBP1a   and   b   in   the  
development   of   the   zebrafish   vasculature;   however,   the   above   mentioned  
differences   suggest   that   the   two   paralogues   could   have   acquired   different  
functions  during  evolution.    
Fgfbp1a  is  likely  to  be  involved  in  the  overall  vascular  development.  Its  expression  
is  mostly  endothelial-­‐‑specific,  and  its  peak  of  expression  is  around  24  hpf,  a  time  
when  active  angiogenic  processes  are  ongoing  both   in   the   trunk  and  in   the  head  
[144].  Consistently  with  a   role   in   the   regulation  of   the  angiogenic   sprouting,   the  
kind   of   vascular   defects   arising   from   Fgfbp1   knock   down   (i.e.   the   lack   of   some  
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cerebral   and   intersomitic  vessels)   resemble   the  phenotype   reported   for   zebrafish  
VEGFR-­‐‑2  mutants  [145],  as  well  as  for  other  mutants  affecting  VEGF  downstream  
signaling,  that  result  all  in  defects  in  ISVs  and  cranial  vessels  formation  [146-­‐‑148].  
Although  in  our  work  we  did  not  analyze  the  structure  and  the  composition  of  AJs  
and   TJs   in   zebrafish   morphants,   it   is   possible   that   the   hemorrhages   and   the  
increased  vascular  permeability  observed  in  MO-­‐‑Fgfbp1a  animals  might  be  due  to  
endothelial   junctional   alterations,   since   defects   in   the   cranial   vasculature  
associated   to   hemorrhagic   phenomena   were   also   reported   by   our   group   after  
injection  of  a  morpholino  targeting  VE-­‐‑cadherin  [149].    
On  the  other  side,  we  reported  that  Fgfbp1b  is  mainly  expressed  by  non-­‐‑ECs  but,  
differently   from   the   other   paralogue,   its   expression   is   not   very   high   at   24   hpf.  
However,  Fgfbp1b  mRNA  levels  tend  to  increase  during  later  stages:  in  particular  
at  72  hpf,  that  is  the  last  time  point  we  considered  in  our  analysis,  its  expression  is  
strongly  enhanced  compared  to  earlier  stages.  The  kinetics  and  the  cell  specificity  
of  this  paralogue  do  not  make  it  a  good  candidate  for  the  regulation  of  angiogenic  
development,  but  they  rather  suggest  that  it  might  be  involved  in  the  later  process  
of  BBB  specification.   Indeed,  although  still   limited  knowledge  is  available  on  the  
BBB   in   zebrafish   from   either   a   developmental,   structural   or   functional   point   of  
view,  it  was  recently  reported  that,  even  if  the  TJ  proteins  ZO-­‐‑1  and  claudin-­‐‑5  in  
zebrafish   brain   vessels   appear   by   48-­‐‑72   hpf,   the   size-­‐‑dependent   exclusion   of  
molecules  from  the  brain  is  a  feature  that  is  acquired  only  later  on  [150].  Moreover,  
it  is  also  reported  that,  as  for  mammals,  also  in  zebrafish  the  brain  vasculature  is  
associated   to   perivascular   cells   like   pericytes   and   astrocytes,   even   though   their  
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role   in   the   control   of   BBB   function   and   permeability   in   this  model   is   still   to   be  
clarified    [150,  151].  In  this  context,  Fgfbp1b  might  represent  a  molecular  mediator  
of   the   interactions  between  endothelium  and  perivascular   cells.  Moreover,  given  
the   observation   that   our   murine   transgenic   model   presents   a   reduction   in   the  
number   of   pericytes,   it   would   be   interesting   to   exploit   the   mural-­‐‑cell   reporter  
animal  developed  by  the  group  of  Dr.  Childs  [151]  to  investigate  whether  Fgfbp1b  
knockdown  can  influence  pericyte  recruitment  and/or  maturation.  
  
4.2  The  glial  barrier:  an  astrocyte  reaction  to  endothelial  barrier  impairment  
One   of   the   most   intriguing   and   puzzling   data   obtained   in   this   work   is   the  
observation,   in   the   EM   ultrastructural   analysis,   that   perivascular   astrocytes   in  
Fgfbp1   ECKO   animals   were   characterized   by   the   presence   of   swelling   and   by  
intercellular   junctions   that   appeared   tighter   than   in   WT   animals.   Taking   in  
consideration   the   numerous   other   defects   observed   in   Fgfbp1   ECKO   mice,  
including   the   reduction   in   the   number   of   pericytes,   the   BM   remodeling   and   its  
reduction   in   thickness   and   the   increased   permeability   to   both   low   and   high  
molecular  weight  molecules,   the  abnormal   appearance  of   the  astrocyte  might  be  
considered  as  a  sort  of  compensatory  reaction  to  the  impairment  in  the  endothelial  
barrier  function.    
This   possibility   is   not   surprising,   since   in   nature   many   animal   species   exist   in  
which  the  brain  endothelial  layer  is  incomplete  or  leaky,  but  the  barrier  properties  
are   took  on  by  perivascular   glial   cells   [152].  Also,   it   has   been  proposed   that   the  
ancestral   vertebrate   had   a   glial   BBB,   while   the   endothelial   BBB   would   have  
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appeared   later   on   during   evolution,   indicating   that   it   confers   a   strong   selective  
advantage  in  certain  environments  [153].  
As  a   further  confirmation  of   this  hypothesis,  other  groups  reported   that   in  some  
pathologies  of  the  CNS  involving  BBB  dysfunction,  such  as  tumors  and  epilepsy,  
compensatory   changes   in   astrocytes   and   glial   cells   are   present   [154,   155],  
indicating  that  astrocyte   layer  “tightening”  might   indeed  represent  a  second  line  
of  defense  in  case  of  endothelial  BBB  disruption.  
  
4.3  Pericyte  decrease  and  BM  rearrangements:  a  “chicken  or  egg”  situation  
The  phenotype  detected  in  our  Fgfbp1  ECKO  model  includes  modifications  in  the  
number   and  maturation   state   of   pericytes   and   a   reshaping   of   BM   composition,  
mainly   represented   by   a   decrease   in   collagen   IV   coverage   and   expression.   As  
already  discussed  in  the  introduction,   in  recent  years  many  groups  have  focused  
their   attention   on   how   these   two   entities   can   influence   the   BBB   functional  
properties   and  how   they   synergically   interact  with   the   endothelium   to   establish  
these   properties,   but   very   less   is   known   about   the   intercommunication   between  
pericytes  and  BM  and  the  ways   in  which  alterations  of  one  of   the   two  can  affect  
the  other.  
In   the   context   of   this   project,   two   possible   scenarios   emerge   to   provide  
explanations  to  our  experimental  phenotype.  
The  first  scenario  presupposes  that  Fgfbp1  ECKO  directly  affects  the  recruitment  
and   maturation   of   pericytes;   then,   as   a   consequence   of   their   reduction,   the  
production  and  secretion  of  collagen  IV  and  other  BM  components  is  altered.  This  
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hypothesis   is   supported   by   the   observation   of   Dr.   Jeon   and   colleagues   that  
pericytes   in   culture   can   produce   the   major   structural   components   of   the   BM,  
including   collagen   IV   and  multiple   laminin   chains   [85].   Complementary   to   this  
observation,  also  Dr.  Stratman  and  coworkers  reported  that,  in  in  vitro  cocultures  
of   ECs   and   pericytes,   the   recruitment   of   pericytes   to   vascular   tubes   and   their  
heterotypic   interaction   with   the   ECs   triggers   the   production   and   deposition   of  
collagen   IV,   laminins  and  other  BM  components,   such  as  nidogens  and  perlecan  
[83,   87].   Also,   it   was   recently   shown   that   the   pericyte-­‐‑specific   ablation   of   NG2  
proteoglycan  was  able  to  reduce  collagen  IV  coverage  of  B16F10  melanoma  vessels  
[156].  On  the  contrary,  this  hypothesis  is  refuted  by  the  work  of  the  group  of  Prof.  
Betsholtz,   that   demonstrated   some   years   ago,   in   a   murine   model   showing   a  
decreased   number   of   pericytes,   that   the   BM   composition   was   not   altered   by  
pericyte   reduction;   in   this   work,   the   only   BM   protein   that   results   modified   by  
pericyte   lack   is   the  pBM  component   laminin  α2,  but   this  change   is  accompanied  
by  modifications   in  aquaporin  IV  expression  and  localization,   indicating  that   the  
observed   laminin   α2   alterations   are   likely   due   to   defects   in   the   astrocytic  
compartment  rather  than  to  defects  in  BM  protein  deposition  [61].  
Conversely,   the   second   scenario   contemplates   the   possibility   that   an   initial  
impairment   in   BM   deposition   might   affect   the   recruitment   of   pericytes.   This  
hypothesis  is  sustained  by  the  observation  that  the  BM  composition,  in  particular  
the  proper  N-­‐‑sulfation  of  HSPGs,   is   critical   for   the  binding  and   the  activation  of  
the  heparin-­‐‑binding  growth  factor  PDGF-­‐‑B  and  subsequent  pericyte  recruitment,  
as   shown   by   the   fact   that   mice   mutant   for   Ndst-­‐‑1   (Ndst-­‐‑1-­‐‑/-­‐‑),   the   enzyme  
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responsible   for   heparan-­‐‑sulfates   N-­‐‑sulfation,   show   decreased   pericyte   coverage  
[38].    
Importantly,  these  two  hypotheses  are  not  mutually  exclusive.  It  is  likely  that  the  
phenotype  observed  in  Fgfbp1  ECKO  mice  might  depend  on  the  influence  of  both  
pericytes  on  BM  and  BM  on  pericytes.  Indeed,  based  on  the  data  we  obtained,  we  
can  postulate  a  model  (schematized  in  Fig.  53)  in  which  FGFBP1  ablation  in  brain  
ECs  directly  causes  cell-­‐‑autonomous  responses  involving  the  acquisition  of  a  tip-­‐‑
like  phenotype  and  the  overexpression  of  tip-­‐‑cell  markers,  such  as  Dll4,  VEGFR2  
and   Nrp1.   As   shown   by   Dr.   del   Toro   and   coworkers   in   2010   [157],   tip-­‐‑cells  
transcriptome   is   enriched   for   proteases,   such   as   ADAM-­‐‑TS   (A  Disintegrin-­‐‑Like  
and  Metalloproteinase  with  Thrombospondin  motif)   family  members,  which   are  
known   to   degrade   the   BM   facilitating   cell   migration;   this   might   explain   the  
reduced   BM   thickness   and   the   modifications   in   BM   composition   observed   in  
Fgfbp1  ECKO  mice.  At  the  same  time,  while  it  is  known  that  tip-­‐‑cells  also  produce  
soluble   factors,   such   as   PDGF-­‐‑B,   to   recruit   pericytes,   the   latter   are   known   to  
preferentially  associate  to  stalk  cells  [30];  in  the  cellular  context  created  by  FGFBP1  
deletion,  where  ECs  “act”  as   tip-­‐‑cells,   this  might  account   for  a  defective  pericyte  
association  to  the  vasculature  and  subsequent  pericyte  number  decrease.  Further  
modifications  in  the  BM  might  occur  as  a  consequence  of  the  impaired  EC-­‐‑pericyte  
association,   that   in   turn  might   cause   ulterior   defects   in   pericyte   physiology.  All  
these   phenomena   might   contribute   in   establishing   a   “vicious   circle”   in   which  
defects  in  the  BM  affect  the  pericytic  compartment  and,  vice  versa,  pericytes  affect  




Figure  53.  Proposed  model  for  pericyte  deficiency  and  BM  impairment   in  brain  vasculature  of  
Fgfbp1  ECKO  mice  
Schematic  representation  of  the  possible  mechanisms  accounting  for  the  defects  in  pericyte  number  
and  BM  deposition  in  the  brain  vasculature  of  Fgfbp1  ECKO  mice.  The  ablation  of  FGFBP1  in  the  
endothelium  originates  a  cell-­‐‑autonomous  switch  of  ECs  to  a  tip-­‐‑like  phenotype,  with  a  subsequent  
acceleration   in  BM  degradation  and  an   impairment   in  EC-­‐‑pericyte  association.   In   turn,   these   two  
phenomena  are  responsible  for  further  defects  in  BM  deposition  and  pericyte  maturation.  The  italic    
within  the  dotted  box  represents  literature-­‐‑based  assumptions  whose  experimental  confirmation  is  
still  pending.  
  
4.5  Small  vessel  disease  (SVD):  a  link  between  FGFBP1,  Collagen  IV  and  increased  
cerebral  hemorrhage  susceptibility  
In  our  work,  we  reported  that  increased  brain  vessel  permeability  in  Fgfbp1  ECKO  
mice  is  associated  to  decreased  collagen  IV  vessel  coverage.  Collagen  IV  is  already  
known  to  be  the  major  BM  component  responsible  for  vessel  stabilization,  and  it  
has   been   shown   to   have   a   fundamental   role   also   in   the   maintenance   of   BM  
integrity   under   mechanical   stress   conditions,   although   it   is   dispensable   for   BM  
assembly  during  development  [79].  Moreover,  mutations  in  Col4a1  and  Col4a2  are  
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reported  to  be  associated  to  hemorrhagic  events:  in  particular,  it  has  been  shown  
that  these  mutations  do  not  affect  the  production  and  the  trimerization  of  collagen  
IV   chains,   but   they   impair   the   secretion   of   collagen   IV   trimer,   that   is   therefore  
retained  within   the  endoplasmic   reticulum  [80,  81,  158].     As  shown  by  our  data,  
also   in  Fgfbp1  ECKO  mice   the   transcription  of  Col4a1  and  Col4a2   is  not  altered,  
possibly   indicating   that   the   decreased   collagen   IV   vessel   coverage   might   be  
ascribed  to  a  defect  in  its  secretion.    
Mutations  in  Col4a1  have  also  been  shown  to  be  one  of  the  genetic  determinants  of  
small   vessel   disease   (SVD),   a   group   of   multifactorial   diseases   characterized   by  
vessel   tortuosity,   vascular   hyperbranching,   BM   focal   disruption   and   increase  
susceptibility  to  cerebral  hemorrhages  [159].  Given  the  similarities  between  these  
clinical  manifestations  and  the  phenotype  observed  in  our  zebrafish  and  mouse  in  
vivo  models,   and  given   the  multiplicity  of  genes   interested  by  genetic  mutations  
causing  a  SVD  phenotype,   it  would  be   interesting   to   further   investigate  whether  
Fgfbp1   might   be   a   candidate   gene   for   mutations   causing   this   disease.   Indeed,  
single   nucleotide   polymorhisms   (SNPs)   in   Fgfbp1   gene   have   been   already  
associated  not  only   to  bone  mineral  density   regulation   [160],  but  notably  also   to  
hypertension   [161],   that   is   reported   to   be   a   risk   factor   for   cerebral   hemorrhages  
and  strokes  [81].  
  
4.6  FGFBP1:  a  novel  regulator  of  Wnt  activity?  
The  observation   that  Plvap  expression   is  differently  downregulated  by  Wnt3a   in  
control   and   siFgfbp1#2-­‐‑treated   cells   prompted   us   to   investigate   more   in   depth  
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whether   the   absence   of   FGFBP1   could   influence  more   generally   the   response   of  
brain  ECs  to  Wnt.  A  first  confirmation  of  this  hypothesis  came  from  the  expression  
of  Axin-­‐‑2,  a  canonical  Wnt  target  gene,  whose  upregulation  upon  Wnt3a  treatment  
was   lower   in   siRNA-­‐‑treated   bMECs   compared   to   control   cells.   In   addition,   by  
Affymetrix  analysis,  we  managed  to  detect  strong  differences  in  the  transcriptome  
of  Fgfbp1  WT  and  knock  down  cells  in  response  to  Wnt3a  stimulation:  indeed,  we  
found   that   some   genes   were   specifically   modulated   in   WT   cells,   some   other  
specifically   in   interfered   cells   and   some  other   in  both   cell   types,   but   to  different  
extents.  These  data  clearly  indicate  that  FGFBP1  is  somehow  able  to  influence  the  
cellular   response   to   Wnt,   at   least   in   our   experimental   setting.   The   mechanism  
through  which  FGFBP1  can  modulate  Wnt  activity  is  still  to  be  defined:  we  aim  at  
clarifying  this  point  in  the  next  future  by  analyzing  the  expression  of  known  Wnt  
signaling   inhibitors,   such   as   Dkk1,   and   the   expression   and   phosphorylation   of  
Frizzled  and  LRP5/6  receptors.  
Interestingly,   the  genes   that   resulted   to  be   affected  by  FGFBP1  presence   in   their  
response   to   Wnt   activation   are   mostly   genes   involved   in   the   regulation   of  
vascularization.  More  specifically,  these  genes  have  been  found  to  be  upregulated  
by   Wnt3a   in   FGFBP1-­‐‑deficient   cells   and   downregulated   by   Wnt3a   in   FGFBP1-­‐‑  
proficient   cells,   possibly   indicating   that   the   role   of   FGFBP1   in   this   conditions  
might   be   to   negatively   modulate   Wnt   action   in   promoting   cerebral  
vascularization.   If   this   hypothesis   is   true,   we   could   start   considering   FGFBP1  
expression  as  a  sort  of  “protective  mechanism”  to  avoid  uncontrolled  angiogenesis  
in  the  CNS,  that  would  occur  in  absence  of  a  proper  fine-­‐‑tuning  of  Wnt  activity.  In  
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this  perspective,   the  upregulation  of  FGFBP1   that  other  groups  have  reported   in  
pathological   angiogenic   conditions   [128]   might   not   be   causative   of   these  
conditions  but  rather  a  “defense  response”  to  them.  
Finally  we  found  that,  among  the  genes  that  are  specifically  upregulated  by  Wnt  
in  absence  of  FGFBP1,  some  might  be  of  particular  relevance  for  the  explanation  of  
FGFBP1  ECKO  mice  phenotype:  Ang-­‐‑2,  whose  overexpression  has  been  shown  to  
cause   pericyte   loss   [49];   ESM-­‐‑1   (endothelial   specific   molecule   1)   and   IGFBP-­‐‑3  
(insulin  growth  factor  binding  protein  3),  that  have  been  shown  to  enhance  VEGF-­‐‑
induced  signaling  in  ECs  and  to  regulate  the  interaction  with  astrocytes,  pericytes  
and  microglial  cells  [157,  162-­‐‑164].  Since  these  genes  have  been  also  reported  to  be  
particularly   enriched   in   tip-­‐‑cells   [157],   their   further   study   could   provide   a   link  
between   the   differential   response   to  Wnt,   the   tip-­‐‑like   phenotype   and   the   NVU  
alterations  that  we  reported  to  occur  in  the  absence  of  FGFBP1.  
	  
4.7  Concluding  remarks  
In   conclusion,   our   work   showed   that   FGFBP1   is   upregulated   by  Wnt/β-­‐‑catenin  
pathway   specifically   in   brain   ECs,  where   it   controls   the   interaction   between   the  
endothelial   compartment   and   the   other   components   of   the   NVU,   possibly   by  
modulating   Wnt   responses.   Although   the   underlying   molecular   mechanisms  
governing   FGFBP1   action   still   need   to   be   clarified,   we   believe   that   our   work  
contributed   in   identifying   a   novel   regulator   of   BBB   physiology,   with   potential  
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